

**Cochrane** Database of Systematic Reviews

# Psychological therapies for the management of chronic and recurrent pain in children and adolescents (Review)

Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C

Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2018, Issue 9. Art. No.: CD003968. DOI: 10.1002/14651858.CD003968.pub5.

www.cochranelibrary.com



#### TABLE OF CONTENTS

#### [Intervention Review]

# Psychological therapies for the management of chronic and recurrent pain in children and adolescents

Emma Fisher<sup>1</sup>, Emily Law<sup>2</sup>, Joanne Dudeney<sup>3</sup>, Tonya M Palermo<sup>2</sup>, Gavin Stewart<sup>4</sup>, Christopher Eccleston<sup>5</sup>

<sup>1</sup>Cochrane Pain, Palliative and Supportive Care Group, Pain Research Unit, Churchill Hospital, Oxford, UK. <sup>2</sup>Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA. <sup>3</sup>Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, Washington, USA. <sup>4</sup>University of Newcastle, Newcastle, UK. <sup>5</sup>Centre for Pain Research, University of Bath, Bath, UK

Contact: Emma Fisher, e.a.fisher@bath.ac.uk.

**Editorial group:** Cochrane Pain, Palliative and Supportive Care Group. **Publication status and date:** Stable (no update expected for reasons given in 'What's new'), published in Issue 10, 2020.

**Citation:** Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2018, Issue 9. Art. No.: CD003968. DOI: 10.1002/14651858.CD003968.pub5.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### ABSTRACT

#### Background

This is an update of the original Cochrane review first published in Issue 1, 2003, and previously updated in 2009, 2012 and 2014. Chronic pain, defined as pain that recurs or persists for more than three months, is common in childhood. Chronic pain can affect nearly every aspect of daily life and is associated with disability, anxiety, and depressive symptoms.

#### Objectives

The aim of this review was to update the published evidence on the efficacy of psychological treatments for chronic and recurrent pain in children and adolescents.

The primary objective of this updated review was to determine any effect of psychological therapy on the clinical outcomes of pain intensity and disability for chronic and recurrent pain in children and adolescents compared with active treatment, waiting-list, or treatment-as-usual care.

The secondary objective was to examine the impact of psychological therapies on children's depressive symptoms and anxiety symptoms, and determine adverse events.

#### Search methods

Searches were undertaken of CENTRAL, MEDLINE, MEDLINE in Process, Embase, and PsycINFO databases. We searched for further RCTs in the references of all identified studies, meta-analyses, and reviews, and trial registry databases. The most recent search was conducted in May 2018.

#### Selection criteria

RCTs with at least 10 participants in each arm post-treatment comparing psychological therapies with active treatment, treatment-asusual, or waiting-list control for children or adolescents with recurrent or chronic pain were eligible for inclusion. We excluded trials conducted remotely via the Internet.



#### Data collection and analysis

We analysed included studies and we assessed quality of outcomes. We combined all treatments into one class named 'psychological treatments'. We separated the trials by the number of participants that were included in each arm; trials with > 20 participants per arm versus trials with < 20 participants per arm. We split pain conditions into headache and mixed chronic pain conditions. We assessed the impact of both conditions on four outcomes: pain, disability, depression, and anxiety. We extracted data at two time points; post-treatment (immediately or the earliest data available following end of treatment) and at follow-up (between three and 12 months post-treatment).

#### **Main results**

We identified 10 new studies (an additional 869 participants) in the updated search. The review thus included a total of 47 studies, with 2884 children and adolescents completing treatment (mean age 12.65 years, SD 2.21 years). Twenty-three studies addressed treatments for headache (including migraine); 10 for abdominal pain; two studies treated participants with either a primary diagnosis of abdominal pain or irritable bowel syndrome, two studies treated adolescents with fibromyalgia, two studies included adolescents with temporomandibular disorders, three were for the treatment of pain associated with sickle cell disease, and two studies treated adolescents with inflammatory bowel disease. Finally, three studies included adolescents with mixed pain conditions. Overall, we judged the included studies to be at unclear or high risk of bias.

#### Children with headache pain

We found that psychological therapies reduced pain frequency post-treatment for children and adolescents with headaches (risk ratio (RR) 2.35, 95% confidence interval (CI) 1.67 to 3.30, P < 0.01, number needed to treat for an additional beneficial outcome (NNTB) = 2.86), but these effects were not maintained at follow-up. We did not find a beneficial effect of psychological therapies on reducing disability in young people post-treatment (SMD -0.26, 95% CI -0.56 to 0.03), but we did find a beneficial effect in a small number of studies at follow-up (SMD -0.34, 95% CI -0.54 to -0.15). We found no beneficial effect of psychological interventions on depression or anxiety symptoms.

#### Children with mixed pain conditions

We found that psychological therapies reduced pain intensity post-treatment for children and adolescents with mixed pain conditions (SMD -0.43, 95% CI -0.67 to -0.19, P < 0.01), but these effects were not maintained at follow-up. We did find beneficial effects of psychological therapies on reducing disability for young people with mixed pain conditions post-treatment (SMD -0.34, 95% CI -0.54 to -0.15) and at follow-up (SMD -0.27, 95% CI -0.49 to -0.06). We found no beneficial effect of psychological interventions on depression symptoms. In contrast, we found a beneficial effect on anxiety at post-treatment in children with mixed pain conditions (SMD -0.16, 95% CI -0.29 to -0.03), but this was not maintained at follow-up.

Across all pain conditions, we found that adverse events were reported in seven trials, of which two studies reported adverse events that were study-related.

#### **Quality of evidence**

We found the quality of evidence for all outcomes to be low or very low, mostly downgraded for unexplained heterogeneity, limitations in study design, imprecise and sparse data, or suspicion of publication bias. This means our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect, or we have very little confidence in the effect estimate; or the true effect is likely to be substantially different from the estimate of effect.

#### **Authors' conclusions**

Psychological treatments delivered predominantly face-to-face might be effective for reducing pain outcomes for children and adolescents with headache or other chronic pain conditions post-treatment. However, there were no effects at follow-up. Psychological therapies were also beneficial for reducing disability in children with mixed chronic pain conditions at post-treatment and follow-up, and for children with headache at follow-up. We found no beneficial effect of therapies for improving depression or anxiety. The conclusions of this update replicate and add to those of a previous version of the review which found that psychological therapies were effective in reducing pain frequency/intensity for children with headache and mixed chronic pain conditions post-treatment.

#### PLAIN LANGUAGE SUMMARY

#### Psychological therapies for the management of chronic and recurrent pain in children and adolescents

#### **Bottom line**

Psychological therapies reduce pain frequency immediately following treatment for children and adolescents with chronic headache and reduce pain intensity for children and adolescents with mixed chronic pain conditions. Psychological therapies also reduce disability for children and adolescents with mixed chronic pain conditions immediately following treatment and up to 12 months later, and for children with headache conditions up to 12 months later.

#### Background

**Psychological therapies for the management of chronic and recurrent pain in children and adolescents (Review)** Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Chronic pain or pain that lasts for longer than three months is common in young people. Psychological therapies (e.g. relaxation, hypnosis, coping skills training, biofeedback, and cognitive behavioural therapy) may help people manage pain and its disabling consequences. Therapies can be delivered face-to-face by a therapist, via the Internet, by telephone call, or by computer programme. This review focused on treatments that are delivered face-to-face by a therapist, which includes therapies delivered by telephone or via a book with exercise instructions. For children and adolescents, there is evidence that relaxation by itself and cognitive behavioural therapy (treatment that helps people test and revise their thoughts and actions) are effective in reducing the intensity of pain in chronic headache, recurrent abdominal pain, fibromyalgia, and sickle cell disease immediately after treatment.

#### **Study Characteristics**

This review included 47 studies with 2884 participants. The average age of the children and adolescents was 12.6 years. Most studies included young people with headache (23 studies) or stomach pain (10 studies), The remaining studies investigated children with irritable bowel syndrome, fibromyalgia, temporomandibular disorders, sickle cell disease, inflammatory bowel disease, or included samples with various chronic pain conditions.

#### **Key results**

Psychological therapies reduced pain frequency immediately following treatment for children and adolescents with chronic headache, and pain intensity and anxiety for children and adolescents with other chronic pain conditions. Psychological therapies also reduced disability for children and adolescents with non-headache chronic pain conditions immediately following treatment and for children with headache and mixed chronic pain conditions up to 12 months later. We did not find any benefit of psychological treatments on reducing anxiety for children with headache or for depression in children with headache or mixed chronic pain conditions.

#### **Quality of evidence**

We judged all outcomes to be low or very low-quality, meaning our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect or we have very little confidence in the effect estimate; or the true effect is likely to be substantially different from the estimate of effect.

# Psychological therapies for the management of chronic and recurrent pain in children and adolescents (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. SUMMARY OF FINDINGS

#### Summary of findings 1. Summary of findings

Psychological therapies compared with any control for children and adolescents with frequent headaches

Patient or population: Children and adolescents with chronic pain

Settings: Community and hospitals

**Intervention:** Psychological therapies (cognitive behavioural therapy or behavioural therapy)

**Comparison:** Any control (active, treatment-as-usual, wait-list)

Outcomes	Probable out- come with con- trol	Probable outcome with inter- vention	NNTB and/or relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Pain: 50% reduction in headache frequency	10 per 1000	24 per 1000	<b>NNTB =</b> 2.86;	644 participants (15 studies)	⊕⊝⊝⊝ very low <sup>b</sup> ,c,h	
Post-treatment			<b>RR</b> 2.35 (1.67 to 3.30)	(13 studies)	very towa,c,	
Lower scores = fewer headaches						
Pain: 50% reduction in headache frequency	10 per 1000	27 per 1000	<b>NNTB =</b> 3.16;	223 participants	⊕⊝⊝⊝ very low-	
Follow-up (up to 12 months)			<b>RR</b> 2.73 (0.98 to 7.63)	(5 studies)	b,c,e,f,g,h	
Lower scores = fewer headaches						
Disability		The mean disability in the inter-		446 participants	<b>000</b>	
Post-treatment		vention groups was 0.26 lower (95% Cl -0.56 to 0.03)		(6 studies)	very low <sup>d,f,g</sup>	
Lower scores = lower reported dis- ability						
Disability		The mean disability in the inter-		209 participants	\$000	
Follow-up		vention groups was 0.37 lower (95% Cl -0.65 to -0.10)		(3 studies)	very low <sup>f,g</sup>	
Lower scores = lower reported dis- ability						

1								
Anxiety	The mean anxiety in the interven- tion groups was 0.11 lower (95%	439 participants	⊕ooo very low					
Post-treatment	CI -0.39 to 0.17)	(7 studies)	a,d,f,h,i					
Lower scores = lower reported anx- iety								
Anxiety	The mean anxiety in the interven-	271 participants	000					
Follow-up	tion groups was 0.12 lower (95% CI -0.46 to 0.21)	(4 studies)	very low <sup>a,f,g</sup>					
Lower scores = lower reported anx- iety								
Depression	The mean depression in the in-	400 participants	000					
Post-treatment	tervention groups was 0.08 lower (95% Cl -0.28 to 0.11)	(6 studies)	very low <sup>a,f,g</sup>					
Lower scores = lower reported de- pression								
<b>CI:</b> Confidence interval; <b>RR:</b> Risk Rati	o; <b>NNTB;</b> Number needed to treat to benefit.							
<ul> <li>GRADE Working Group grades of evidence</li> <li>High-quality: we are very confident that the true effect lies close to that of the estimate of the effect;</li> <li>Moderate-quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different;</li> <li>Low-quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;</li> <li>Very low-quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</li> </ul>								
<ul> <li><sup>a</sup>50 to 75% risk of bias ratings were unclear/high.</li> <li><sup>b</sup>&gt; 75% of risk of bias ratings were unclear or high.</li> <li><sup>c</sup>Confidence intervals were wide.</li> <li><sup>d</sup>Heterogeneity (l<sup>2</sup>) was 46 to 65%.</li> <li><sup>e</sup>Heterogeneity (l<sup>2</sup>) was 66 to 100%.</li> <li><sup>f</sup>75 to 100% of studies eligible to be included in the analysis were not included in the analysis.</li> <li><sup>g</sup>Small number of participants contributing to the outcome.</li> <li><sup>h</sup>Asymmetrical funnel plots suggesting publication bias.</li> <li><sup>i</sup>There was mostly unclear/high risk of bias in the selective reporting category.</li> </ul>								
Summary of findings 2. Summary of findings								
Psychological therapies compared	with any control for children and adolescents with ch	Psychological therapies compared with any control for children and adolescents with chronic pain conditions (mixed)						

Cochrane Library

Trusted evidence. Informed decisions. Better health. Settings: Community and hospitals

Intervention: Psychological therapies (cognitive behavioural therapy or behavioural therapy)

**Comparison:** Any control (active, treatment-as-usual, wait-list)

Outcomes	Probable outcome with control	Probable outcome with intervention	No of Participants (studies)	Quality of the evi- Comments dence (GRADE)
Pain		The mean pain intensity in the intervention group was 0.43 lower (95% CI -0.67 to -0.19)	1210 participants	⊕⊝⊝⊝ very low <sup>d,f</sup>
Post-treatment		group was 0.45 tower (55% CI -0.67 to -0.19)	(16 studies)	very low <sup>a</sup> ,
Lower scores = lower reported pain intensity				
Pain		The mean pain intensity in the intervention	763 participants	000
Follow-up		group was 0.08 lower (95% CI -0.30 to 0.13)	(9 studies)	very low <sup>b,c,e,f</sup>
Lower scores = lower reported pain intensity				
Disability		The mean disability in the intervention	1226 participants	000
Post-treatment		group was 0.34 lower (95% CI -0.54 to -0.15)	(14 studies)	low <sup>c,f</sup>
Lower scores = lower reported disability				
Disability		The mean disability in the intervention	866 participants	<b>000</b>
Follow-up		group was 0.27 lower (95% CI -0.49 to -0.06)	(9 studies)	low <sup>c,e</sup>
Lower scores = lower reported disability				
Anxiety		The mean anxiety in the intervention group	883 participants	\$\$ \$
Post-treatment		was 0.16 lower (95% CI -0.29 to -0.03)	(8 studies)	low <sup>f</sup>
Lower scores = lower reported anxiety				

Cochrane Database of Systematic Reviews

Anxiety Follow-up	The mean anxiety in the intervention group was 0.01 lower (95% CI -0.20 to 0.18)	805 participants (8 studies)	⊕⊕⊝⊝ low <sup>b</sup> ,f
Lower scores = lower reported anxiety			
Depression	The mean disability in the intervention group was 0.05 lower (95% CI -0.23 to 0.12)	757 participants	⊕ooo very low <sup>b,e,f</sup>
Post-treatment	group was 0.05 rower (5570 cr-0.25 ro 0.12)	(8 studies)	very towester.
Lower scores = lower reported depression			
<b>CI:</b> Confidence interval.			
<b>Moderate-quality:</b> we are moder tially different;	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo		
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th	ent that the true effect lies close to that of the estimate of the effect;	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 750 to 75% risk of bias ratings were	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 250 to 75% risk of bias ratings were Confidence intervals were wide.	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 250 to 75% risk of bias ratings were Confidence intervals were wide. Heterogeneity (I <sup>2</sup> ) was 46 to 65%. Heterogeneity (I <sup>2</sup> ) was 66 to 100%.	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub unclear/high.	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 250 to 75% risk of bias ratings were Confidence intervals were wide. Heterogeneity (I <sup>2</sup> ) was 46 to 65%. Heterogeneity (I <sup>2</sup> ) was 66 to 100%.	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub unclear/high.	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 250 to 75% risk of bias ratings were Confidence intervals were wide. Heterogeneity (I <sup>2</sup> ) was 46 to 65%. Heterogeneity (I <sup>2</sup> ) was 66 to 100%. 50 to 75% of studies eligible to be	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub unclear/high.	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 250 to 75% risk of bias ratings were Confidence intervals were wide. Heterogeneity (I <sup>2</sup> ) was 46 to 65%. Heterogeneity (I <sup>2</sup> ) was 66 to 100%. 50 to 75% of studies eligible to be	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub unclear/high.	ent from the estimate	of the effect;
High-quality: we are very confide Moderate-quality: we are moder tially different; Low-quality: our confidence in th Very low-quality: we have very li 250 to 75% risk of bias ratings were Confidence intervals were wide. Heterogeneity (I <sup>2</sup> ) was 46 to 65%. Heterogeneity (I <sup>2</sup> ) was 66 to 100%. 50 to 75% of studies eligible to be	ent that the true effect lies close to that of the estimate of the effect; ately confident in the effect estimate; the true effect is likely to be clo ne effect estimate is limited; the true effect may be substantially differ ttle confidence in the effect estimate; the true effect is likely to be sub unclear/high.	ent from the estimate	of the effect;

7

Cochrane Database of Systematic Reviews

Cochrane Library

Trusted evidence. Informed decisions. Better health.



#### BACKGROUND

#### **Description of the condition**

This review is an update of a previously published review in the Cochrane Library on 'Psychological therapies for the management of chronic and recurrent pain in children and adolescents' (Eccleston 2003; Eccleston 2009; Eccleston 2012; Eccleston 2014). Chronic (pain lasting more than three months) and recurrent pain is a common problem in young people. Recent epidemiology suggests a prevalence of 15% to 30%, with 8% of children described as having severe and frequent pain (King 2011; Perquin 2000; Perquin 2001; Stanford 2008). The most common pain locations are the head, abdomen, and limbs (King 2011). Girls more commonly report all types of chronic and recurrent pain, and there is a peak in incidence at ages 14 to 15 years (Stanford 2008). Young people report pain to be distressing and interfering, and in some cases this can be severely debilitating, affecting all aspects of a child's life, and the lives of the parents and family members (Palermo 2005; Palermo 2014). The deleterious effects of chronic pain in childhood can also extend to adulthood (Horst 2014; Walker 2012).

#### **Description of the intervention**

Psychological treatments for children and adolescents with chronic pain conditions are specifically designed to alter psychological processes thought to underlie, or significantly contribute to, pain, distress, and disability. The design of psychological treatments is informed by specific theories of the causes of human behaviour, or has developed pragmatically through observation and study of response to intervention. Behavioural and cognitive treatments designed to ameliorate pain, distress, and disability were first introduced in adults over 40 years ago (Fordyce 1968; Keefe 2004), and were used to inform the development of psychological treatments for children and adolescents with chronic pain. In paediatric practice, the treatments have different therapeutic aims and components than those for adults. In general, psychological treatments for children and adolescents aim to control pain and modify situational, emotional, familial, and behavioural factors that play a role in the onset and maintenance of pain (Palermo 2012).

Treatments were originally delivered in a face-to-face format in which the patients and therapists worked together in person to implement therapeutic strategies. Methods of remote delivery of psychological treatments for children with chronic pain conditions have also been developed; these are the subject of a separate Cochrane review 'Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents' (Fisher 2015). A companion review of psychological treatments for the management of chronic pain in adults is also published (Williams 2012). Pharmacological interventions are also delivered to children and adolescents with chronic pain and a recent suite of Cochrane reviews have investigated the efficacy of opioids, paracetamol, antidepressants, anti-epiletic drugs, and NSAIDs, but there is little evidence in young people (Cooper 2017a; Cooper 2017c; Cooper 2017c; Eccleston 2017).

#### How the intervention might work

A variety of intervention strategies have been designed to reduce pain, increase comfort, and reduce associated disability and dysfunction in children with pain conditions. Behavioural strategies include relaxation training, biofeedback, and behavioural management programmes (e.g. teaching parents strategies to reinforce adaptive behaviours such as school attendance). Cognitive strategies include hypnosis, stress management, guided imagery, and cognitive coping skills (Palermo 2012). Cognitive-behavioural therapy programmes incorporate elements of both behavioural and cognitive strategies. Parent interventions may include operant strategies, communication strategies, or problem-solving skills (PST). PST is aimed at decreasing distress in parents of children with chronic pain by teaching problem-solving skills, including steps to define a problem, generate possible solutions, implement a solution, and then evaluate (D'Zurilla 1999; D'Zurilla 2007). The efficacy of parent therapies are investigated in a sister review (Eccleston 2015) which is currently being updated.

Given that headache and abdominal pain are the most common types of recurrent pain in children, most of the treatment literature has focused on these two populations. By far the most commonly described treatment is relaxation training or biofeedback, or both, for headache (Law 2017), and recommendations have been made to offer psychological treatment as a matter of routine care for children with headaches (Ernst 2015; Palermo 2014). Older trials investigated efficacy of treatment predominantly for children with headache, comparing different elements of relaxation training and biofeedback and with different treatment doses, and treatment setting (clinic, school, and home; Griffiths 1996; Larsson 1987a). More recently, the quality of trials has improved to include larger sample sizes, multiple recruitment sites, and active control comparator conditions (e.g. Kashikar-Zuck 2012; Levy 2016; Levy 2017; Palermo 2016; Powers 2013). Indeed, psychological therapies have now been developed and evaluated for children with a variety of chronic pain conditions including abdominal pain (Levy 2017), musculoskeletal pain (Kashikar-Zuck 2012) and disease-related pain (Barakat 2010; Levy 2016).

In clinical practice, psychological therapies for children with chronic pain are often delivered as one component of a multidisciplinary treatment programme (Palermo 2012). Such programmes aim to restore function and ameliorate pain through physical rehabilitation, psychological pain management strategies, and medical strategies (Palermo 2012). This treatment is typically offered in specialised outpatient clinics or more intensive day treatment or inpatient rehabilitation programs housed within tertiary medical centres (Hechler 2015).

#### Why it is important to do this review

Several reviews have documented the effectiveness of psychological therapies for children with headache, abdominal, and disease-related pain (Fisher 2015; Huertas-Ceballos 2008; Kibby 1998; Ng 2017; Walco 1999). Reviews have used data pooling techniques for studies of children with headache (Eccleston 2014; Fisher 2015; Ng 2017). In the previously published Cochrane review (Eccleston 2014), we found that psychological treatments were effective in reducing pain intensity in youth with headache. Since the protocol of this review, there has been growing awareness of the limitations of smaller trials. Small studies are now a significant problem in pain research (Moore 2013) and are typically pilot studies or older trials. Therefore, in this update we have presented subgroup analyses to investigate smaller versus larger trials.

#### OBJECTIVES

cochrane

The aim of this review was to update the published evidence on the efficacy of psychological treatments for chronic and recurrent pain in children and adolescents.

- The primary objective of this updated review was to determine any effect of psychological therapy on the clinical outcomes of pain intensity and disability for chronic and recurrent pain in children and adolescents compared with active treatment, waiting-list, or treatment-as-usual care.
- The secondary objective was to examine the impact of psychological therapies on children's depressive symptoms and anxiety symptoms, and determine adverse events.

#### METHODS

#### Criteria for considering studies for this review

#### **Types of studies**

Randomised controlled trials (RCTs) comparing a credible psychological treatment, or a compound treatment with credible primary psychological content, to an active treatment, treatmentas-usual, or waiting-list control. We judged content as credible if it was based on an extant psychological theory or framework. We excluded studies if the pain was associated with life-limiting conditions (e.g. cancer) or if the therapy was delivered remotely using methods such as telephone or Internet.

We included studies if they:

- were available as a full report of a RCT;
- had a design that placed a psychological treatment as an active treatment of primary interest;
- had a psychological treatment with definable psychotherapeutic content (although not necessarily delivered by someone with psychological qualifications);
- were published (or electronically pre-published) in a peerreviewed scientific journal;
- had participants who reported chronic pain (i.e. pain that recurs or persists for at least three months duration);
- had 10 or more participants in each treatment arm at the endof-treatment assessment; and
- included a psychological intervention that was delivered in person (face-to-face treatment), via telephone and at home via a written instruction booklet. We excluded studies delivered via technology (e.g. Internet, smartphone).

#### **Types of participants**

Children and adolescents (< 18 years) reporting chronic or recurrent pain in any body site, not associated with cancer. We separated conditions into headache conditions or mixed pain conditions. Mixed pain conditions (previously referred to as 'non-headache conditions') refer to other types of chronic pain (e.g. recurrent abdominal pain, musculoskeletal pain, disease-related pain).

#### **Types of interventions**

We included studies if at least one trial arm consisted of a psychological intervention (not delivered via technology), and a comparator arm consisted of active treatment, treatment-asusual, or waiting-list control. We excluded primary interventions that were delivered remotely via other methods (e.g. Internet, telephone).

#### Types of outcome measures

We assessed and recorded data from all measurement instruments reported in each study. We extracted data from the most appropriate measurement instruments for the outcomes below. We decided on the most appropriate measurement instruments as measures that were psychometrically established and frequently used across the studies.

#### **Primary outcomes**

- Pain intensity
- Pain-related disability

#### Secondary outcomes

- Depression
- Anxiety
- Adverse events

#### Search methods for identification of studies

#### **Electronic searches**

For this update, searching the following databases identified RCTs of any psychological therapy for paediatric chronic or recurrent pain:

- CENTRAL (CRSO): searched 22/1/14 to 1/5/18
- MEDLINE and MEDLINE in Process (OVID): searched January 2017 to 1/5/18
- Embase (OVID): searched January 2014 to 2018 week 18
- PsycINFO (OVID): searched January 2014 to May week 1 2018

#### Searching other resources

We searched clinicaltrials.gov for possible ongoing or completed trials in this area on 1 May 2018. We also examined reference lists and citation searches of included studies and relevant systematic reviews for other potential RCTs.

#### Data collection and analysis

#### **Selection of studies**

For this update, two authors sifted abstracts (EF, JD), and a third author (TP) arbitrated any disagreements. We selected studies for inclusion based on the following criteria: the study had to be a RCT in design and published in a peer-reviewed journal, included children (< 18 years of age) who had chronic or recurrent pain (non-cancer pain), included a psychological intervention as an active treatment, and had  $\geq$ 10 participants in each arm at each extraction time point. Studies that had not been peer-reviewed were excluded in order to keep the quality of included studies high. Consistent with our last update (Eccleston 2014), remotely-delivered interventions were excluded from this review. We considered psychological interventions for inclusion if they had credible, recognisable psychological/psychotherapeutic content and were specifically designed to change the child's behaviour, cognition, or social-environmental contingencies. All trials included in our previous systematic review and meta-analysis were considered automatically eligible for inclusion (Eccleston 2014).



#### Data extraction and management

Data extracted included: details relating to the design of the study, the participants, primary diagnosis, characteristics of treatment (e.g. treatment setting, treatment delivered, and length of treatment), adverse events, outcome measurement tools used, and outcome data for computation of effect sizes. We contacted trial authors via email to obtain data necessary for effect size calculations if data were missing for primary outcomes of interest. We entered data suitable for pooling into RevMan 5.3 (RevMan 2014).

#### Assessment of risk of bias in included studies

We measured risk of bias using the recommended Cochrane 'Risk of bias' tool (Higgins 2011). We assessed five categories from this tool: random sequence generation (selection bias), allocation concealment (selection bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias). We excluded 'Blinding of participant or personnel' (performance bias) for the purposes of this review as we deemed it redundant because of the nature of delivering or receiving a psychological intervention. We made judgements on the 'risk of bias' categories using the following rules.

## Selection bias (random sequence generation and allocation concealment)

We based judgements of random sequence generation on whether authors used a convincing method of randomisation. We judged studies that provided an adequate method of randomisation as at low risk of bias. We judged studies that did not provide a convincing method of randomisation as at unclear risk of bias. Studies that did not randomise participants were excluded from this review.

We based judgements of allocation concealment on whether there were convincing methods used for random allocation to take place. We did not deem studies as biased if participants were stratified by age or gender. We judged studies that provided a convincing method of allocation concealment (e.g. opaque envelopes) as at low risk of bias. We judged studies that did not report allocation concealment as at unclear risk of bias.

#### Detection bias (blinding of outcome assessment)

We based judgements of blinding of outcome assessment on whether the measures were taken by a third party who was blind to the treatment condition. We judged studies that reported an outcome assessor blinded to treatment as having a low risk of bias. We judged studies where a description was not provided, as at unclear risk of bias.

#### Attrition bias (incomplete outcome data)

We based judgements of incomplete outcome data on whether attrition was fully reported. Authors had to report attrition at each measurement time point (post-treatment and follow-up), and state whether there were any significant differences between completers and non-completers. We judged studies as having low risk of bias if studies reported attrition and no differences between completers and non-completers. We judged studies to be at unclear risk of bias if they reported attrition but did not report if there were differences between completers and non-completers. Finally, we judged studies to be at high risk of bias if they did not report attrition.

#### Reporting bias (selecting reporting bias)

Finally, we based judgements of selective reporting bias on whether data could be fully extracted for analyses in this review. We judged studies that reported all outcomes in the manuscript as having low risk of bias. We marked this category as 'unclear bias' if authors provided data when requested. We allocated high risk of bias to studies that did not report all outcomes.

#### Measures of treatment effect

We combined all treatments labelled as psychological in the following meta-analyses, and designated these as 'Treatment'. Similarly, we combined all control conditions and designated these as 'Control'. We combined the intervention or control arms if more than one intervention or control group was reported to create a single pairwise comparison in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The studies were divided into two groups based on pain condition. We labelled the first group 'headache' and the second group 'mixed chronic pain conditions'. We also selected two assessment points: post-treatment and follow-up. Post-treatment was the assessment point occurring soonest following treatment (often after a delay of several weeks to allow for recording of episodic pain), and follow-up was the assessment point at least three months after the post-treatment assessment point, but not more than 12 months. We selected the longer time point if there were two or more follow-up assessments within this time frame. Therefore, we designed four separate comparisons comprising two forms of comparator (Treatment, Control) and two assessment time points (post-treatment and follow-up). They were labelled as follows.

- Treatment versus control (headache) post-treatment.
- Treatment versus control (headache) follow-up.
- Treatment versus control (mixed chronic pain) post-treatment.
- Treatment versus control (mixed chronic pain) follow-up.

For each comparison, we identified five outcomes labelled 'Pain', 'Disability', 'Depression', 'Anxiety', and 'Adverse events'. From each trial we selected the measure considered most appropriate for each outcome. We applied two rules to guide the choice of outcome measure. First, if an outcome measure was established and occurred frequently among studies it was selected over more novel instruments. Second, given a choice between single item and multi-item self-report tools, multi-item tools were chosen on the basis of inferred increased reliability. Studies did not necessarily report data on all five outcomes. For headache treatments, we preferentially extracted the proportion of participants achieving a clinically significant (50%) reduction in headache frequency as the outcome for pain. We extracted the proportion of participants achieving a 50% reduction in pain intensity when headache frequency was not reported. Thus, for pain outcomes for headache treatments, we used relative ratios or risk ratios (RR) and we calculated numbers needed to treat for an additional beneficial outcome (NNTBs). All other extracted outcomes were continuous. Due to different populations and measures used, we analysed data using random effect models and standardised mean differences. We calculated effect sizes for the continuous outcomes which could be interpreted as follows; small = 0.2, medium = 0.5, large = 0.8 (Cohen 1992).

Due to the number of analyses in this review, we checked for model overfitting using Aikaike Information Criteria (AIC) comparing meta-

Psychological therapies for the management of chronic and recurrent pain in children and adolescents (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

analysis and the additive combination of risk of bias and sample size in random-effects meta-regressions without an interaction term.

#### Unit of analysis issues

Randomisation occurred at the individual level. When studies included both children with headache and children with mixed pain conditions, we included the data in both analyses.

#### Dealing with missing data

We contacted study authors if there were missing data in the peer reviewed manuscript needed for data analysis.

#### Assessment of heterogeneity

We followed the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) to interpret heterogeneity in our metaanalyses. We interpreted heterogeneity in analyses as follows: 0 to 40% as not important, 30 to 60% as moderate, 50 to 90% as substantial, and 75 to 100% as considerable heterogeneity.

#### Assessment of reporting biases

We checked for publication bias by using contour-enhanced funnel plots, tests of funnel plot asymmetry, and meta-regressions including total sample size as a moderator.

#### **Quality of Evidence**

Two review authors (EF, JD) rated the quality of the outcomes. We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system to rank the quality of the evidence using the RevMan 'Summary of Findings' table, and the guidelines provided in Chapter 12.2 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grades of evidence:

- High: we are very confident that the true effect lies close to that of the estimate of the effect;
- Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different;
- Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
- Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

The GRADE system uses the following criteria for assigning a quality level to a body of evidence (Chapter 12, Higgins 2011).

- High: randomised trials; or double-upgraded observational studies;
- Moderate: downgraded randomised trials; or upgraded observational studies;
- Low: double-downgraded randomised trials; or observational studies;

• Very low: triple-downgraded randomised trials; or downgraded observational studies; or case series/case reports.

Factors that may decrease the quality level of a body of evidence are:

- limitations in the design and implementation of available studies suggesting high likelihood of bias;
- indirectness of evidence (indirect population, intervention, control, outcomes);
- unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses);
- imprecision of results (wide confidence intervals);
- high probability of publication bias.

Factors that may increase the quality level of a body of evidence are:

- large magnitude of effect;
- all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results show no effect;
- dose-response gradient.

We decreased the grade rating by one (- 1) or two (- 2) if we identified:

- Serious (- 1) or very serious (- 2) limitations to study quality;
- Important inconsistency (- 1);
- Some (-1) or major (-2) uncertainty about directness;
- Imprecise or sparse data (- 1);
- High probability of reporting bias (- 1).

There are sometimes reasons to downgrade an outcome directly to 'very low-quality', as recommended by GRADE guidelines (Guyatt 2013). Where relevant, we describe all our reasons for making this judgement.

#### 'Summary of findings' table

We included two 'Summary of findings' tables to present the main findings in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes, pain intensity, and disability post-treatment and at follow-up. We also included anxiety and depression post-treatment, and anxiety at follow-up.

#### Subgroup analysis and investigation of heterogeneity

In this update, we included two sets of subgroup analyses for each analysis, where data were available. We chose 20 participants as a cutoff to be consistent with other reviews (e.g. Eccleston 2015 (currently being updated); Williams 2012) which have raised their minimum n from 10 to 20 participants per arm. As a group of authors, we still feel it is premature to raise the minimum n to 20 participants per arm and therefore, in this update, we conducted the following subgroup analyses:

- trials including fewer than 20 participants in each arm (n < 20);
- trials including more than 20 participants in each arm (n > 20).



#### Sensitivity analysis

For this update, we conducted sensitivity analyses on analyses that included more than 10 studies. We removed studies where we judged high or unclear risk of reporting biases to determine whether higher quality studies reported similar effects.

#### RESULTS

#### **Description of studies**

See: Characteristics of included studies; Characteristics of excluded studies.


#### **Results of the search**

Five separate searches were undertaken using databases from inception to May 2018. Details of the previous four searches can be found in Appendix 1. In the most recent search, we searched databases from January 2014 to May 2018 (see Figure

1). The current search yielded 3021 abstracts (2110 abstracts after duplication) and we included nine trials (Chen 2014; Daniel 2015; Greenley 2015; Hickman 2015; Levy 2016; Levy 2017; Palermo 2016; Wahlund 2003; Wahlund 2015). Due to the revised inclusion criteria to include trials delivered via the telephone, we also included one trial (Cottrell 2007) from Fisher 2015. Therefore, we included 10 new studies (n = 869 at post-treatment), a total of 47 RCTs (49 papers) (Abram 2007; Alfven 2007; Barakat 2010; Barry 1997; Bussone 1998; Chen 2014; Cottrell 2007; Daniel 2015; Duarte 2006; Fichtel 2001; Gil 1997; Greenley 2015; Griffiths 1996; Grob 2013; Gulewitsch 2013; Hechler 2014; Hickman 2015; Humphreys 2000; Kashikar-Zuck 2005; Kashikar-Zuck 2012; Kroener-Herwig 2002; Labbe 1984; Labbe 1995; Larsson 1987a; Larsson 1987b; Larsson 1990; Larsson 1996; Levy 2010; Levy 2016; Levy 2017; McGrath 1988; McGrath 1992; Osterhaus 1997; Palermo 2016; Passchier 1990; Powers 2013; Richter 1986; Robins 2005; Sanders 1994; Sartory 1998; Scharff 2002; Van der Veek 2013; Van Tilburg 2009; Vlieger 2007; Wahlund 2003; Wahlund 2015; Wicksell 2009).



### Figure 1. Study flow diagram.





#### Figure 1. (Continued)

47 trials, 49 papers, included in quantitative synthesis (meta-analysis)

#### **Included studies**

The total number of participants completing treatments from the 47 studies was 2884. Of the 47 studies, one had four treatment arms, 12 had three arms, and 30 had two arms. Twenty-five studies included fewer than 20 participants per arm. We included these in separate subgroup analyses in this update (Barakat 2010; Barry 1997; Bussone 1998; Cottrell 2007; Duarte 2006; Fichtel 2001; Griffiths 1996; Grob 2013; Gulewitsch 2013; Hickman 2015; Humphreys 2000; Kashikar-Zuck 2005; Kroener-Herwig 2002; Labbe 1984; Labbe 1995; Larsson 1987a; Larsson 1987b; Larsson 1990; Larsson 1996; Osterhaus 1997; Richter 1986; Sartory 1998; Scharff 2002; Van Tilburg 2009; Wicksell 2009). Two studies delivered treatment to parents only (Levy 2017; Palermo 2016). Incidentally, both studies included more than 20 participants per arm. Across all studies, the mean number of participants per study at the end of treatment was 68 (standard deviation (SD) = 45.04). For studies including fewer and more than 20 participants per arm, the mean number of participants per study at the end of treatment was 36 (SD = 8.17) for studies including less than 20 participants per arm, and 91 (SD = 48.61) for studies including more than 20 participants per arm. Girls outnumbered boys in most studies (mean 66% girls). Child age was reported in 44 studies (Mean 12.65 years, SD 2.21 years).

Young people were recruited from a range of healthcare settings and other sources. Thirty trials recruited from hospital or clinic settings and 12 recruited participants from a mixture of of advertisements, schools, community, or hospital settings. Five trials did not report their recruitment source.

There were 23 trials of treatments for children with headache (including migraine). Of the remainder, 10 were for abdominal pain (Alfven 2007; Duarte 2006; Grob 2013; Humphreys 2000; Levy 2010; Levy 2017; Robins 2005; Sanders 1994; Van der Veek 2013; Van Tilburg 2009) and two studies treated participants with either a primary diagnosis of abdominal pain or irritable bowel syndrome (Gulewitsch 2013; Vlieger 2007). Two studies treated children with fibromyalgia (Kashikar-Zuck 2005; Kashikar-Zuck 2012), two studies included children with temporomandibular disorders (Wahlund 2003; Wahlund 2015), three were for the treatment of pain associated with sickle cell disease (Barakat 2010; Daniel 2015; Gil 1997), and two studies treated children and adolescents with inflammatory bowel disease (Greenley 2015; Levy 2016). Finally, three studies included mixed pain conditions including headache and mixed chronic pain conditions (Hechler 2014; Palermo 2016; Wicksell 2009) For these three studies, we included data in both analyses, as appropriate.

We classified treatment arms on the basis of their content and of the label given by the study authors. We classified interventions into four broad groups. The first is best described as behavioural, typically relaxation-based, with or without biofeedback, and including autogenic or hypnotherapeutic content (Bussone 1998; Chen 2014; Fichtel 2001; Labbe 1984; Labbe 1995; Larsson 1987a; Larsson 1987b; Larsson 1990; Larsson 1996; McGrath 1988; McGrath 1992; Passchier 1990; Wahlund 2003; Wahlund 2015; Van Tilburg 2009; Vlieger 2007). The second is best described as cognitive behavioural therapy, including coping skills training (Abram 2007; Alfven 2007; Barakat 2010; Barry 1997; Duarte 2006; Gil 1997; Griffiths 1996; Grob 2013; Gulewitsch 2013; Hickman 2015; Humphreys 2000; Kashikar-Zuck 2005; Kashikar-Zuck 2012; Kroener-Herwig 2002; Levy 2010; Levy 2017; McGrath 1992; Osterhaus 1997; Powers 2013; Richter 1986; Robins 2005; Sanders 1994; Sartory 1998; Scharff 2002; Van der Veek 2013; Wicksell 2009). Problem-solving therapy was the third category, which involved problem-solving strategies delivered to the family (Daniel 2015). We also included interventions delivered exclusively to parents, which is new to this update. Parent interventions included cognitive-behavioural therapy (Levy 2016) and problem-solving therapy (Palermo 2016), with a primary aim to improve parenting behaviour or parent mental health, or both, and a secondary aim to improve children's pain, disability, and/or emotional functioning. One trial (Hechler 2014) evaluated the efficacy of a three-week intensive inpatient pain rehabilitation programme, which included psychological therapy.

We categorised different control conditions into either treatmentas-usual (n = 8), active (e.g. education, sham therapy; n = 27) or wait-list (n = 12). We were able to extract post-treatment data for outcomes included in this review from 31 studies post-treatment, and for 16 studies at follow-up. Thirty-nine studies reported the treatment length; this was typically short (mean = 6 hours 36 minutes for headache studies, mean = 5 hours for mixed chronic pain studies (Table 1, note - these averages excluded Hechler 2014 as they delivered an in-patient programme which would have skewed the findings). Six studies did not report the duration of psychological treatment (Alfven 2007; Chen 2014; Humphreys 2000; Larsson 1990; Sartory 1998; Wahlund 2003).

The setting of treatment delivery varied between studies (Table 1). Twenty-three studies delivered treatment in a clinic, eight were based either in a clinic or at home, and five delivered treatment to families at home, so exposure to treatment was uncontrolled. One study delivered treatment in an inpatient hospital setting. A further three were based in schools and seven studies were unclear as to the location of treatment delivery. Home maintenance or practice of treatment was a common and important feature of many studies, but overall treatment exposure including home practice was not reported.

Cochrane Database of Systematic Reviews

**Psychological therapies for the management of chronic and recurrent pain in children and adolescents (Review)** Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



#### **Excluded studies**

Nineteen studies were excluded, of which four were new to this update (Jastrowski Mano 2013; Korterink 2016; Rapoff 2014; Rutten 2017). We excluded Connelly 2006, Hicks 2006, Palermo 2009, Rapoff 2014, Stinson 2010, Trautmann 2010 as they were delivered remotely, so did not meet the new inclusion criteria. Eight studies were excluded as they had fewer than 10 participants in a treatment arm at the end of treatment (Fentress 1986; Jastrowski Mano 2013; Kroener-Herwig 1998; Larsson 1986; Sanders 1989; Trautmann 2008; Weydert 2006; Youssef 2009), three studies were judged to have insufficient psychological content in the treatment (Koenig 2013; Korterink 2016; Olness 1987), one study reported only followup data of more than one year (Vlieger 2012), and one trial was had a non-inferiority design (Rutten 2017).

#### **Risk of bias in included studies**

We rated all included studies for risk of bias in five categories: random sequence generation (selection bias), allocation concealment (selection bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias) (Figure 2; Figure 3).

# Figure 2. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.







Figure 3. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.





#### Figure 3. (Continued)

Larsson 1987b	. <b>.</b> .		<b>.</b>		
Larsson 1990	<b>?</b>	?	?	?	+
Larsson 1996	?	?	?	Ŧ	Ŧ
Levy 2010	+	+	+	?	?
Levy 2016	Ŧ	?	+	?	+
Levy 2017	+	?	+	?	+
McGrath 1988	?	?	?	+	+
McGrath 1992	?	?	?	?	•
Osterhaus 1997	?	?	?	•	+
Palermo 2016	Ŧ	+	+	+	+
Passchier 1990	?	?	?	+	•
Powers 2013	+	+	+	?	?
Richter 1986	?	?	?	Ŧ	•
Robins 2005	+	?	?	?	•
Sanders 1994	?	?	?	•	•
Sartory 1998	?	?	?	?	+
Scharff 2002	Ŧ	?	?	+	•
Van der Veek 2013	?	?	?	?	?
Van Tilburg 2009	?	Ŧ	?	?	?
Vlieger 2007	+	Ŧ	Ŧ	?	+
Wahlund 2003	?	?	+	Ŧ	+
Wahlund 2015	+	Ŧ	?	?	Ŧ
Wicksell 2009	+	+	+	?	+

#### Allocation

#### Random sequence generation

We found 16 trials used a convincing method of randomisation which we judged as having low risk of bias and we found a further 31 trials were judged at unclear risk of bias on random sequence generation, as they did not provide an adequate description of the method of randomisation. We scored none as having high risk of bias as the inclusion criteria required that studies randomised participants.

#### Allocation concealment

We found 12 trials adequately concealed allocation of participants, 31 had unclear allocation concealment, and we judged four studies as having high risk of bias.

#### Blinding

We found 11 trials that described adequate blinding of outcome assessors and, therefore, we allocated these trials as having low risk of bias. We found the remaining trials did not report on blinding and so were judged as having unclear risk of bias.

#### Incomplete outcome data

We found 17 studies reported attrition fully, reporting that there was no significant difference between completers and noncompleters. We found 24 studies only partially reported attrition and so we judged them to be at unclear risk of bias and we judged six studies to have a high risk of bias as they did not report attrition.

#### Selective reporting

We found 25 studies reported data fully, which could be extracted and used in analyses; seven studies did not fully report data in the published trial, but provided data when contacted via email; we judged 15 studies to have high risk of bias for selective reporting as they did not provide full extractable data.

#### **Effects of interventions**

See: Summary of findings 1 Summary of findings; Summary of findings 2 Summary of findings

For this update, we conducted subgroup analyses of trials that included fewer than 20 participants per arm or more than 20 participants per arm. A scorecard outlining the treatment effects is included in Table 2.

#### Treatment versus control (headache) post-treatment

#### Headache frequency/intensity, post-treatment

We included 15 studies with 644 participants in an analysis of the effects of treatment on headache frequency/intensity posttreatment (Barry 1997; Fichtel 2001; Griffiths 1996; Kroener-Herwig 2002; Labbe 1984; Labbe 1995; Larsson 1987a; Larsson 1987b; Larsson 1990; Larsson 1996; McGrath 1992; Osterhaus 1997; Powers 2013; Sartory 1998; Scharff 2002). Overall, the analysis suggested

a risk ratio (RR) of 2.35 (95% confidence interval (CI) 1.67 to 3.30; P < 0.01) for a beneficial reduction in headache frequency (number needed to treat for an additional beneficial outcome (NNTB) = 2.86) (Analysis 1.1; Figure 4). However, the GRADE quality rating for this outcome was very low, meaning we have very little

confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. We downgraded this outcome due to limitations in design, imprecision of results, and asymmetrical funnel plot.

Figure 4. Forest plot of comparison: 1 Treatment versus control (headache) post-trea	atment, outcome: 1.1 Pain.
--------------------------------------------------------------------------------------	----------------------------

	Experin	nental	Cont	rol		<b>Risk Ratio</b>	<b>Risk Ratio</b>
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.1.1 N < 20							
Barry 1997	2	12	2	17	3.1%	1.42 [0.23 , 8.70]	
Fichtel 2001	10	20	2	16	4.9%	4.00 [1.02 , 15.72]	<b>_</b>
Griffiths 1996	12	15	3	12	7.6%	3.20 [1.16 , 8.80]	
Kroener-Herwig 2002	16	29	8	19	13.1%	1.31 [0.70 , 2.44]	_ <b>_</b>
Labbe 1984	13	14	1	14	2.9%	13.00 [1.96 , 86.42]	
Labbe 1995	19	20	6	10	15.1%	1.58 [0.95 , 2.65]	L
Larsson 1987a	7	14	1	11	2.7%	5.50 [0.79 , 38.30]	
Larsson 1987b	1	10	1	12	1.6%	1.20 [0.09 , 16.84]	
Larsson 1990	6	31	0	17	1.4%	7.31 [0.44 , 122.42]	
Larsson 1996	9	13	1	13	2.8%	9.00 [1.32 , 61.24]	<b>_</b>
Osterhaus 1997	13	25	0	14	1.5%	15.58 [1.00 , 243.71]	
Sartory 1998	20	30	5	13	11.2%	1.73 [0.83 , 3.61]	<b></b>
Scharff 2002	7	13	1	23	2.6%	12.38 [1.71 , 89.86]	
Subtotal (95% CI)		246		191	70.5%	2.86 [1.73 , 4.72]	
Fotal events:	135		31				•
Heterogeneity: Tau <sup>2</sup> = 0.3	82; Chi <sup>2</sup> = 23.	42, df = 12	2 (P = 0.02)	; I <sup>2</sup> = 49%			
Test for overall effect: Z	= 4.10 (P < 0.)	.0001)					
1.1.2 N > 20							
McGrath 1992	26	47	6	25	11.0%	2.30 [1.10 , 4.85]	
Powers 2013	42	64	26	71	18.5%	1.79 [1.26 , 2.55]	-
Subtotal (95% CI)		111		96	29.5%	1.88 [1.36 , 2.58]	
Total events:	68		32			-	•
Heterogeneity: $Tau^2 = 0.0$	00; Chi <sup>2</sup> = 0.3	7, df = 1 (1	P = 0.54); I	$^{2} = 0\%$			
Test for overall effect: Z	= 3.87 (P = 0.	.0001)					
Total (95% CI)		357		287	100.0%	2.35 [1.67 , 3.30]	
Total events:	203		63				
Heterogeneity: Tau <sup>2</sup> = 0.1	3; Chi <sup>2</sup> = 22.	62, df = 14	4(P = 0.07)	; I <sup>2</sup> = 38%			0.01 0.1 1 10
Test for overall effect: Z							Favours control Favours tre

Test for subgroup differences:  $Chi^2 = 1.92$ , df = 1 (P = 0.17), I<sup>2</sup> = 47.9%

#### Subgroup analysis:

We found 13 studies (n = 437) that included fewer than 20 participants per arm for a beneficial reduction in headache frequency post-treatment (RR 2.86; 95% CI 1.73 to 4.72, P < 0.01; NNTB = 2.59). Two studies (McGrath 1992; Powers 2013; n = 207), including more than 20 participants per arm, also had a beneficial effect on reducing headache frequency (RR 1.88, 95% CI 1.36 to 2.58, P < 0.01; NNTB = 3.58).

#### Disability, post-treatment

We included six studies with 446 participants in the analysis of the effects of treatment on disability (Chen 2014; Hechler 2014; Hickman 2015; Palermo 2016; Powers 2013; Wicksell 2009). Overall, we did not find a beneficial effect of psychological therapies on reducing disability in children with headache (Standardised mean difference (SMD) -0.26, 95% Cl -0.56 to 0.03, P = 0.08; Analysis 1.2). The GRADE quality rating for this outcome was very low, downgraded due to limitations in the design, unexplained heterogeneity, and for sparse data.

#### Subgroup analysis:

First, in two studies (Hickman 2015; Wicksell 2009, n = 61) that included fewer than 20 participants per arm, we did not find a beneficial effect of psychological treatment (SMD 0.04, 95% CI -0.47 to 0.54, P = 0.88). Second, for studies that included more than 20 participants per arm (Chen 2014; Hechler 2014; Palermo 2016; Powers 2013, n = 385), we found a medium beneficial effect of treatment on reducing disability (SMD -0.35, 95% CI -0.69 to 0.00, P = 0.05).



#### Depression, post-treatment

We entered six studies with 400 participants in an analysis of the effects of treatment on depression (Griffiths 1996; Hechler 2014; Hickman 2015; Palermo 2016; Powers 2013; Wicksell 2009). We found psychological therapies did not show a beneficial effect for reducing depression for children with headache (SMD -0.08, 95% CI -0.28 to 0.11, P = 0.41; Analysis 1.3). We judged this outcome as having a very low-quality rating, meaning we have very little confidence in the effect estimate. We downgraded the outcome due to limitations of study design, high probability of publication bias, and sparse data.

#### Subgroup analyses:

We found three trials that included fewer than 20 participants per arm (Griffiths 1996; Hickman 2015; Wicksell 2009, n = 103) but did not find a beneficial effect of therapy on depression (SMD -0.16, 95% CI -0.68 to 0.35, P = 0.53). In three studies that included more than 20 participants per arm (Hechler 2014; Palermo 2016; Powers 2013, n = 297), we found no beneficial effect of treatment on depression (SMD -0.06, 95% CI -0.29 to 0.17; P = 0.60).

#### Anixety, post-treatment

We entered data from seven studies with 439 participants into an analysis of the effects of treatment on anxiety at posttreatment (Bussone 1998; Griffiths 1996; Hechler 2014; Hickman 2015; Palermo 2016; Powers 2013; Wicksell 2009). We found no beneficial effect for psychological therapies (SMD -0.11, 95% CI -0.39 to 0.17, P = 0.43; Analysis 1.4). We have low confidence in this estimate of effect, meaning our confidence in the effect estimate was limited; the true effect may be substantially different from the estimate of the effect. We judged the quality of evidence to be very low due to limitations in study design, unexplained heterogeneity, high probability of publication bias, and asymmetrical funnel plot.

#### Subgroup analyses:

We found four studies that included fewer than 20 participants per arm (Bussone 1998; Griffiths 1996; Hickman 2015; Wicksell 2009, n = 136), but we found no beneficial effect of psychological treatments on reducing anxiety (SMD 0.01, 95% CI -0.54 to 0.57, P = 0.97). In three studies that included more than 20 participants (Hechler 2014; Palermo 2016; Powers 2013; n = 303), we also found no beneficial effect of treatment on reducing anxiety (SMD -0.19, 95% CI -0.49 to 0.11; P = 0.21)

#### Adverse events

Out of the 23 headache studies, Larsson 1990, Palermo 2016, Powers 2013, and Wicksell 2009 reported adverse events. Larsson 1990 reported four adverse events in relation to medications that were part of the trial. All participants dropped out. Palermo 2016 reported that there were no study-related adverse events. Powers 2013 categorised adverse events into different grades dependent on severity. There were 199 adverse events in total, although the authors did not state how many were due to the psychological intervention. However, this trial delivered amitriptyline to participants. There was no difference in the severity of events between the cognitive behaviour therapy (CBT) and headache education group. Wicksell 2009 reported that two participants dropped out due to adverse events associated with amitriptyline.

#### Treatment versus control (headache) follow-up

#### Headache frequency, follow-up

We entered data from five studies of 223 participants into analysis of the effects of treatment on headache frequency at followup (Labbe 1984; Larsson 1987a; Larsson 1987b; Larsson 1996; Powers 2013). This analysis produced a RR of 2.73 (95% CI 0.98 to 7.63; P = 0.06; Analysis 2.1), for a clinically beneficial change in pain (NNTB = 3.16). Using the GRADE criteria, pain at followup was based on studies having very low-quality, meaning we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. We downgraded the outcome due to limitations in the design, unexplained heterogeneity, imprecision of results and sparse data, high probability of publication bias, and asymmetrical funnel plot.

#### Subgroup analyses:

Out of the five trials included in the analysis, four included fewer than 20 participants per arm (Labbe 1984; Larsson 1987a; Larsson 1987b; Larsson 1996; n = 99), and we found a beneficial effect of psychological treatments at reducing headache frequency (RR = 3.49, 95% Cl 1.31 to 9.26; P = 0.01; NNTB = 1.77). Only one study (Powers 2013) could be included in the second subgroup analysis, therefore we did not report the findings.

#### Disability, follow-up

We included data from three studies with 209 participants in the analysis to determine the effects of treatment on disability at follow-up (Palermo 2016; Powers 2013; Wicksell 2009). Psychological therapies appeared to indicate a medium beneficial effect for reducing disability at follow-up (SMD -0.37, 95% CI -0.65 to -0.10, P < 0.01; Analysis 2.2). We judged the quality of evidence for this outcome as very low, which we downgraded, due to high probability of publication bias and sparse data.

#### Subgroup analyses:

Due to the small number of studies included in this analysis, we could not conduct a subgroup analysis for studies including fewer than 20 participants per arm. For studies including more than 20 participants per arm, we included two studies (Palermo 2016; Powers 2013; n = 185). We found a medium effect on disability at follow-up (SMD -0.36, 95% CI -0.65 to -0.07; P = 0.02).

#### Depression, follow-up

We found three studies that assessed depression at follow-up (Palermo 2016; Powers 2013; Wicksell 2009, n = 228). We did not find a beneficial effect of psychological treatments for reducing depression at follow-up (SMD -0.05, 95% CI -0.62 to 0.52, P = 0.86; Analysis 2.3). We judged the quality of evidence as very low, downgraded due to unexplained heterogeneity and imprecision of the result.

#### Subgroup analyses:

Similar to disability, due to the small number of studies included in this analysis, we could not conduct a subgroup analysis for studies including fewer than 20 participants per arm. We did not find a significant effect for depression at follow-up in two studies (Palermo 2016; Powers 2013; n = 204; SMD 0.11, 95% CI -0.61 to 0.83; P = 0.76).



#### Anxiety, follow-up

We found four studies with 271 participants that assessed anxiety at follow-up (Bussone 1998; Palermo 2016; Powers 2013; Wicksell 2009). We found no beneficial effect of psychological interventions in reducing anxiety at follow-up (SMD -0.12, 95% CI -0.46 to 0.21; P = 0.47; Analysis 2.4). We judged the quality of evidence for this outcome as very low, which we downgraded due to limitations in study design and sparse data. Therefore, we were very uncertain of this estimate of effect.


#### Subgroup analyses:

We were able to conduct a subgroup analysis on studies including fewer than 20 participants per arm (Bussone 1998; Wicksell 2009, n = 67) and did not find a beneficial effect of treatment on anxiety (SMD -0.28, 95% CI -1.00 to 0.45; P = 0.45). For studies including more than 20 participants per arm, we also did not find a beneficial effect of psychological therapies on anxiety at follow-up (Palermo 2016; Powers 2013; n = 204; SMD -0.04, 95% CI -0.48 to 0.41; P = 0.88).

#### Treatment versus control (mixed chronic pain) post-treatment

#### Pain intensity

To assess the effects of psychological therapies on pain intensity post-treatment, we included 16 studies of 1210 participants (Barakat 2010; Grob 2013; Gulewitsch 2013; Hechler 2014; Humphreys 2000; Kashikar-Zuck 2005; Kashikar-Zuck 2012; Levy 2010; Levy 2017; Palermo 2016; Robins 2005; Van der Veek 2013; Van Tilburg 2009; Vlieger 2007; Wahlund 2015; Wicksell 2009) in an analysis. When analysing all studies combined, we found a moderate beneficial effect of psychological treatments on reducing pain intensity (SMD -0.43, 95% CI -0.67 to -0.19, P < 0.01; Analysis 3.1; Figure 5). According to the GRADE criteria for assessing quality of outcomes, pain post-treatment was based on studies of very low-quality, meaning we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. We downgraded the outcome twice due to unexplained heterogeneity and asymmetrical funnel plot.



		perimenta	-		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.1.1 N < 20									
Barakat 2010	16.6	16.57	17	17.29	23.21	20	5.6%	-0.03 [-0.68 , 0.61]	
Grob 2013	0.16	0.32	15	1.93	1.64	14	4.4%	-1.48 [-2.32 , -0.65]	
Gulewitsch 2013	1.6	2.45	20	4.46	2.33	18	5.2%	-1.17 [-1.86 , -0.47]	<b>_</b>
Humphreys 2000	0.77	3.04	46	4.3	2.77	15	5.8%	-1.17 [-1.79 , -0.55]	
Kashikar-Zuck 2005	4.4	1.91	13	5.92	2.04	14	4.7%	-0.74 [-1.53 , 0.04]	
Van Tilburg 2009	9	8.3	15	16.9	11.5	14	4.8%	-0.77 [-1.53 , -0.01]	
Wicksell 2009	3.6	2.3	15	5	2.9	14	4.9%	-0.52 [-1.26 , 0.22]	<b>_</b>
Subtotal (95% CI)			141			109	35.4%	-0.83 [-1.19 , -0.46]	•
Heterogeneity: Tau <sup>2</sup> = 0.1	1; Chi <sup>2</sup> = 10	).96, df = 6	6 (P = 0.09	); I <sup>2</sup> = 45%					•
Test for overall effect: Z	= 4.40 (P < 0	0.0001)							
3.1.2 N > 20									
Hechler 2014	5.7	2.4	51	5.9	2.5	52	7.5%	-0.08 [-0.47 , 0.31]	
Kashikar-Zuck 2012	5.3	2.3	57	6	1.9	57	7.6%	-0.33 [-0.70 , 0.04]	
Levy 2010	1.64	2.02	84	1.25	1.75	84	8.1%	0.21 [-0.10 , 0.51]	
Levy 2017	4.09	2.21	159	4.57	2.28	81	8.3%	-0.21 [-0.48 , 0.05]	
Palermo 2016	5.58	2.03	31	5.7	2.05	30	6.6%	-0.06 [-0.56 , 0.44]	
Robins 2005	16.19	7.76	36	19.72	9.66	25	6.5%	-0.41 [-0.92 , 0.11]	_ <b></b> +
Van der Veek 2013	23.1	15.9	52	26.51	14.38	52	7.5%	-0.22 [-0.61 , 0.16]	
Vlieger 2007	3	3.4	27	9.4	5.7	25	5.8%	-1.36 [-1.96 , -0.75]	
Wahlund 2015	4.4	1.8	28	3.7	2	29	6.5%	0.36 [-0.16 , 0.89]	+
Subtotal (95% CI)			525			435	64.6%	-0.20 [-0.45 , 0.05]	
Heterogeneity: Tau <sup>2</sup> = 0.0	)9; Chi <sup>2</sup> = 26	6.54, df = 8	B (P = 0.00	09); I <sup>2</sup> = 70	)%				•
Test for overall effect: Z	= 1.60 (P = 0	0.11)							
Total (95% CI)			666			544	100.0%	-0.43 [-0.67 , -0.19]	
Heterogeneity: Tau <sup>2</sup> = 0.1	16; Chi <sup>2</sup> = 56	5.09, df =	15 (P < 0.0	0001); I <sup>2</sup> =	73%				•
Test for overall effect: Z	2 40 (D	0.0005							

Test for subgroup differences:  $Chi^2 = 7.68$ , df = 1 (P = 0.006),  $I^2 = 87.0\%$ 

#### Subgroup analyses:

We found seven studies including 250 participants (Barakat 2010; Grob 2013; Gulewitsch 2013; Humphreys 2000; Kashikar-Zuck 2005; Van Tilburg 2009; Wicksell 2009) that included fewer than 20 participants per arm. We found a large beneficial effect of psychological therapies on reducing pain intensity (SMD -0.83, 95% CI -1.19 to -0.46, P < 0.01). In contrast, we found a small but nonbeneficial effect for studies including more than 20 participants per arm on reducing pain intensity (9 studies, 960 participants; SMD -0.20, 95% CI -0.45 to 0.05; P = 0.11).



#### Disability

We found 14 studies, 1226 participants, that investigated the effects of psychological interventions on disability post-treatment (Grob 2013; Gulewitsch 2013; Hechler 2014; Humphreys 2000; Kashikar-Zuck 2005; Kashikar-Zuck 2012; Levy 2010; Levy 2016; Levy 2017; Palermo 2016; Robins 2005; Van der Veek 2013; Van Tilburg 2009; Wicksell 2009). We found a small beneficial effect of psychological therapies on reducing disability for children with chronic pain (SMD -0.34, 95% CI -0.54 to -0.15, P < 0.01; Analysis 3.2). We judged the quality of the evidence to be low, meaning our confidence in the effect estimate was limited; the true effect may be substantially different from the estimate of the effect. The outcome was downgraded once due to unexplained heterogeneity and asymmetrical funnel plot.

#### Subgroup analyses:

We found six studies including 213 participants that included fewer than 20 participants per arm. We found a large beneficial effect in this subgroup analysis for reducing disability post-treatment (SMD -0.72, 95% CI -1.17 to -0.26, P = 0.01). For the eight studies that included more than 20 participants per arm (n = 1013), we found a small beneficial effect of psychological therapies for reducing disability (SMD -0.20, 95% CI -0.37 to -0.04; P = 0.02).

#### Depression

Overall, we found eight studies with 757 participants that evaluated the effects of psychological treatment on depression (Hechler 2014; Kashikar-Zuck 2005; Kashikar-Zuck 2012; Levy 2010; Levy 2016; Palermo 2016; Van der Veek 2013; Wicksell 2009). The analysis revealed no beneficial effect of psychological therapies on depression (SMD -0.05, 95% CI -0.23 to 0.12, P = 0.54; Analysis 3.3). We judged the quality of evidence to be very low. We downgraded the outcome twice due to high probability of publication bias and asymmetrical funnel plot.

#### Subgroup analyses:

We found two studies (n = 59) that included fewer than 20 participants per arm. There was no beneficial effect of psychological treatment on depression across these two studies (SMD -0.27, 95% CI -0.95 to 0.41, P = 0.44). Similarly, we found no beneficial effect of six studies with more than 20 participants per arm that included 698 participants post-treatment, for reducing depression symptoms (SMD -0.03, 95% CI -0.21 to 0.15; P = 0.74).

#### Anxiety

We found eight studies including 957 participants that assessed the effect of psychological therapies on the outcome of anxiety post-treatment (Hechler 2014; Kashikar-Zuck 2012; Levy 2010; Levy 2016; Levy 2017; Palermo 2016; Van der Veek 2013; Wicksell 2009). The results revealed a beneficial effect of psychological therapies on anxiety in children with chronic pain, (SMD -0.16, 95% CI -0.29 to -0.03, P = 0.02; Analysis 3.4). Similar to depression, we judged the evidence for this estimate of effect as low; we downgraded the outcome twice due to high probability of publication bias.

#### Subgroup analyses:

Only one study assessed anxiety post-treatment and included fewer than 20 participants per arm, therefore we did not report the finding here. We found seven studies including 851 participants with more than 20 participants per arm. These studies indicated a small beneficial effect of psychological the rapies for reducing anxiety at post-treatment (SMD -0.17, 95% CI -0.30 to -0.04; P = 0.01).

#### Adverse events

Of the 24 mixed pain studies, six reported adverse events. Gulewitsch 2013, Kashikar-Zuck 2012, Levy 2017, Palermo 2016, and Van der Veek 2013 reported no adverse events that were study-related. Wicksell 2009reported that two participants withdrew due to adverse effects of amitriptyline, which was part of the study conditions.

#### Treatment versus control (mixed chronic pain) follow-up

#### Pain intensity

We found nine studies of 833 participants that investigated the effect of psychological treatments on pain at follow-up (Barakat 2010; Grob 2013; Hechler 2014; Kashikar-Zuck 2012; Levy 2010; Levy 2017; Palermo 2016; Van der Veek 2013; Wicksell 2009). Overall, we did not find a beneficial effect on reducing pain intensity at follow-up (SMD -0.08, 95% CI -0.30 to 0.13, P = 0.45; Analysis 4.1). The quality was very low for this outcome, meaning we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. We downgraded the outcome once due to unexplained heterogeneity, once due to high probability of publication bias and asymmetrical funnel plot.

#### Subgroup analyses:

We found two studies with 53 participants that included fewer than 20 participants per arm. We found a beneficial effect of psychological therapies on reducing pain intensity at follow-up (SMD -0.94, 95% CI -1.75 to -0.13, P = 0.02). Seven studies with 780 participants included more than 20 participants per arm but in contrast to the prior subgroup analysis, we did not find a beneficial effect for reducing pain intensity (SMD -0.00, 95% CI -0.15 to 0.14; P = 0.99).

#### Disability

Overall, we found nine studies that included 935 participants that assessed the effect of psychological interventions on disability at follow-up (Grob 2013; Hechler 2014; Kashikar-Zuck 2012; Levy 2010; Levy 2016; Levy 2017; Palermo 2016; Van der Veek 2013 Wicksell 2009). We found a beneficial effect of psychological treatments on reducing disability at follow-up (SMD -0.27, 95% CI -0.49 to -0.06, P = 0.01; Analysis 4.2). We judged the quality of evidence to be low due to unexplained heterogeneity and once due to high probability of publication bias.

#### Subgroup analyses:

We were able to conduct three subgroup analyses. For trials including fewer than 20 participants per arm, we found two studies including 53 participants. We did not find a beneficial effect of psychological treatments on disability at follow-up (SMD-1.17, 95% CI -2.60 to 0.26, P = 0.11). In seven trials including 882 participants, we found a small beneficial effect of psychological treatments for reducing disability (SMD -0.20, 95% CI -0.34 to -0.07; P < 0.01).

#### Depression

We found seven studies including 667 participants reporting on the effects of treatment on depression at follow-up (Hechler 2014; Kashikar-Zuck 2012; Levy 2010; Levy 2016; Palermo 2016; Van der Veek 2013; Wicksell 2009). We did not find a beneficial effect of

psychological therapies on depression at follow-up (SMD 0.09, 95% CI -0.10 to 0.28, P = 0.35; Analysis 4.3). We judged the quality of evidence to be very low due to unexplained heterogeneity, high probability of publication bias, and asymmetrical funnel plot.

#### Subgroup analyses:

We were only able to conduct a subgroup analysis of trials that included more than 20 participants per arm. In six studies including 643 participants, we did not find a beneficial effect of treatment for reducing depression at follow-up (SMD 0.12, 95% CI -0.06 to 0.30; P = 0.20).

#### Anxiety

Eight studies including 975 participants assessed anxiety at followup (Hechler 2014; Kashikar-Zuck 2012; Levy 2010; Levy 2016; Levy 2017; Palermo 2016; Van der Veek 2013; Wicksell 2009). We did not find a beneficial effect of psychological therapies on anxiety outcomes at follow-up (SMD 0.01, 95% CI -0.20 to 0.18, P = 0.92; Analysis 4.4). Similar to anxiety post-treatment, we have low confidence in the estimate of effect, downgraded twice due to high probability of publication bias.

#### Subgroup analyses:

We were able to conduct a subgroup analysis on studies including more than 20 participants per arm. In seven studies (n = 843) we found that psychological therapies did not have a beneficial effect on anxiety outcomes at follow-up (SMD -0.01, 95% CI -0.22 to 0.19; P = 0.89).

#### Heterogeneity

We conducted 16 analyses and found that six analyses indicated low heterogeneity, six analyses indicated moderate heterogeneity, and three analyses had considerable heterogeneity.

#### **Reporting biases**

We checked for publication bias using contour-enhanced funnel plots, tests of funnel plot asymmetry and meta-regressions including total sample size as a moderator. We conducted the analysis for all analyses conducted in the review, and we found evidence of significant funnel plot asymmetry for the following analyses:

Children and adolescents with headache:

- Headache frequency at post-treatment;
- Headache frequency at follow-up;
- Anxiety post-treatment for children.

Children and adolescents with mixed pain conditions:

- Pain intensity at post-treatment;
- Pain intensity at follow-up;
- Disability at post-treatment;
- Depression at post-treatment;
- Depression at follow-up.

Funnel plot asymmetry is not synonymous with publication bias but leads us to suspect its presence which may lead to overestimates of effectiveness, particularly where regression tests of asymmetry are statistically significant. However, there was no evidence of statistically significant linear relationships between effect size and sample size for these analyses, with the exception of pain intensity in children with mixed pain conditions at posttreatment.

#### **Quality of evidence**

The quality of evidence was assessed separately for headache and mixed pain condition studies using the GRADE criteria. For headache conditions, we judged all outcomes as being based on studies of low or very low-quality meaning we were very uncertain of the estimates and that future research is very likely to have an important impact on the estimate of effect (Summary of findings table 1). We judged the outcomes of pain post-treatment and at follow-up, disability at follow-up and anxiety at follow-up as being based on studies of very low-quality. We judged disability, anxiety, and depression post-treatment as being based on studies of lowquality. For mixed pain conditions, we judged all outcomes as lowquality or very low-quality (Summary of findings table 2).

#### Sensitivity analyses

We conducted sensitivity analyses on three analyses that included more than 10 studies: pain outcomes in children with headache pain and mixed chronic pain, and disability in children with mixed chronic pain. All analyses were conducted at post-treatment (Table 3). We did not find any differences in the beneficial effects of treatment. For children with headache, the sensitivity analysis indicated a beneficial effect (RR 2.79, 95% CI 2.01 to 3.89; participants = 325; studies = 15; I<sup>2</sup> = 56%), although heterogeneity remained high. Similar findings were found for children with mixed pain conditions for pain post-treatment (SMD -0.57, 95% CI -0.90 to -0.24, I<sup>2</sup> = 74%, 11 studies, 671 participants, P < 0.001) and disability post-treatment (SMD -0.37, 95% CI -0.64 to -0.11, I<sup>2</sup> = 60%, 9 studies, 687 participants, P < 0.001). Please see Appendix 2 for results regarding model over-fitting for the sensitivity analyses.

#### DISCUSSION

#### Summary of main results

We assessed the evidence for psychological therapies on pain, disability, anxiety, and depression in children and adolescents with chronic pain. We found 10 new trials and included an additional 869 participants in this update, resulting in 47 randomised controlled trials (end of treatment, N = 2884). In each update, the author team discussed the validity of the inclusion and exclusion criteria. We were aware that small studies are a significant problem in pain research (Moore 2013) and sought, wherever possible, to increase the accuracy of our review by controlling for the imprecision inherent in small n studies. In this case, the trade-off between accuracy and comprehensiveness was considered and we decided to retain the previous criteria (included studies should have a minimum of 10 participants per arm). For transparency, however, we decided to present subgroup analyses. We undertook subgroup analyses of those studies with fewer than 20 participants per arm, and those with more, allowing for an indirect comparison between analyses based on sample size. Typically, the studies with fewer participants were older or pilot studies. The majority of studies evaluated one or two treatment conditions in comparison to a waiting-list or to a treatment-as-usual control group. For the first time in the history of this review, we included a treatment that we categorised as problem-solving, adding to the previously included

behavioural and cognitive-behavioural treatments delivered to children with chronic pain. The average length of treatment in studies of headache conditions and mixed chronic pain studies was very similar, between five and seven hours. Follow-up data were increasingly being reported in more recent studies and we included these, when available.

The inclusion of new studies in this updated meta-analysis has extended the evidence base. Of the 16 possible analyses, psychological therapies were beneficial for six outcomes. For children with headache, we found psychological treatments were beneficial at reducing headache pain frequency/intensity posttreatment, but the effect was not maintained at follow-up. We found a NNTB of 2.86 for psychological therapies post-treatment, and 3.16 at follow-up for more than 50% reduction in pain frequency/intensity in children with headaches. In the sub-group analyses of more than and less than 20 participants per arm, we also found that psychological therapies demonstrated beneficial effects on reducing pain intensity. We found a beneficial effect on reducing disability at follow-up, but findings at post-treatment showed an overall null effect of psychological therapies on reducing disability. However, in the subgroup analysis including more than 20 participants per arm, we found a beneficial effect on disability whereas there was no effect in studies including fewer than 20 participants per arm. For the outcomes of depressive and anxious symptoms, we did not detect an effect at either post-treatment or follow-up.

There were similar findings for analyses investigating children with mixed pain conditions. First, we found that psychological therapies were beneficial at reducing pain intensity, disability, and anxiety post-treatment, but only the benefits for disability were maintained at follow-up. Interestingly, larger studies (> 20 per arm) did not show a beneficial effect for pain reduction at post-treatment whereas smaller studies in this analysis (< 20 per arm) indicated a large beneficial effect. In the subgroup analysis investigating disability post-treatment, we found improvements in disability, regardless of the size of the study. At follow-up, we found an overall beneficial effect for disability, but when investigating the subgroups, we found only larger studies (n > 20 participants per arm) were significant. Similar to headache conditions, no effect was found for depressive symptoms.

#### **Overall completeness and applicability of evidence**

More recent trials typically used cognitive behavioural therapy rather than behavioural therapy, likely reflecting changes in practice by psychologists entering the field of paediatric pain management. For the first time in the history of this review, we included a trial that used problem-solving therapy for parents of children with chronic pain. This is consistent with recent calls to develop and evaluate other types of therapies for children with chronic pain conditions and their families (Eccleston 2015; Law 2014).

In regard to pain conditions, this review included 23 trials of children and adolescents with headache pain, 10 abdominal pain studies, two abdominal pain and irritable bowel syndrome studies, two fibromyalgia studies, two temporomandibular disorder studies, three sickle cell disease studies, two studies with inflammatory bowel disease, and three mixed pain studies (including headache and mixed chronic pain conditions). There was limited evidence to draw conclusions about the effects of psychological treatment on disability in headache conditions. Although we found psychological therapies to be beneficial for disability outcomes, only six studies could be included in this analysis post-treatment, and three at follow-up. In addition, we were only able to include a small number of studies in the follow-up analyses for the outcomes of depression and anxiety, meaning we were unable to draw any conclusions regarding whether psychological interventions resulted in long-term changes in anxiety and depressive symptoms for children with headaches.

In 2008, consensus guidelines were published which outlined core outcome domains and measures for clinical trials of psychological interventions for children and adolescents with chronic pain (McGrath 2008). Adherence to these guidelines has increased over time. In the previous update, we encouraged trial authors to include anxiety and depression symptom measures as outcomes, in addition to pain and disability outcomes. Most of the trials included in this update did include such measures.

One limitation of this review is that we did not conduct a subgroup analysis comparing results from trials that used an active control condition versus a wait-list control condition. This has been explored in our companion review of psychological treatments for adults with pain, and findings suggested that larger effects were found when a waiting-list or treatment-as-usual control was used (Williams 2012). Thus, findings from this update may have overestimated the treatment effects, since some of the trials included in our meta-analyses used less rigorous control conditions. However, we did conduct subgroup analyses on smaller versus larger trials based on the number of participants.

#### **Quality of the evidence**

We judged the quality of the evidence to be low or very low for all outcomes. The primary reason for low and very low judgements for studies treating children with headache was due to high risk of bias, high levels of heterogeneity, suspicion of publication bias, and most studies did not assess depression and anxiety outcomes. With regards to low and very low judgements for mixed pain conditions, we found high levels of heterogeneity in the analyses and a large proportion of studies did not report on the outcomes. Therefore, this evidence is likely to change when more data are available and interpretations should be made cautiously.

There was widespread evidence of funnel plot asymmetry leading us to suspect publication bias in many of our findings. This means that it is likely there are unpublished studies investigating psychological therapies for children with chronic pain conditions. This has resulted in reductions in the strength of evidence for many outcomes but the impact of the potential bias is unknown. For the pain intensity for children with mixed pain, there was strong evidence of small study effects, suggesting that the effect size was an overestimate of effectiveness. Coupled with the high level of unexplained and clinically significant inconsistency, this resulted in low strength of the evidence for this combination of population, intervention, and outcome.

#### Potential biases in the review process

We have conducted searches of four large databases, we checked the reference lists and conducted citation searches of included studies, and searched trial registries for studies. Therefore, we think it is unlikely that we have missed any published, randomised

Cochrane Library

controlled trials eligible for this review. An author of this review conducted one trial included in this update. Review authors not involved in the trial or the publication of the trial extracted data and conducted 'risk of bias' assessments for this trial.

## Agreements and disagreements with other studies or reviews

The findings from this review largely supports findings from previous updates of this review (Eccleston 2003; Eccleston 2009; Eccleston 2012; Eccleston 2014). It also supports the findings of the sister review that investigated remotely delivered trials to children with chronic pain (Fisher 2015). Further, a separate systematic review, that included all trials that delivered psychological therapies to children with chronic pain, also supports the majority of the findings here (Fisher 2014). However, in the current review we found beneficial effects at follow-up on disability for children with mixed pain conditions, whereas Fisher 2014 did not find beneficial effects at follow-up. There are also reviews of individual pain conditions in the field. A systematic review investigating children with migraine found beneficial effects of migraine posttreatment and at follow-up (Ng 2017). A review investigating rheumatic diseases did not have enough data to combine in a metaanalysis and found conflicting evidence (Cohen 2017). Similarly, a review investigating sickle cell disease (Anie 2015) identified five studies but a meta-analysis could not be conducted. Results from individual studies indicated that cognitive behavioural therapy was not beneficial at reducing pain outcomes in this population. No studies reported on mood, and disability was not assessed in children with sickle cell disease (Anie 2015). Finally, a review investigating recurrent abdominal pain did not find a significant reduction in pain intensity at short-term follow-up for children and adolescents receiving CBT, but significant beneficial effects were identified for children with recurrent abdominal pain receiving hypnotherapy (Abbott 2017). Despite some disagreement with findings in this review, Abbott 2017 included fewer studies, due to only including children with abdominal pain. Therefore, this may indicate that psychological therapies may have different effects for different populations. Further, in agreement with this review, Abbott 2017 found no beneficial effect for improving anxiety and depressive symptoms.

#### AUTHORS' CONCLUSIONS

#### Implications for practice

#### For children and adolescents with chronic pain

Most therapies that have been delivered to children and adolescents with chronic pain, their parents, or both, are cognitive behavioural therapy or behavioural therapy. We found that these psychological therapies are effective for reducing pain for children with headaches, and reducing pain intensity and disability in children with mixed chronic pain conditions. However, most effects were not maintained at follow-up, with the exception of disability for children with mixed chronic pain conditions. The treatments had no positive effect on anxiety or depression immediately after treatment or at follow-up. Quality issues in these trials reduced our confidence in the effect estimates, meaning that new studies could substantially alter the findings.

#### For clinicians

Taken together, these findings suggested that behavioural and cognitive-behavioural treatment should be considered as part of standard care for children and adolescents with chronic pain conditions to improve pain and reduce disability. We did not find any beneficial effects for the outcomes of depression at any time point, and only for anxiety in mixed pain conditions posttreatment. This lack of effect may be due to the fact that anxiety and depression are typically not a specific intervention target of cognitive and behavioural pain management interventions, and enrolled youth had varying levels of anxiety and depression (including many youth with nonclinical levels of anxiety and depression). We also found two trials (n = 277 participants across both trials) that delivered therapy to parents of children with chronic pain, but these should be interpreted with caution. Further data are needed to understand possible downstream effects for children.

#### For policy makers

The quality of evidence for psychological therapies to reduce pain, disability, anxiety, and depression was mostly low or very low, meaning our confidence in the effect estimate is limited, open to change with future study, and, therefore, should be interpreted with caution. A sister review (Eccleston 2015) included an analysis investigating parent interventions for children with chronic pain and found beneficial effects on parent mental health and behaviour as well as child outcomes. However, the downstream effects for children with chronic pain in trials that only included parents are unknown. More studies will determine this, but this type of treatment could be beneficial for both parent and child.

#### Implications for research

#### General

Since the original version of this review, there has been an improvement in the evidence base by the addition of new studies, including additional studies of youth with a variety of chronic pain conditions and the development of treatments that target parents as well as children. We also conducted new subanalyses to evaluate outcomes in larger versus smaller trials. The author team will continue to consider the following changes in the next version of the review.

- Splitting the title into two: one for headache only and one for mixed pain conditions.
- Exploring the possibility of subgroup analyses to try to identify variance attributable to nonspecific factors which can affect treatment outcome, such as type of therapy.
- Exploring the possibility of subgroup analyses by pain condition (e.g. recurrent abdominal pain versus musculoskeletal pain versus headache).
- Exploring the possibility of subgroup analyses to try to identify whether effects differ by type of comparator (e.g. wait-list versus active comparators).

#### Design

Methodologically, there were challenges in this review with trial designs. The majority of included studies were relatively small randomised controlled trials, recruiting fewer than 100 participants. Most trials have evaluated the efficacy of treatment



for children with headache, while few trials have been conducted in young people with other chronic pain conditions (e.g. complex regional pain syndrome, sickle cell disease, arthritis). Indeed, it was unclear whether children had different treatment needs, depending on the characteristics of their pain problem, or if a one-size-fits-all approach is appropriate. Treatments tailored to children and adolescents to treat distress before working to reduce pain and disability might find larger effect sizes. Finally, we still do not know the active ingredient of psychological therapies. More detailed description of treatments and inclusion of process measures would help to identify active components of therapies, and allow the development of more targeted interventions for this population. In this update, one trial used problem-solving therapy delivered to parents of children with chronic pain (Palermo 2016). Divergence from traditional cognitive behavioural therapy and from models where the child is the treatment target may be beneficial, and we encourage further exploration of these alternatives in future trials.

#### Measurement

Although guidelines for measurement in clinical trials for young people with chronic pain have been published (McGrath 2008), consensus between researchers and clinicians is still needed with regards to gold standard measures of disability, depression, and anxiety. This would reduce the heterogeneity of analyses. Sensitivity to change should be a core psychometric property for measures used in randomised controlled trials (Fisher 2017). Further, clinically meaningful change should be established for outcomes used in trials to help interpret whether therapies are achieving meaningful change for participants. Researchers and clinicians have previously agreed on headache outcomes for young

people. There is consensus amongst headache researchers and clinicians that 50% reduction in headache frequency is clinically meaningful and should be used as a primary outcome in headache trials. However, such consensus has not been reached for other pain characteristics and for other pain conditions. Finally, adverse events should be reported in every trial. Although more trials reported adverse events in this update, this was not universal. Development of a common measure of adverse events might encourage more widespread use and reporting of this outcome.

#### ACKNOWLEDGEMENTS

We would like to thank Stephen Morley (deceased), Amy Lewandowski, and Amanda Williams for their contributions to the original review and previous updates.

We would like to thank Kiki Mastroyannopoulou and Louise Yorke for their contributions to the original version of this review. Thank you also to Hannah Somhegyi for help with coding and data management during previous versions of this review. Thanks to Jane Hayes and Jo Abbott for running the updated searches. Finally, thanks also go to the PaPaS review group team and to the peer referees for their helpful comments.

Cochrane Review Group funding acknowledgement: this project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health.

#### REFERENCES

#### References to studies included in this review

#### Abram 2007 {published data only}

Abram HS, Buckloh LM, Schilling LS, Armatti Wiltrout S, Ramirez-Garnica G, Turk WR. A randomized, controlled trial of a neurological and psychoeducational group appointment model for pediatric headaches. *Children's Healthcare* 2007;**36**:249-65.

#### Alfven 2007 {published data only}

Alfven G, Lindstrom A. A new method for the treatment of recurrent abdominal pain of prolonged negative stress origin. *Acta Paediatrica* 2007;**96**:76-81.

#### Barakat 2010 {published data only}

Barakat LP, Schwartz LA, Salamon KS, Radcliffe J. A familybased randomized controlled trial of pain intervention for adolescents with sickle cell disease. *Journal of Pediatric Hematology/Oncology* 2010;**32**(7):540-7.

#### Barry 1997 {published data only}

Barry J, Von Baeyer CL. Brief cognitive-behavioral group treatment for children's headache. *Clinical Journal of Pain* 1997;**13**:215-20.

#### Bussone 1998 {published data only}

Bussone G, Grazzi L, D'Amico D, Leone M, Andrasik F. Biofeedback-assisted relaxation training for young adolescents with tension-type headache: a controlled study. *Cephalalgia* 1988;**18**:463-7.

#### Chen 2014 {published data only}

Chen YZ, Li N, Zhou KY. Preventive effect of behavioral therapy plus flunarizine in children with migraine. *Chinese Journal of Contemporary Pediatrics* 2014;**16**(11):1105-8.

#### Cottrell 2007 {published data only}

Cottrell C, Drew J, Gibson J, Holroyd, K, O'Donnell F. Feasibility assessment of telephone-administered behavioral treatment for adolescent migraine. *Headache* 2007;**47**:1293-302.

#### Daniel 2015 {published data only}

Daniel LC, Li Y, Smith K, Tarazi R, Robinson R, Patterson CA, et al. Lessons learned from a randomized controlled trial of a family-based intervention to promote school functioning for school-age children with sickle cell disease. *Journal of Pediatric Psychology* 2015;**40**(10):1085-94.

#### Duarte 2006 {published data only}

Duarte MA, Penna FJ, Andrade EM, Cancela CSP, Neto JCA, Barbosa TF. Treatment of nonorganic recurrent abdominal pain: cognitive-behavioral family intervention. *Journal of Pediatric Gastroenterology and Nutrition* 2006;**43**:59-64.

#### Fichtel 2001 {published data only}

Fichtel A, Larsson B. Does relaxation treatment have differential effects on migraine and tension-type headache in adolescents. *Headache* 2001;**41**:290-6.

#### **Gil 1997** {*published data only*}

Gil KM, Wilson JJ, Edens JL, Workman E, Ready J, Sedway J, et al. Cognitive coping skills training in children with sickle cell disease pain. *International Journal of Behavioural Medicine* 1997;**4**:364-77.

#### Greenley 2015 {published data only}

Greenley RA, Gumidyala AP, Nguyen E, Plevinsky JM, Poulopoulos N, Thomason MM, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. *Inflammatory Bowel Disease* 2015;**21**:2649-57.

#### Griffiths 1996 {published data only}

Griffiths JD, Martin PR. Clinical versus home-based treatment formats for children with chronic headache. *British Journal of Health Psychology* 1996;**1**:151-66.

#### Grob 2013 {published data only}

Grob M, Warschburger P. Evaluation of a cognitive-behavioral pain management program for children with chronic abdominal pain: a randomized controlled study. *International Journal of Behavioral Medicine* 2013;**20**:434-43. [DOI: 10.1007/ s12529-012-9228-3]

#### Gulewitsch 2013 {published data only}10.1007/ s00431-013-1990-y

Gulewitsch MD, Muller J, Hautzinger M, Schlarb AA. Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial. *European Journal of Pediatrics* 2013;**172**:1043-51.

#### Hechler 2014 {published data only}

Hechler T, Ruhe A, Schmidt P, Hirsch J, Wager J, Dobe M, et al. Inpatient-based intensive interdisciplinary pain treatment for highly impaired children with severe chronic pain: randomized controlled trial of efficacy and economic effects. *Pain* 2014;**155**:118-28.

#### Hickman 2015 {published data only}

Hickman C, Jacobson D, Melnyk B. Randomized controlled trial of the acceptability, feasibility, and preliminary effects of a cognitive behavioral skills building intervention in adolescents with chronic daily headaches: a pilot study. *Journal of Pediatric Health Care* 2015;**29**(1):5-16.

#### Humphreys 2000 {published data only}

Humphreys PA, Gevirtz RN. Treatment of recurrent abdominal pain: components analysis of four treatment protocols. *Journal of Pediatric Gastroenterology and Nutrition* 2000;**31**:47-51.

#### Kashikar-Zuck 2005 {published data only}

Kashikar-Zuck S, Swain NF, Jones BA, Graham TB. Efficacy of cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. *Journal of Rheumatology* 2005;**32**:1594-602.



#### Kashikar-Zuck 2012 {published data only}

Kashikar-Zuck S, Sil S, Lynch-Jordan AM, Ting TV, Peugh J, Schikler KN, et al. Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgia. *Journal of Pain* 2013;**14**(5):492-501.

\* Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham B, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia. *Arthritis & Rheumatism* 2012;**64**(1):297-305.

#### Kroener-Herwig 2002 {published data only}

Kroener-Herwig B, Denecke H. Cognitive-behavioral therapy of pediatric headache: are there differences in efficacy between a therapist-administered group training and a self-help format? *Journal of Psychosomatic Research* 2002;**53**:1107-14.

#### Labbe 1984 {published data only}

Labbe EE, Williamson DA. Treatment of childhood migraine using autogenic feedback training. *Journal of Consulting and Clinical Psychology* 1984;**52**(6):968-76.

#### Labbe 1995 {published data only}

Labbe EE. Treatment of childhood migraine with autogenic training and skin temperature biofeedback: a component analysis. *Headache* 1995;**35**:10-3.

#### Larsson 1987a {published data only}

Larsson B, Daleflod B, Hakansson L, Melin L. Therapist-assisted versus self-help relaxation treatment of chronic headaches in adolescents: a school-based intervention. *Journal of Child Psychology* 1987;**28**(1):127-36.

#### Larsson 1987b {published data only}

Larsson B, Melin L, Lamminen M, Ullstedt F. A school-based treatment of chronic headaches in adolescents. *Journal of Pediatric Psychology* 1987;**12**(4):553-66.

#### Larsson 1990 {published data only}

Larsson B, Melin L, Doberl A. Recurrent tension headache in adolescents treated with self-help relaxation training and a muscle relaxant drug. *Headache* 1990;**30**:665-71.

#### Larsson 1996 {published data only}

Larsson B, Carlsson J. A school-based, nurse-administered relaxation training for children with chronic tension-type headache. *Journal of Pediatric Psychology* 1996;**21**(5):603-14.

#### Levy 2010 {published data only}

\* Levy RL, Langer SL, Walker LS, Romano JM, Christie DL, Youssef N, et al. Cognitive-behavioral therapy for children with functional abdominal pain and their parents decreases pain and other symptoms. *American Journal of Gastroenterology* 2010;**105**(4):946-56.

Levy RL, Langer SL, Walker LS, Romano JM, Christie DL, Youssef N, et al. Twelve-month follow-up of cognitive behavioral therapy for children with functional abdominal pain. *JAMA Pediatrics* 2013;**167**(2):178-84.

#### Levy 2016 {published data only}

Levy RL, Van Tilburg MAL, Langer SL, Romano JM, Walker LS, Mancl LA, et al. Effects of a cognitive behavioral therapy intervention trial to improve disease outcomes in children with inflammatory bowel disease. *Inflammatory Bowel Diseases* 2016;**22**(9):2134-48.

#### Levy 2017 {published data only}

Levy RL, Langer SL, Van Tilburg MAL, Romano JM, Murphy TB, Walker LS, et al. Brief telephone-delivered cognitive behavioral therapy targeted to parents of children with functional abdominal pain: a randomized controlled trial. *Pain* 2017;**158**:618-28.

#### McGrath 1988 {published data only}

McGrath PJ, Humphreys P, Goodman JT, Keene D, Firestone P, Jacob P, et al. Relaxation prophylaxis for childhood migraine: a randomized placebo-controlled trial. *Developmental Medicine* and Child Neurology 1988;**30**:626-31.

#### McGrath 1992 {published data only}

McGrath PJ, Humphreys P, Keene D, Goodman JT, Lascelles MA, Cunningham SJ, et al. The efficacy and efficiency of a selfadministered treatment for adolescent migraine. *Pain* 1992;**49**:321-4.

#### Osterhaus 1997 {published data only}

Osterhaus SOL, Lange A, Linssen WHJP, Passchier J. A behavioral treatment of young migrainous and nonmigrainous headache patients: prediction of treatment success. *International Journal of Behavioral Medicine* 1997;**4**(4):378-96.

#### Palermo 2016 {published data only}

Palermo TM, Law EF, Bromberg M, Fales J, Ecceston C, Wilson AC. Problem-solving skills training for parents of children with chronic pain: a pilot randomized controlled trial. *Pain* 2016;**157**:1213-23.

#### Passchier 1990 {published data only}

Passchier J, Van Den Bree MBM, Emmen HH, Osterhaus SOL, Orlebeke JF, Verhage F. Relaxation training in school classes does not reduce headache complaints. *Headache* 1990;**30**:660-4.

#### Powers 2013 {published data only}

Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents. A randomized clinical trial. *JAMA* 2013;**310**(24):2622-30. [DOI: 10.1001/ jama.2013.282533]

#### Richter 1986 {published data only}

Richter IL, McGrath PJ, Humphreys PJ, Goodman JT, Firestone P, Keene D. Cognitive and relaxation treatment of paediatric migraine. *Pain* 1986;**25**:195-203.

#### Robins 2005 {published data only}

Robins PM, Smith SM, Glutting JJ, Bishop CT. A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain. *Journal of Pediatric Psychology* 2005;**30**:397-408.



#### Sanders 1994 {published data only}

Sanders MR, Shepherd RW, Cleghorn G, Woolford H. The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care. *Journal of Consulting and Clinical Psychology* 1994;**62**(2):306-14.

#### Sartory 1998 {published data only}

Sartory G, Muller B, Metsch J, Pothmann R. A comparison of psychological and pharmacological treatment of pediatric migraine. *Behaviour Research and Therapy* 1998;**36**:1155-70.

#### Scharff 2002 {published data only}

Scharff L, Marcus DA, Masek BJ. A controlled study of minimalcontact thermal biofeedback treatment in children with migraine. *Journal of Pediatric Psychology* 2002;**27**:109-19.

#### Van der Veek 2013 {published data only}

Van der Veek SMC, Derkx BHF, Benninga MA, Boer F, De Haan E. Cognitive behavior therapy for pediatric functional abdominal pain: a randomized controlled trial. *Pediatrics* 2013;**132**(5):e1163-72. [DOI: 10.1542/peds.2013-0242]

#### Van Tilburg 2009 {published data only}

Van Tilburg MAL, Chitkara DK, Palsson OS, Turner M, Blois-Martin N. Audio-recorded guided imagery treatment reduces functional abdominal pain in children: a pilot study. *Pediatrics* 2009;**124**(5):e890-7.

#### Vlieger 2007 {published data only}

Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC, Tromp E, Benninga MA. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. *Gastroenterology* 2007;**133**:1430-6.

#### Wahlund 2003 {published data only}

Wahlund K, List, T, Larsson B. Treatment of temporomandibular disorders among adolescents: a comparison between occlusal appliance, relaxation training, and brief information. *Acta Odontologica Scandinavica* 2003;**34**(4):203-11.

#### Wahlund 2015 {published data only}

Wahlund K, Nilsson I, Larsson B. Treating temporomandibular disorders in adolescents: a randomized, controlled, sequential comparison of relaxation training and occlusal appliance therapy. *Journal of Oral & Facial Pain and Headache* 2015;**29**:41-50.

#### Wicksell 2009 {published data only}

Wicksell RK, Melin L, Lekander M, Olsson GL. Evaluating the effectiveness of exposure and acceptance strategies to improve functioning and quality of life in longstanding pediatric pain - a randomized controlled trial. *Pain* 2009;**141**:248-57.

#### References to studies excluded from this review

#### Connelly 2006 {published data only}

Connelly M, Rapoff MA, Thompson N, Connelly W. Headstrong: a pilot study of a CD-ROM intervention for recurrent pediatric headache. *Journal of Pediatric Psychology* 2006;**31**:737-47.

#### Fentress 1986 {published data only}

Fentress DW, Masek BJ, Mehegan JE, Benson H. Biofeedback and relaxation-response training in the treatment of pediatric migraine. *Developmental Medicine and Child Neurology* 1986;**28**:139-46.

#### Gulewitsch 2017 {published data only}

Gulewitsch MD, Schlarb AA. Comparison of gut-directed hypnotherapy and unspecific hypnotherapy as self-help format in children and adolescents with functional abdominal pain or irritable bowel syndrome: a randomized pilot study. *European Journal of Gastroenterology & Hepatology* 2017;**29**:1351-60.

#### Hicks 2006 {published data only}

Hicks CL, Von Baeyer CL, McGrath PJ. Online psychological treatment for pediatric recurrent pain: a randomized evaluation. *Journal of Pediatric Psychology* 2006;**31**:724-36.

#### Jastrowski Mano 2013 {published data only}

Jastro-Mano KE, Salamon KS, Hainsworth KR, Anderson-Khan KJ, Ladwig RJ, Davies WH, et al. A randomized, controlled pilot study of mindfulness-based stress reduction for pediatric chronic pain. *Alternative Therapies in Health and Medicine* 2013;**19**(6):8-14.

#### Koenig 2013 {published data only}

Koenig J, Oelkers-Ax R, Kaess M, Parzer P, Lenzen C, Hillecke TK, et al. Specific music therapy techniques in the treatment of primary headache disorders in adolescents: a randomized attention-placebo-controlled trial. *Journal of Pain* 2013;**14**(10):1196-207.

#### Korterink 2016 {published data only}

Koterink JJ, Ockeloen LE, Hilbink M, Benninga MA, Deckers-Krocken JM. Yoga therapy for abdominal pain-related functional gastrointestinal disorders in children: a randomized controlled trial. *Journal of Pediatric Gastroenterology and Nutrition* 2016;**63**(5):481-7.

#### Kroener-Herwig 1998 {published data only}

Kroner-Herwig B, Mohn U, Pothmann R. Comparison of biofeedback and relaxation in the treatment of pediatric headache and the influence of parent involvement on outcome. *Applied Psychophysiology and Biofeedback* 1998;**23**:143-57.

#### Larsson 1986 {published data only}

Larsson B, Melin L. Chronic headaches in adolescents: treatment in a school setting with relaxation training as compared with information-contact and self-registration. *Pain* 1986;**25**:325-36.

#### Olness 1987 {published data only}

Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. *Pediatrics* 1987;**79**(4):593-7.

#### Palermo 2009 {published data only}

Palermo TM, Wilson AC, Peters M, Lewandowski A, Somhegyi H. Randomized controlled trial of an internet delivered family cognitive behavioral therapy intervention for children and adolescents with chronic pain. *Pain* 2009;**146**(1-2):205-13.



#### Rapoff 2014 {published data only}

Rapoff MA, Connelly M, Bickel JL, Powers SW, Hershey AD, Allen JR, et al. Headstrong intervention for pediatric migraine headache: a randomized clinical trial. *Journal of Headache and Pain* 2014;**15**(1):1-10.

#### Rutten 2017 {published data only}

Rutten J, Vlieger AM, Frankenhuis C, George EK, Groeneweg M, Norbrius OF, et al. Home-based hypnotherapy self-exercises vs individual hypnotherapy with a therapist for treatment of pediatric irritable bowel syndrome, functional abdominal pain, or functional abdominal pain syndrome: a randomized clinical trial. *JAMA* 2017;**171**(5):470-7.

#### Sanders 1989 {published data only}

Sanders MR, Rebgetz M, Morrison M, Bor W, Gordon A, Dadds M, et al. Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects. *Journal of Consulting and Clinical Psychology* 1989;**57**(2):294-300.

#### Stinson 2010 {published data only}

Stinson JN, McGrath PJ, Hodnett ED, Feldman BM, Duffy CM, Huber AM, et al. An internet-based self-management program with telephone support for adolescents with arthritis: a pilot randomized controlled trial. *Journal of Rheumatology* 2010;**37**(9):1944-52.

#### Trautmann 2008 {published data only}

Trautmann E, Kroner-Herwig B. Internet-based self-help training for children and adolescents with recurrent headache: a pilot study. *Behavioural and Cognitive Psychotherapy* 2008;**36**:241-5.

#### Trautmann 2010 {published data only}

Trautmann E, Kroner-Herwig B. A randomized controlled trial of internet-based self-help training for recurrent headache in childhood and adolescence. *Behaviour Research and Therapy* 2010;**48**:28-37.

#### Vlieger 2012 {published data only}

Vlieger AM, Rutten JMTM, Govers AMAO, Frankenhuis C, Benninga MA. Long-term follow-up of gut-directed hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome. *American Journal* of Gastroenterology 2012;**107**:627-31.

#### Weydert 2006 {published data only}

Weydert JA, Shapiro DE, Acra SA, Monheim CJ, Chambers AS, Ball TM. Evaluation of guided imagery as treatment for recurrent abdominal pain in children: a randomized controlled trial. *BMC Pediatrics* 2006;**6**(29):1-10.

#### Youssef 2009 {published data only}

Youssef NN, Van Tilburg MA, Matta EN, Langseder A, Whitehead WE. Feasibility and efficacy of pilot study investigating a school nurse administered guided imagery program for childhood functional abdominal pain. *Gastroenterology* 2009;**136**(5):156-7.

#### **Additional references**

#### Abbott 2017

Abbott RA, Martin AE, Newlove-Delgado TV, Bethel A, Thompson-Coon J, Whear R, et al. Psychosocial interventions for recurrent abdominal pain in childhood. *Cochrane Database of Systematic Reviews* 2017, Issue 1. Art. No: CD010971. [DOI: 10.1002/14651858.CD010971.pub2]

#### Anie 2015

Anie KA, Green J. Psychological therapies for sickle cell disease and pain. *Cochrane Database of Systematic Reviews* 2015, Issue 5. Art. No: CD001916. [DOI: 10.1002/14651858.CD001916.pub3]

#### Cohen 1992

Cohen J. A power primer. *Psychological Bulletin* 1992;**112**(1):155-9.

#### Cohen 2017

Cohen EM, Morley-Fletcher A, Mehta DH, Lee YC. A systematic review of psychosocial therapies for children with rheumatic diseases. *Pediatric Rheumatology* 2017;**15**(6):1-9.

#### Cooper 2017a

Cooper TE, Fisher E, Gray AL, Krane E, Sethna N, Van Tilburg MAL, et al. Opioids for chronic non-cancer pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2017, Issue 7. Art. No: CD012538. [DOI: 10.1002/14651858.CD012538.pub2]

#### Cooper 2017b

Cooper TE, Fisher E, Anderson B, Wilkinson NMR, Williams DG, Eccleston C. Paracetamol (acetaminophen) for chronic noncancer pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2017, Issue 8. Art. No: CD012539. [DOI: 10.1002/14651858.CD012539.pub2]

#### Cooper 2017c

Cooper TE, Heathcote LC, Clinch J, Gold JI, Howard R, Lord SM, et al. Antidepressants for chronic non-cancer pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2017, Issue 8. Art. No: CD012535. [DOI: 10.1002/14651858.CD012535.pub2]

#### Cooper 2017d

Cooper TE, Wiffen PJ, Heathcote LC, Clinch J, Howard R, Krane E, et al. Antiepileptic drugs for chronic non-cancer pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2017, Issue 8. Art. No: CD012536. [DOI: 10.1002/14651858.CD012536.pub2]

#### D'Zurilla 1999

D'Zurilla TJ, Nezu AM. Problem Solving Therapy: A Social Competence Approach to Clinical Intervention. 2nd edition. New York: Springer Publishing, 1999.

#### D'Zurilla 2007

D'Zurilla TJ, Nezu AM. Problem Solving Therapy: A Positive Approach to Clinical Intervention. 3rd edition. New York: Springer Publishing Company, LLC, 2007.



#### Eccleston 2015

Eccleston C, Fisher E, Law EF, Bartlett J, Palermo TM. Psychological interventions for parents of children and adolescents with chronic illness. *Cochrane Database of Systematic Reviews* 2015, Issue 4. Art. No: CD009660. [DOI: 10.1002/14651858.CD009660.pub3]

#### Eccleston 2017

Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson NMR. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2017, Issue 8. Art. No: CD012537. [DOI: 10.1002/14651858.CD012537.pub2]

#### Ernst 2015

Ernst MM, O'Brien H, Powers SW. Cognitive-behavioral therapy: how medical providers can increase patient and family openness and access to evidence-based multimodal therapy for pediatric migraine. *Headache* 2015;**55**(1-):1382-96.

#### Fisher 2014

Fisher E, Heathcote L, Palermo TM, Williams DCA, Lau J, Eccleston C. Systematic review and meta-analysis of psychological therapies for children with chronic pain. *Journal of Pediatric Psychology* 2014;**39**(8):763-82.

#### Fisher 2015

Fisher E, Law E, Palermo TM, Eccleston C. Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2015, Issue 3. Art. No: CD011118. [DOI: 10.1002/14651858.CD011118.pub2]

#### Fisher 2017

Fisher E, Heathcote LC, Eccleston C, Simons LE, Palermo TM. Assessment of pain anxiety, pain catastrophizing, and fear of pain in children and adolescents with chronic pain: a systematic review and meta-analysis. *Journal of Pediatric Psychology* 2018;**43**(3):314-25.

#### Fordyce 1968

Fordyce WE, Fowler RS Jr, Lehmann JF, DeLateur BJ. Some implications of learning on problems of chronic pain. *Journal of Chronic Disease* 1968;**21**:179-90.

#### Guyatt 2013

Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *Journal of Clinical Epidemiology* 2013;**66**:151-7.

#### Hechler 2015

Hechler T, Kanstrup M, Lewandowski Holley A, Simons LE, Wicksell R, Hirschfeld G, et al. Systematic review on intensive interdisciplinary pain treatment of children with chronic pain. *Pediatrics* 2015;**136**(1):115-27.

#### Higgins 2011

Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated Cochrane Database of Systematic Reviews

March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

#### Horst 2014

Horst S, Shelby G, Anderson J, Acra S, Polk DB, Saville BR, et al. Predicting persistence of functional abdominal pain from childhood into young adulthood. *Clinical Gastroenterology and Hepatology* 2014;**12**(12):2026-32.

#### **Huertas-Ceballos 2008**

Huertas-Ceballos A, Logan S, Bennett C, Macarthur C. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No: CD003014. [DOI: 10.1002/14651858.CD003014.pub2]

#### Keefe 2004

Keefe FJ, Rumble ME, Scipio CD, Giordano LA, Perri LM. Psychological aspects of persistent pain: current state of the science. *Journal of Pain* 2004;**5**:195-211.

#### Kibby 1998

Kibby MY, Tyc VL, Mulhern RK. Effectiveness of psychological intervention for children and adolescents with chronic medical illness: a meta-analysis. *Clinical Psychology Reviews* 1998;**18**:103-17.

#### King 2011

King S, Chamber CT, Huguet A, MacNevin RC, McGrath PJ, Parker L, et al. The epidemiology of chronic pain in children and adolescents revisited: a systematic review. *Pain* 2011;**152**:2729– 38.

#### Law 2014

Law EF, Fisher E, Fales J, Noel M, Eccleston C. Systematic review and meta-analysis of parent and family-based interventions for children and adolescents with chronic medical conditions. *Journal of Pediatric Psychology* 2014;**39**(8):866-86.

#### Law 2017

Law EF, Fisher E, Beals-Erickson S, Fisher E, Lang E, Palermo TM. Components of effective cognitive-behavioral therapy for pediatric headache: a mixed methods approach. *Clinical Practice in Pediatric Psychology* 2017;**5**(4):376-91.

#### McGrath 2008

McGrath PJ, Walco G, Turk DC, Dworkin RH, Brown MT, Davidson K, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. *Journal of Pain* 2008;**9**:771-83.

#### Moore 2013

Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. *British Journal of Anaesthesia* 2013;**111**(1):38-45.

#### Ng 2017

Ng QX, Venkatanarayanan N, Kumar L. A systematic review and meta-analysis of the efficacy of cognitive behavioral therapy for the management of pediatric migraine. *Headache: The Journal of Head and Face Pain* 2017;**57**:349-62.



#### Palermo 2005

Palermo TM, Chambers CT. Parent and family factors in pediatric chronic pain and disability: an integrative approach. *Pain* 2005;**119**:1-4.

#### Palermo 2012

Palermo TM. Cognitive-Behavioral Therapy for Chronic Pain in Children and Adolescents. New York: Oxford University Press, 2012.

#### Palermo 2014

Palermo TM, Valrie CR, Karlson CW. Family and parent influences on pediatric chronic pain: a developmental perspective. *American Psychologist* 2014;**69**(2):142-52.

#### Perquin 2000

Perquin CW, Hazebroek-Kampscheur AAJM, Hunfeld JAM, Bohnene AM, Van Suijlekom-Smit LWA, Passchier J, et al. Pain in children and adolescents: a common experience. *Pain* 2000;**87**:51-8.

#### Perquin 2001

Perquin CW, Hazebroek-Kampscheur AAJM, Hunfeld JAM, Van Suijlekom-Smit LWA, Passchier J, Van der Wouden JC. Chronic pain among children and adolescents: physician consultation and medication use. *Clinical Journal of Pain* 2001;**16**:229-35.

#### RevMan 2014 [Computer program]

Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

#### Stanford 2008

Stanford EA, Chambers CT, Biesanz JC, Chen E. The frequency, trajectories and predictors of adolescent recurrent pain: a population-based approach. *Pain* 2008;**138**:11-21.

#### Walco 1999

Walco GA, Sterling CM, Conte PM, Engel RG. Empirically supported treatments in pediatric psychology: disease related pain. *Journal of Pediatric Psychology* 1999;**24**:155-67.

#### Walker 2012

Walker LS, Sherman AL, Bruehl S, Garber J, Smith CA. Functional abdominal pain patient subtypes in childhood predict

#### CHARACTERISTICS OF STUDIES

#### **Characteristics of included studies** [ordered by study ID]

functional gastrointestinal disorders with chronic pain and psychiatric co morbidities in adolescence and adulthood.. *Pain* 2012;**153**(9):1798-806.

#### Williams 2012

Williams ACDC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database of Systematic Reviews* 2012, Issue 11. Art. No: CD007407. [DOI: 10.1002/14651858.CD007407]

#### References to other published versions of this review

#### Eccleston 2003

Eccleston C, Yorke L, Morley S, Williams ACDC, Mastroyannopoulou A. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2003, Issue 1. Art. No: CD003968. [DOI: 10.1002/14651858.CD003968]

#### **Eccleston 2009**

Eccleston C, Palermo TM, Williams ACDC, Lewandowski A, Morley S. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No: CD003968. [DOI: 10.1002/14651858.CD003968.pub2]

#### Eccleston 2012

Eccleston C, Palermo TM, Williams ACDC, Lewandowski A, Morley S, Fisher E, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2012, Issue 12. Art. No: CD003968. [DOI: 10.1002/14651858.CD003968.pub3]

#### Eccleston 2014

Eccleston C, Palermo TM, Williams ACDC, Lewandowski Holley A, Morley S, Fisher E, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Systematic Reviews* 2014, Issue 5. Art. No: CD003968. [DOI: 10.1002/14651858.CD003968.pub4]

\* Indicates the major publication for the study

Abram 2007	
Study characteristic	S
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment (3-month follow-up), 6 months
Participants	End of treatment: n = 50
	Start of treatment: n = 81
	Sex: 45 F, 36 M



Abram 2007 (Continued)	
	Mean age = 12.7 years (range 10 to 18)
	Source = hospital and clinic
	Diagnosis = headache
	Mean years of pain = not given
Interventions	"Headache Clinical Model: behavioural intervention"
	"Headache Traditional Model: consultation with neurologist"
Outcomes	Primary pain outcome: none
	Primary disability outcome: Ped-MIDAS
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Pediatric Migraine Disability Assessment (Ped-MIDAS)
	2. FDI-C
	3. Headache Knowledge test
	4. Use of Healthcare measure
Notes	COI: not reported

Funding: "This study was funded by the Nemours Clinical Management Program, Orlando, FL."

Risk	of	bias
------	----	------

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"If the family was interested in the study, they were randomised (using a random number table) to either a TCM appointment or a HCM appointment." Comment: probably done
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however no significant differences between com- pleters and non-completers were reported
Selective reporting (re- porting bias)	High risk	Data were incompletely reported

#### Alfven 2007

Study characteristics		
Methods	RCT. 2 arms. Assessed at pretreatment and 1-year follow-up	
Participants End of treatment: n = 48		



Alfven 2007 (Continued)				
	Start of treatment: n = 48			
	Sex: 35 F, 12 M			
	Mean age = 9.5 years (range 6 to 18)			
	Source = hospital			
	Diagnosis = recurrent abdominal pain			
	Mean years of pain = 2.3			
Interventions	"Psychological treatment and physiotherapy"			
	"Physiotherapy alone"			
Outcomes	Primary pain outcome: pain score			
	Primary disability outcome: none			
	Primary depression outcome: none			
	Primary anxiety outcome: none			
	<ol> <li>Pain intensity (VAS)</li> <li>Pain score         <ul> <li>a. frequency</li> <li>b. intensity</li> <li>c. duration</li> </ul> </li> <li>Tender points (algorithm)</li> </ol>	meter)		
Notes	COI: "No conflict of interestexists."			
	Funding: "Nofunding exists."			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	"The children recruited during 1996–1999 were randomised" Comment: probably done, method not described		
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done		
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported		
Selective reporting (re- porting bias)	High risk	Data were incompletely reported		



#### Barakat 2010

#### Study characteristics

Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment and 12 months	
Participants	End of treatment: n = 42; follow-up 1 year: n = 34	
	Start of treatment: n = 42	
	Sex: 12 F, 15 M	
	Mean age = 14.17 years (1.75)	
	Source = sickle cell centre	
	Diagnosis = sickle cell disease	
	Mean years of pain = lifetime	
Interventions	"Pain Management Intervention" "Disease Education Intervention"	
Outcomes	Primary pain outcome: pain diary	
	Primary disability outcome: none	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Pain diary	
	2. Health-related Hindrance Inventory	
	3. Child Health Questionnaire	
	4. Family Cohesion Scale	
	5. Disease Self-efficacy Scale	
	6. Coping Strategies Inventory	
	7. SCD Transition Knowledge Questionnaire	
	8. Medical chart review	
	9. School attendance	
Notos	COL: not reported	

Notes

COI: not reported

Funding: "This research was funded by National Heart, Lung, and Blood Institute (U54 30117 to J.R.)."

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"A 2-group, randomised treatment design was used." Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias)	Unclear risk	Attrition was described; no significant differences between completers and non-completers were reported



#### Barakat 2010 (Continued) All outcomes

Selective reporting (re- Low risk Data were fully reported porting bias)

#### Barry 1997

Study characteristics		
Methods	RCT. 2 arms. Assessed a	at pretreatment, post-treatment, 3 months
Participants	End of treatment: n = 29	
	Start of treatment: n = 36	
	Sex: 19 F, 10 M	
	Mean age = 9.4 years	
	Source = volunteers via ondary care	a school and primary healthcare settings; referrals invited from primary and sec-
	Diagnosis = headache	
	Mean years of pain not	given
Interventions	"Cognitive behaviour therapy" "waiting-list control"	
Outcomes	Primary pain outcome: headache intensity	
	Primary disability outcome: school absence	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Headache intensity	
	2. Headache duration	
	3. Mood	
	4. School absence due to headache	
	5. Activities missed due to headache	
	6. Medication intake	
	7. Pain management s	trategies used
Notes	COI: not described	
	Funding: not described	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Each parent-child pair was initially matched with another pair based on the child's age, sex and headache pain as indicated by the parents' ratings of average duration, frequency, and intensity of headaches. Subsequently, one of each of the matched parent child pairs was randomly assigned to either the

each of the matched parent-child pairs was randomly assigned to either the

treatment condition or the waiting-list control condition."



Barry 1997 (Continued)		Comment: probably done, method not described
Allocation concealment (selection bias)	High risk	"Each parent-child pair was initially matched with another pair based on the child's age, sex and headache pain as indicated by the parents' ratings of av- erage duration, frequency, and intensity of headaches. Subsequently, one of each of the matched parent-child pairs was randomly assigned to either the treatment condition or the waiting-list control condition."
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described; no significant differences between completers and non-completers were reported
Selective reporting (re- porting bias)	Unclear risk	Data were completely reported on request

### Bussone 1998

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 6 months, 12 months
Participants	End of treatment: n = 35
	Start of treatment: n = 35
	Sex: 17 F, 18 M
	Mean age = 11.4 years (range 11 to 15)
	Source = specialised headache clinic
	Diagnosis = headache
	Mean years of pain (mean) = 2.6
Interventions	"Biofeedback (assisted relaxation)"
	"Relaxation"
Outcomes	Primary pain outcome: Pain Index
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: State Trait Anxiety Index
	1. Pain Total Index (headache diary)
	<ol> <li>State Trait Anxiety Index (STAI)</li> <li>Analgesic use</li> </ol>
Notes	COI: not reported
	Funding: "Preparation of this research was supported in part by a research grant from the National In- stitute of Nuerological Disorders and Stroke, NS-29855."



### Bussone 1998 (Continued)

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Patients were randomly assigned to one of two experimental conditions" Comment: probably done, method not described
Allocation concealment (selection bias)	High risk	" with the constraint that subjects be over-sampled in BFB-REL treatment (2:1 ratio) in order to make actual treatment available to as many children as possible."
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported in study
Selective reporting (re- porting bias)	High risk	Data incompletely reported

### Chen 2014

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment and post-treatment.
Participants	End of treatment: n = unknown
	Start of treatment: n = 90
	Sex: 52 F, 38 M
	Mean age = 11.6 years (SD = 2.0; range 8 to 12)
	Source = unknown
	Diagnosis = migraine
	Mean years of pain (range) = 1 to 4 years
Interventions	"Standard treatment (0.2 mg/kg of oral flunarizine) + Behavior therapy"
	"Standard treatment" (0.2 mg/kg of oral flunarizine)"
Outcomes	Primary pain outcome: Headache frequency
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Ped-MIDAS
	2. Headache diary 3. Bussone Index
	5. Dussone muex



### Chen 2014 (Continued)

COI: none stated

Funding: none stated

# Risk of bias

Notes

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"We adapt prospective randomized controlled study method, where the 90 pa- tients (children) were randomized to control group and treatment group." Comment: unclear randomization procedure
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition in the study was not described
Selective reporting (re- porting bias)	High risk	Not all data was included in the paper

#### Cottrell 2007

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, and 8 months
Participants	End of treatment: n = 30, follow-up n = 28 Start of treatment: n = 34 Sex: 15 F, 15 M Mean age: 14.1 years (SD 1.91) Source: referral by neurologist and community advertisement Diagnosis: headache Duration (mean): unknown
Interventions	"STOP Migraines treatment" - behavioural treatment delivered via telephone Triptan treatment
Outcomes	<ul> <li>Primary pain outcome: none</li> <li>Primary disability outcome: hours disabled by headache</li> <li>Primary depression outcome: none</li> <li>Primary anxiety outcome: none</li> <li>1. Participant feedback including evaluation of the manual, relaxation tapes, home biofeedback equipment, telephone versus clinic treatment format, satisfaction, and quality of relationship</li> <li>2. Daily diary including headache duration, headache severity, number of hours participant was totally disabled</li> <li>3. Migraine Specific Quality of Life Questionnaire - Adolescent</li> </ul>



Cottrell 2007 (Continued)

### 4. Satisfaction from participant feedback

Notes

Funding source: National Institutes of Health (NINDS #N32374) Declarations of interest: Dr. O'Donnell was an employee of OrthoNeuro Inc.

#### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Thus, 34 adolescents were randomized to treatment (16 TT and 18 TAT)." Comment: probably done; description of randomisation not provided
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition completely reported; significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	High risk	Outcomes incompletely reported

### Daniel 2015

Study characteristics		
Methods	RCT. 2 arms. Assessed pretreatment and post-treatment (6 months)	
Participants	End of treatment: n = 62	
	Start of treatment: n = 83	
	Sex of children: 42 M, 41 F	
	Mean age of children = 8.48 years (± 2.11)	
	Source = two comprehensive sickle cell clinics in children's hospitals	
	Diagnosis = sickle cell disease	
	Mean years of illness = lifetime	
Interventions	"Families Taking Control" (PSST)	
	"Delayed Intervention Control"	
Outcomes	Primary pain outcome: none	
	Primary disability outcome: none	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Child measures	



Daniel 2015 (Continued)		
	a. Medical chart rev	view to collect genotype and disease complications
	b. Pediatric Quality	of Life Inventory
	c. Woodcock Johns	son III
	d. Weschler Abbreviated Scale of Intelligence	
	e. Social Problem-Solving Inventory Revised Short Form	
	f. Expectancy Form	
	g. Expectancy Form	
	h. Engagement Rat	ing Form
	2. Parent measures	
	a. Hemotology/One	cology Psycho-Educational Needs Assessment
	b. Pediatric Quality	of Life Inventory
	c. Expectancy Form	
	d. Expectancy Form	1
	e. Engagement Rat	ing Form
Notes	COI: "Conflicts of intere	est: None declared."
	Funding: "NHLBI (U54 HL070585) to M.S. (PI), BTRP to LPB (PI); and NCMHD (1RC1MD004418) to L.P.B. (PI)."	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Randomization (stratified by gender in blocks of 10) was concealed from the family and the study team until after completing the baseline assessment when an envelope with randomization status was opened and the family was informed of next steps." Comment: insufficient information about the se- quence generation process to permit judgement

### Duarte 2006

Blinding of outcome as-

All outcomes

(attrition bias)

All outcomes

porting bias)

sessment (detection bias)

Incomplete outcome data

Selective reporting (re-

Unclear risk

Low risk

Low risk

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment
ParticipantsEnd of treatment: n = 32	

Insufficient information to permit judgement; no statement about whether or

Attrition was reported, no significant differences between completers and

not blinding of outcome assessment occurred

non-completers were reported

Data were fully reported



Duarte 2006 (Continued)	
	Start of treatment: n = 32
	Sex: 22 F, 10 M
	Mean age = 9.1 years (SD 2.1)
	Source = paediatric gastroenterology service
	Diagnosis = recurrent abdominal pain
	Mean years of pain = 2.1
Interventions	"Cognitive behavioural family intervention"
	"Standard paediatric care, 4 sessions"
Outcomes	Primary pain outcome: pain intensity VAS
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Pain VAS (reduced to 4 categories), completed daily
	2. Parent estimate of frequency over last month
	3. Pressure point threshold using algometer
Notes	COI: not reported
	Funding: not reported
Risk of bias	
Bias	Authors' judgement Support for judgement

Random sequence genera- tion (selection bias)	Unclear risk	"Randomly allocated to 2 groups." Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts were reported in the study
Selective reporting (re- porting bias)	High risk	Data were incompletely reported

# Fichtel 2001

Study characteristics		
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 8 to 12 months	



Fichtel 2001 (Continued)	
Participants	End of treatment: n = 36
	Start of treatment: n = 36
	Sex: 25 F, 11 M
	Mean age = 15.4 years (range 13 to 18)
	Source = school
	Diagnosis = headache
	Mean years of pain = not given
Interventions	"Relaxation"
	"waiting-list control"
Outcomes	Primary pain outcome: total headache score
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Total headache score (headache diary)
	2. Medication consumption
Notes	COI: not reported
	Funding: not reported

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The subjects were randomly assigned to the relaxation treatment or wait- ing-list groups" Comment: probably done, no method was described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts were reported in the study
Selective reporting (re- porting bias)	Low risk	Data were fully reported

### Gil 1997

Study characteristics



Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment
Participants	End of treatment: n = 49
	Start of treatment: n = 49
	Sex: 23 F, 26 M
	Mean age = 11.9 years
	Source = university medical centre, sickle cell centre
	Diagnosis = sickle cell anaemia (SS), sickle cell disease (SC), sickle beta thalassaemia
	Mean years of pain = not given
Interventions	"Cognitive coping skills"
	"Standard care control"
Outcomes	Primary pain outcome: none
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Pain sensitivity (pressure stimulator)
	2. Coping strategy questionnaire
	3. Disease severity: acute and chronic complications in past 12 months
Notes	COI: not reported
	Funding: "This work was supported by Grant RO1 HL46953-06, by Project VI.B.2 in the Duke Universi- ty-University of North Carolina Sickle Cell Center Grant in P60HL2839-13, and by the University of Nort Carolina at Chapel Hill GCRC Grant RR00046."

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Participants were then randomly assigned to one of two conditions.' Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported in study
Selective reporting (re- porting bias)	High risk	Data not fully reported



## Greenley 2015

Study characteristics	
Methods	RCT. 3 Arms. Assessed pretreatment, after initial treatment (12 weeks), after additional treatment (20 weeks)
Participants	End of treatment (12 weeks): n = 65; end of treatment (20 weeks): n = 65 Start of treatment: n = 76 Sex of children: 46 M, 30 F Sex of parents: not reported Mean age of children = 14.54 ± 1.84 years Mean age of parents = not reported Source = Paediatric IBD Center Diagnosis = inflammatory bowel disease Mean years of illness = not reported
Interventions	"PSST IBD" "Wait-list control"
Outcomes	Primary pain outcome: none
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	<ol> <li>Child measures         <ul> <li>Disease information (from medical records)</li> <li>Medical Adherence Measure</li> <li>Intervention satisfaction</li> <li>Treatment fidelity (from audio recording of intervention sessions)</li> <li>Oral Medication Adherence (using MEMS Track Caps)</li> <li>Health-related Quality of Life</li> </ul> </li> <li>Parent measures         <ul> <li>Demographics</li> <li>Intervention satisfaction</li> <li>Treatment fidelity (from audio recording of intervention sessions)</li> </ul> </li> </ol>
Notes	Funding: "Supported by the Crohn's and Colitis Foundation of America (Senior Research Award #2838; PI: Greenley)." COI: "The authors have no conflicts of interest to disclose."
Risk of bias	
Bias	Authors' judgement Support for judgement

Bias	Authors' judgement Support for judgement	
Random sequence genera- tion (selection bias)	enera- Low risk "The randomization sequence was generated by a biostatisticia dows version 6.0 of randomization program 'Rand.exe.'" Comm done	
Allocation concealment (selection bias)	Low risk	"The random allocation sequence was stored electronically in a password-pro- tected file accessible only to the research assistant in charge of informing par- ticipants of randomization outcomes. Research assistants enrolling partici- pants and those conducting assessment visits were blind to participant inter- vention condition." Comment: probably done



## Greenley 2015 (Continued)

Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"All assessments were conducted in participants' homesResearch assis- tantsconducting assessment visits were blind to participant intervention condition." Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was reported but differences between completers and non-completers are not reported
Selective reporting (re- porting bias)	Unclear risk	All data reported

# **Griffiths 1996**

Study characteristics	Study ch	naracte	ristics
-----------------------	----------	---------	---------

Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment and 9 weeks post-treatment		
Participants	End of treatment: n = 42; follow-up: n = 42		
	Start of treatment: n = 51		
	Sex: 21 F, 21 M		
	Mean age = 11.3 years		
	Source = not known		
	Diagnosis = migraine		
	Mean years of pain = not given: minimum 6 months		
Interventions	"Cognitive behavioural therapy (clinic-based)" (n = 15) "Cognitive behavioural therapy (home-based)" (n = 15) "Self monitoring" (n = 12)		
Outcomes	Primary pain outcome: headache index		
	Primary disability outcome: none		
	Primary depression outcome: Child Depression Scale		
	Primary anxiety outcome: Child Manifest Anxiety Scale (CMAS)		
	1. Headache index (averaged intensity)		
	2. Medication used		
	3. Child Manifest Anxiety Scale (CMAS)		
	<ol> <li>Children's Depression Scale (CDS)</li> <li>Self efficacy</li> </ol>		
	<ol> <li>Sentencacy</li> <li>Coping responses from Children's Headache Assessment Scale (CHAS)</li> </ol>		
Notes	COI: not reported		
	Funding: not reported		
Risk of bias			
Bias	Authors' judgement Support for judgement		

### Griffiths 1996 (Continued)

Random sequence genera- tion (selection bias)	Unclear risk	"It was decided to assign children to groups by true randomisation rather than on the basis of headache diagnosis" Comment: probably done, no method was described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition was not described
Selective reporting (re- porting bias)	Low risk	Data were fully reported

## Grob 2013

Study characteristics	
Methods	RCT. 2 arms. Assessed pretreatment, post-treatment and at 3 months
Participants	End of treatment: n = 28; follow-up: n = 28
	Start of treatment: n = 29
	Sex: 25 F, 4 M
	Mean age = 9.6 years (SD = 1.47)
	Source = schools
	Diagnosis = chronic abdominal pain
	Mean years of pain = 2.8 years (SD = 1.71)
Interventions	"Stop the pain with Happy Pingu" CBT
	"Wait-list control"
Outcomes	Primary pain outcome: pain intensity
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	<ol> <li>Pain diary (intensity, frequency, duration)</li> <li>KINDL-R disease-specific module</li> <li>PEDSQL</li> <li>Self-administered questionnaire based on Itch-questionnaire for pain-related cognitions</li> </ol>
Notes	COI: "There are no conflicts of interest."
	Funding: "This work was supported by a grant to M. G. of Potsdam Graduate School."



### Grob 2013 (Continued)

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Computer-aided randomization was performed by a person who was not in- volved in the study" Comment: probably done, no method was described
Allocation concealment (selection bias)	Low risk	"Computer-aided randomization was performed by a person who was not in- volved in the study" Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described; differences between completers and non-completers were not described
Selective reporting (re- porting bias)	Low risk	Data were fully reported

## Gulewitsch 2013

Study characteristics			
Methods	RCT. 2 arms. Assessed pretreatment, post-treatment (3 months)		
Participants	End of treatment: n = 37		
	Start of treatment: n = 38		
	Sex: 24 F, 14 M		
	Mean age = 9.4 years (SD = 1.72)		
	Source = adverts in local newspapers and paediatricians' offices		
	Diagnosis = functional abdominal pain or irritable bowel syndrome		
	Mean years of pain = 34.84 months (SD = 40.7)		
Interventions	"Hypnotherapeutic therapy" (hypnotherapeutic and behavioural methods)		
	"Wait-list control group"		
Outcomes	Primary pain outcome: mean pain intensity		
	Primary disability outcome: Paediatric Pain Disability Index		
	Primary depression outcome: none		
	Primary anxiety outcome: none		
	1. Mean pain intensity		
	<ol> <li>Number of days with AP</li> <li>Mean duration of pain episodes</li> </ol>		



Gulewitsch 2013 (Continued)	8. KINDL child report (	-
Notes	COI: "The authors declare that they have no conflict of interest." Funding: not reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"Families were randomly assigned following simple randomization procedures (computerized random number generator)" Comment: probably done
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described; differences between completers and non-completers were not described
Selective reporting (re- porting bias)	Low risk	Data fully reported

## Hechler 2014

Study characteristics	
Methods	RCT. 2 arms. Assessed pretreatment, post-treatment, 6 months, and 12 months
Participants	End of treatment: n = 108
	Start of treatment: n = 120
	Sex: 87 F, 27 M
	Mean age = 14 years (SD 2.85)
	Source = clinic
	Diagnosis = chronic pain (mixed conditions)
	Mean years of pain = median of 18 months (intervention group) and 13.5 months (control group)
Interventions	"Intensive interdisciplinary pain treatment"
	"Wait-list control"



Hechler 2014 (Continued)				
Outcomes	Primary pain outcome: mean pain intensity Primary disability outcome: Paediatric Pain Disability Index			
	Primary depression ou	tcome: Depression Inventory for Children and Adolescents (DIKJ)		
	Primary anxiety outcor scale)	me: Pain-Related Cognitions Questionnaire for Children (catastrophising sub-		
	<ol> <li>Mean pain intensity</li> <li>Paediatric Pain Disability Index</li> <li>School absence</li> <li>Anxiety Questionnaire for Pupils</li> <li>Pain-Related Cognitions Questionnaire for Children (Catastrophising subscale)</li> <li>Depression Inventory for Children and Adolescents (DIKJ)</li> <li>Questionnaire to assess the economic effects of chronic pain</li> <li>Utilisation of healthcare services</li> <li>Parental work absenteeism</li> <li>Work days lost</li> <li>Subjective financial burden</li> </ol>			
Notes	COI: "The authors declare no conflict of interest." Funding: "The present study was supported in part by the Robert Bosch Foundation GmbH (Grant 11.5.1344.0010.0). The Robert Bosch Foundation was not involved in (1) the study design; (2) collection, analysis, and interpretation of data; (3) the writing of the report; and (4) the decision to submit the pa- per for publication."			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	"Randomisation was conducted with a 1:1 approach and in blocks of 4 and blocks or 6 for both groups and was stratified for gender" Comment: probably done		
Allocation concealment (selection bias)	Low risk	"The individual who carried out the randomization procedure was blinded to the treatment condition" Comment: probably done		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done		

were not described

Data fully reported on request

Attrition was described; differences between completers and non-completers

Hickman 2015

(attrition bias)

All outcomes

porting bias)

Study characteristics

Incomplete outcome data

Selective reporting (re-

Unclear risk

Unclear risk



Methods	RCT. Two arms. Assessed pretreatment and post-treatment.		
Participants	End of treatment: n = 32		
	Start of treatment: n = 36		
	Sex: 87 F, 27 M		
	Mean age = 14 years (SD 2.85)		
	Source = clinic		
	Diagnosis = chronic pain (mixed conditions)		
	Mean years of pain = unknown		
Interventions	"COPE-HEP; Creating Opportunities for Personal Empowerment - Headache Education Program"		
	"Treatment-as-usual"		
Outcomes	Primary pain outcome: none		
	Primary disability outcome: Ped-MIDAS		
	Primary depression outcome: Beck Youth Inventory II, Depressive symptoms		
	Primary anxiety outcome: Beck Youth Inventory II, Anxiety symptoms		
	1. Beck Youth Inventory II		
	2. Healthy Lifestyle Beliefs Scale		
	3. Perceived Stress Scale		
	4. Ped-MIDAS		
	5. Parent Perception of Pain Interference		
	6. Treatment acceptance and feasibility		
Notes	COI: The authors report no financial incentives that may create a conflict of interest."		
	Funding: "This research was supported by a grant from the National Institute of Nursing Research/Na- tional Institutes of Health (1F31NR012112-01A1)."		
Risk of bias			

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Adolescents were randomized to the COPE-HEP intervention or a comparison headache education group."
		Comment: no method described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was reported but differences between completers and non-com- pleters were not described



Low risk

## Hickman 2015 (Continued)

Selective reporting (reporting bias) All outcomes were reported

Study characteristics	
Methods	RCT. 4 arms. Assessed at pretreatment, post-treatment
Participants	End of treatment: n = 61
	Start of treatment: n = 64
	Sex: 38 F, 26 M
	Mean age = 9.8 years (SD 2.5)
	Source = advertisement and physician referral
	Diagnosis = recurrent abdominal pain
	Mean years of pain = none given
Interventions	"CBT + biofeedback + parental support + fibre"
	"CBT + biofeedback + fibre"
	"Biofeedback + fibre"
	"Fibre"
Outcomes	Primary pain outcome: pain diary
	Primary disability outcome: school attendance
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Child pain diary
	2. Parental observation record
	3. Healthcare utilisation record
	4. Medical record
	5. School attendance
Notes	COI: none stated.Funding: none stated
Risk of bias	
Bias	Authors' judgement Support for judgement

Random sequence genera- tion (selection bias)	Unclear risk	"Patients were randomly assigned to one of the four groups" Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done



## Humphreys 2000 (Continued)

Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition not described; significant differences between completers and non- completers not reported
Selective reporting (re- porting bias)	Low risk	Data fully reported

# Kashikar-Zuck 2005

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment (week 8), 6 weeks
Participants	End of treatment: n = 27
	Start of treatment: n = 30
	Sex: 30 F, 0 M
	Median age = 15.8 years (SD 1.3)
	Source = paediatric rheumatology clinic of a children's hospital
	Diagnosis = juvenile primary fibromyalgia (JPFM criteria; Yunus)
	Mean years of pain = 19 for > 2 years, 11 for 6 months to 2 years
Interventions	"Coping skills training"
	"Self-monitoring"
Outcomes	Primary pain outcome: average pain VAS
	Primary disability outcome: Functional Disability Inventory
	Primary depression outcome: Children's Depression Inventory
	Primary anxiety outcome: none
	1. Average pain VAS 0 to 100
	2. Highest pain VAS 0 to 100
	3. Functional Disability Inventory (FDI)
	4. Children's Depression Inventory (CDI)
	5. Pain Coping Questionnaire (PCQ)
	<ol> <li>Pain Coping Efficacy (items from PCQ)</li> <li>Tender points</li> </ol>
Notes	COI: not reported
	Funding: "Supported by grants from the Cincinnati Children's Hospital Research Foundation and Na- tional Institutes of Health Grant 1P60AR47784-01."

### Kashikar-Zuck 2005 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"A computer generated pseudo-random number list was used. A simple ran- domisation technique was used with a 1:1 allocation ratio for 30 subjects as a single block." Comment: probably done
Allocation concealment (selection bias)	Low risk	"A computer generated pseudo-random number list was used. A simple ran- domisation technique was used with a 1:1 allocation ratio for 30 subjects as a single block." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"A research assistant who was blind to the study objectives and to the sub- jects' treatment assignment administered the self-report measures. The rheumatologist or occupational therapist who conducted the tender point as- sessments was blind to the subjects' treatment assignment." Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition is described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	Low risk	Data were fully reported on request for additional data

## Kashikar-Zuck 2012

Study characteristics		
Methods	RCT. 2 arms. Assessed pretreatment, post-treatment, 6-month follow-up	
Participants	End of treatment: n = 106; follow-up 6 months n = 100	
	Start of treatment: n = 114	
	Sex: 105 F, 9 M	
	Mean age = 15.0 years (1.8)	
	Source = paediatric rheumatology centres in Midwestern USA	
	Diagnosis = fibromyalgia syndrome	
	Mean years of pain = 2 years, 10 months (2 years, 6 months)	
Interventions	"Cognitive behavioural therapy" "Fibromyalgia education"	
Outcomes	Primary pain outcome: pain severity VAS (averaged over 7 days)	
	Primary disability outcome: Functional Disability Scale	
	Primary depression outcome: Children's Depression Inventory	
	Primary anxiety outcome: Pain Coping Questionnaire	
	<ol> <li>Pain severity VAS (averaged over 7 days)</li> <li>Functional Disability Scale</li> </ol>	



Kashikar-Zuck 2012 (Continued)	3. Children's Depression Inventory		
	4. Tender point sensitivity		
	5. Pedatric Quality of Life Inventory		
	6. Sleep quality VAS (averaged over 7 days)		
	7. Physician's global assessment VAS		
Notes	COI: "Dr. Passo has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than \$10,000)."		
	Funding: "Supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01-AR-050028 to Dr. Kashikar-Zuck)."		

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"Eligible patients were randomly assigned to 1 of the 2 treatment arms based upon a computer-generated randomisation list. Randomisation was stratified by site." Comment: probably done
Allocation concealment (selection bias)	Low risk	"When a patient was enrolled, the study therapist contacted the biostatistician to obtain the subject identification number and treatment allocation." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"The principal investigator, study physicians, study coordinator, and assess- ment staff were all blinded to the patients' treatment condition throughout the trial. Patients were asked not to divulge what treatment they were receiv- ing to the study physician." Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was described; no significant differences between completers and non-completers were reported
Selective reporting (re- porting bias)	Low risk	Data were fully reported

## **Kroener-Herwig 2002**

Study characteristics	
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, 6 months
Participants	End of treatment: n = 75
	Start of treatment: n = 78
	Sex: 35 F, 40 M
	Mean age = 12.1 years (SD 1.3)
	Source = newspaper advertisement - 2 or more headaches per month reported by parents
	Diagnosis = paediatric headache: migraine (30%), tension-type (40%), combined (30%)
	Mean years of pain = 4.0 (SD 2.6)

## Kroener-Herwig 2002 (Continued)

Interventions	"Cognitive behavioural training group" (n = 29)	
	"Self-help" (n = 27)	
	"Waiting-list control" (n = 19)	
Outcomes	Primary pain outcome: pain intensity	
	Primary disability outcome: none	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Headache frequency (mean number per day)	
	2. Pain intensity (mean daily)	
	3. Headache duration (mean number of hours per day)	
Notes	COI: not reported	
	Funding: "The study was supported by a grant from the Technician's Health Care Insurance of Germany (Technikerkrankenkasse)."	

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Assignment to the treatment groups was random." Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	Low risk	Data were fully reported

### Labbe 1984

Study characteristic	s
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment (1 month after end of treatment), 6 months
Participants	End of treatment: n = 28
	Start of treatment: n = 28
	Sex: 14 F, 14 M
	Mean age = 10.8 years

Labbe 1984 (Continued)	Source = community paediatrician referral, newspaper advertisement	
	Diagnosis = migraine headache	
	Mean years of pain = 4.3	
Interventions	"Autogenic feedback training" "waiting-list control"	
Outcomes	Primary pain outcome: headache diary	
	Primary disability outcome: none	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Headache index	
	2. Headache frequency	
	3. Headache duration	
	4. Headache peak intensity	
	5. Medication use	
Notes	COI: not reported	
	Funding: not reported	

#### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The children who attended the first session were matched on age, sex, and baseline headache index and then randomly assigned to either a treatment group or waiting-list control group." Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported in study
Selective reporting (re- porting bias)	Low risk	Data were reported fully

## Labbe 1995

Study characteristics	
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, 6 months
Participants	End of treatment: n = 30



abbe 1995 (Continued)			
	Start of treatment: n =	46	
	Sex: 17 F, 13 M		
	Mean age = 12.0 years		
	Source = not given		
	Diagnosis = vascular or	r migraine headache	
	Mean years of pain = no	ot given	
Interventions	"Skin temperature biofeedback and autogenic relaxation" "Autogenic relaxation" "Waiting-list control"		
Outcomes	Primary pain outcome:	: headache diary	
	Primary disability outc	ome: none	
	Primary depression ou	tcome: Childhood Depression Inventory	
	Primary anxiety outcome: How-I-Feel questionnaire		
	<ol> <li>Headache index</li> <li>Headache frequency</li> <li>Headache duration</li> <li>Child aggression parent-rated (Myth Type A)</li> <li>Childhood Depression Inventory</li> <li>How-I-Feel questionnaire: anxiety</li> </ol>		
Notes	COI: not reported		
	Funding: not reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	"Children were matched by age, sex, and baseline headache activity and then randomly assigned to one of three groups." Comment: probably done, no method described	
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done	
Incomplete outcome data (attrition bias) All outcomes	Low risk	"Data on the dropouts were compared to those children participating in the treatment sessions. No differences were found in sex, age or headache histo- ry." Comment: probably done	
Selective reporting (re- porting bias)	Low risk	Data were fully reported	



### Larsson 1987a

Study characteristics	
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, 5 months
Participants	End of treatment: n = 41
	Start of treatment: n = 46
	Sex: 40 F, 6 M
	Mean age = not given: range 16 to 18 years
	Source = not given
	Diagnosis = headache (migraine, tension, or both)
	Mean years of pain = mostly 1 to 5 years
Interventions	"Therapist assisted relaxation" (n = 14)
	"Self-help relaxation" (n = 16)
	"Self monitoring group" (n = 11)
Outcomes	Primary pain outcome: headache sum
	Primary disability outcome: school absence
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Headache sum
	2. Headache frequency
	3. Headache-free days
	4. Headache duration
	5. Peak headache intensity
	6. Medication
	<ol> <li>School absence</li> <li>Significant other rating of headache improvement</li> </ol>
	9. Cost-effectiveness
Notes	COI: not reported
	Funding: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"In the randomisation procedure" Comment: probably done, no method described
Allocation concealment (selection bias)	High risk	"In the randomisation procedure the following restrictions were applied: (a) class mates were assigned to the same treatment group in order to lessen the risk of treatment contamination, (b) subjects were evenly distributed across groups within separate schools." Comment: probably done



### Larsson 1987a (Continued)

Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	High risk	Data were not fully reported

## Larsson 1987b

Participants En Sta Sez	T. 3 arms. Assessed at pretreatment, post-treatment, 5 months
Sta Sex	
Sex	d of treatment: n = 36; follow-up: n = 34
	art of treatment: n = 36
Ме	x: 32 F, 2 M
	ean age = 17 years
So	urce = not given
Dia	agnosis = headache
Ме	ean years of pain = mostly 1 to 5 years
"Pi	elf-help relaxation" (n = 12) roblem discussion group" (n = 10) elf monitoring (control)" (n = 12)
Outcomes Pri	imary pain outcome: headache sum
Pri	imary disability outcome: school absence
Pri	imary depression outcome: Depression Scale for Female Adolescents
Pri	imary anxiety outcome: Swedish translation of Children's Manifest Anxiety Scale
1.	Headache sum
2.	Headache frequency
3.	Headache-free days
4.	Headache duration
5.	Peak headache intensity
	Medicine consumption
	School absence
8.	Headache annoyance
	Depression/anxiety
	.Social relationship-competence questionnaire
11.	.Significant other rating of headache improvement
Notes CO	)I: not reported



Larsson 1987b (Continued)

Funding: not reported
-----------------------

Risk of bi	as
------------	----

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Finally, 36 students were randomly assigned to the three experimental condi- tions." Comment: probably done, no method described
Allocation concealment (selection bias)	High risk	"The allocation of subjects was conducted with two restrictions on the proce- dure: (a) Classmates were assigned to the same treatment condition (to lessen the risk of treatment contamination), and (b) students with a high frequency of headaches were identified and evenly distributed across groups." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition was not described
Selective reporting (re- porting bias)	High risk	Data were not fully reported

### Larsson 1990

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment
Participants	End of treatment: n = 43
	Start of treatment: n = 49
	Sex: 44 F, 5 M
	Mean age = 17 years Source = school
	Diagnosis = headache
	Mean years of pain = median 2 to 5 years
Interventions	"Self help relaxation"
	"Waiting-list control"
Outcomes	Primary pain outcome: headache activity
	Primary disability outcome: none given
	Primary depression outcome: Beck Depression Inventory
	Primary anxiety outcome: Modified Child Manifest Anxiety Scale
	1. Headache index
	2. Medication use
	3. Headache annoyance
	4. Modified Child Manifest Anxiety Scale (CMAS)
	5. Depression - Beck Depression Inventory



Larsson 1990 (Continued)

6. Somatic complaints (composite of multiple complaints)

**C**+ 11 noin

	7. Stress (4-point scale	
Notes	COI: none stated.	
	Funding: none stated.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"the outlines of the study including the use of randomisation and a placebo treatment period." Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	"A graduate student in psychology administered the assessment instruments and the treatment material used in the study." Comment: unsure

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	Low risk	Data were fully reported

## Larsson 1996

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 6 months
Participants	End of treatment: n = 26
	Start of treatment: n = 26
	Sex: 25 F, 1 M
	Mean age = not given: range 10 to 15 years
	Source = school
	Diagnosis = headache
	Mean years of pain = 2.1
Interventions	"Relaxation treatment" "No treatment"
Outcomes	Primary pain outcome: headache intensity
	Primary disability outcome: none

### Larsson 1996 (Continued) Primary depression outcome: none

## Primary anxiety outcome: none

- 1. Headache intensity ('sum')
- 2. Headache-free days
- 3. Headache frequency

Notes

### COI: not reported

Funding: "This study was supported by grants from the First May Flower Annual Campaign and from the Glaxo and Allenburys AB, Sweden."

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Thus, 26 pupils were randomly allocated into a relaxation training group or to a no-treatment control group". Comment: probably done, no method described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	There were no dropouts reported in the study
Selective reporting (re- porting bias)	Low risk	Data were fully reported

#### Levy 2010

Study characteristics			
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 3-month follow-up, 6-month follow-up		
Participants	End of treatment: n = 168; follow-up 3 months: n = 143; follow-up 6 months: n = 154		
	Start of treatment: n = 200		
	Sex: 145 F, 55 M		
	Mean (SD) age = 11.21 years (2.55)		
	Source = paediatric gastroenterology clinics at Seattle Children's Hospital and the Atlantic Health S tem in Morristown, New Jersey. Seattle participants were also recruited through local area clinics a community-posted flyers		
	Diagnosis = functional abdominal pain		
	Mean years of pain = 3+ episodes of abdominal pain during a 3-month period		
Interventions	"Cognitive-behavioural treatment"		

Levy 2010 (Continued)	"Educational intervention"			
Outcomes	Primary pain outcome: Faces Pain Scale-Revised			
	Primary disability outcome: Functional Disability Inventory			
	Primary depression outcome: Children's Depression Inventory			
	Primary anxiety outcome: Multidimensional Anxiety Scale for Children			
	1. Faces Pain Scale - Revised			
	2. Functional Disability Inventory			
	3. Children's Depression Inventory			
	4. Children's Somatization Inventory			
	5. Multidimensional Anxiety Scale for Children			
Notes	COI: "William E. Whitehead is a member of the Board of Directors of the Rome Foundation. Nader Youssef is currently the Director of Clinical Research at AstraZeneca LP. At the time the study was con- ducted, however, he was not affiliated with this company and contributed to the project by his appoint- ment at Goryeb Children's Hospital."			
	Funding: "This study was supported by grant number 5R01HD036069 from the National Institutes of Health — National Institute of Child Health and Human Development."			

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"Randomisation was then performed by a different researcher using a comput- erised random-number generator, stratifying by age." Comment: probably done
Allocation concealment (selection bias)	Low risk	"Randomisation was then performed by a different researcher using a comput- erised random-number generator, stratifying by age." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"Nurse assessors were blind to the treatment assignment of the children." Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described; significant differences between completers and non- completers are not reported
Selective reporting (re- porting bias)	Unclear risk	Data were fully reported when requested

## Levy 2016

Study characteristics	
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 3 months, 6 months, and 12 months
Participants	End of treatment: n = 158; follow-up 3 months: n = 137; follow-up 6 months: n = 144, follow-up 12 months: n = 133
	Start of treatment: n = 185



Bias	Authors' judgement Support for judgement		
Risk of bias			
	Funding: "Supported by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (award number R01HD050345 to R. L. Levy)."		
Notes	COI: "The authors have no conflict of interest to disclose."		
	12.IBD specific medical information		
	11.Flare counts		
	10.Pediatric Crohn's Disease Activity Index/Pediatric Ulcerative Colitis Activity Index		
	<ol> <li>Children's Depression Inventory</li> <li>Multidimensional Anxiety Scale for Children</li> </ol>		
	7. Functional Disability Inventory		
	6. IMPACT-III (quality of life)		
	5. School attendance		
	4. Healthcare utilisation		
	<ol> <li>Pain Response Inventory</li> <li>Pain Beliefs Questionnaire</li> </ol>		
	1. Adults' Responses to Children's Symptoms		
	Primary anxiety outcome: Multidimensional Anxiety Scale for Children		
	Primary depression outcome: Children's Depression Inventory		
	Primary disability outcome: Functional Disability Inventory		
Outcomes	Primary pain outcome: none		
	"Education support"		
Interventions	"Social learning cognitive-behavioral therapy"		
	Mean years of pain = not reported		
	Diagnosis = Crohn's disease or ulcerative colitis		
	Source = paediatric GI clinics		
	Mean age = 13.5 years (SD = 2.7)		
evy 2016 (Continued)	Sex: 87 F, 98 M		

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"Randomization was then performed by a different researcher using a comput- erized random-number generator, stratifying by age (7–11 or 12–18 years old) and then by physician-reported disease severity (quiescent, mild, or moder- ate/severe based on either the Pediatric Ulcerative Colitis Activity Index (PU- CAI) for patients with UC or the Pediatric Crohn's Disease Activity Index (PCDAI) for Crohn's patients) completed during enrolment." Comment: probably done
Allocation concealment	Unclear risk	No description
(selection bias)		Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"At all assessment points, parents completed questionnaires online or by mail (whichever modality they preferred). Children completed assessments



### Levy 2016 (Continued)

		through a scheduled telephone call with a highly trained research nurse who was blinded to the participant's treatment assignment."
		Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described; significant differences between completers and non- completers were not reported
Selective reporting (re- porting bias)	Low risk	Data were fully reported.

## Levy 2017

Study characteristics		
Methods	RCT. 3 arms (only 2 arms included here, see Interventions below). Assessed at pretreatment, 1 week, 3 months, and 6 months after treatment.	
Participants	End of treatment: n = 166 children; 170 parents.	
	3 month follow-up: n = 160 children; 164 parents.	
	6 months follow-up: n = 159 children; 164 parents.	
	Start of treatment: n = 216	
	Child Sex: 140 F, 76 M; Parent Sex: 205 F, 11 M	
	Child mean age = 9.4 years (SD = 1.7); parent mean age = 39.8 years (7.7)	
	Source = paediatric GI clinics	
	Diagnosis = functional abdominal pain	
	Mean years of pain = not reported	
Interventions	"Social learning cognitive-behavioral therapy (face-to-face)"	
	"Social learning cognitive-behavioral therapy-Remote (delivered via the telephone)" - this condition was excluded from this review. See Fisher 2015 for remotely-delivered psychological interventions.	
	"Education support"	
Outcomes	Primary pain outcome: Abdominal Pain Index- Severity	
	Primary disability outcome: Functional Disability Inventory (parent report)	
	Primary depression outcome: None	
	Primary anxiety outcome: Pain Response Inventory - Catastrophizing subscale	
	<ol> <li><u>Child reported measures</u> <ul> <li>Abdominal Pain Index (child report)</li> <li>Pain Response Inventory</li> </ul> </li> </ol>	
	c. Children's Somatization Inventory	
	<ul> <li>d. Pediatric Quality of Life Inventory</li> <li>2. <u>Parent reported measures</u> <ul> <li>a. Adults' Responses to Children's Symptoms</li> <li>b. Pain Beliefs Questionnaire</li> </ul> </li> </ul>	



Levy 2017 (Continued)	
	c. Pain Catastrophizing Scale for Parents
	d. Functional Disability Inventory
	e. Healthcare utilisation
	f. School attendance
	g Pain Behavior Child Lise (narent report)

- g. Pain Behavior Child Lise (parent report)
- h. Children's Somatization Inventory
- i. Pediatric Quality of Life Inventory

Notes

COI: "The authors have no conflicts of interest relevant to this article to disclose."

Funding: "This study was supported by award R01HD36069-0981 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R.L.L.)."

Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"Randomization using a computer-generated randomization sequence oc- curred after baseline assessments, stratified by child gender and baseline parent-reported child pain severity scores on the Abdominal Pain Index (API) (scores at or above 1.75 [the median value from our previous study] vs below)
		Comment: probably done
Allocation concealment (selection bias)	Unclear risk	"After enrolment and completion of baseline assessments, the study coordi- nator queried the randomization database for treatment assignment and ther scheduled sessions with the participant."
		Comment: unclear allocation concealment
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"Parents completed questionnaires online or by mail (90.5% online). Children completed assessments through a telephone call with a trained interviewer blinded to study hypotheses and treatment assignment."
		Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Data attrition fully reported. Differences between completers and non-completers of the study
Selective reporting (re- porting bias)	Low risk	All data was reported

### McGrath 1988

Study characteristics		
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, 3 months, 12 months	
Participants	End of treatment: n = 99	
	Start of treatment: n = 136	
	Sex: 69 F, 30 M	
	Mean age = 13.1 years (range 11 to 18)	

	Source = hospital Diagnosis = headache Mean years of pain = not given: minimum 3 months	
	Mean years of pain = not given: minimum 3 months	
Interventions	"Relaxation training" "Attention control" "Own best efforts"	
Outcomes	Primary pain outcome: headache index	
	Primary disability outcome: none	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Headache index	
	2. Headache-free days	
	3. Highest pain intensity	
Notes	COI: not reported	
	Funding: "Research supported by the Ontario Ministry of Health, Ontario Ministry of Community and Social Services and the Children's Hospital of Eastern Ontario. Dr. McGrath is supported by a Career Scientist Award of the Ontario Ministry of Health."	

Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	"Randomly assigned to one of three groups" Comment: probably done, no method described	
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was described, however significant differences between completers and non-completers were not reported	
Selective reporting (re- porting bias)	Low risk	Data were completely reported	

# McGrath 1992

Study characteristics		
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, 3 months, and 1-year follow-up	
Participants	End of treatment: n = 74	
	Start of treatment: n = 87	



McGrath 1992 (Continued)				
	Sex: 63 F, 24 M			
	Mean age = not given: range 11 to 18 years			
	Source = paediatricians and family physicians			
	Diagnosis = migraine			
	Mean years of pain not	given: minimum 3 months		
Interventions	"Therapist administered cognitive behavioural/stress coping/relaxation training"			
	"Self-administered cognitive behavioural/stress coping/relaxation training"			
	"Information and support"			
Outcomes	Primary pain outcome: headache diary			
	Primary disability outcome: none			
	Primary depression outcome: Poznanski Depression Scale			
	Primary anxiety outcome: none			
	1. Headache index			
	<ol> <li>2. Efficiency of treatment</li> <li>3. Poznanski Depression Scale</li> </ol>			
Notes	COI: not reported			
	Funding: "This research was funded by the National Health and Welfare Research and Developm Program of Canada. Dr. McGrath was supported by a Career Scientist Award of the Ontario Minist Health."			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	"Randomised to 1 of the 8-week treatments" Comment: probably done, no method described		
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done		
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported		

Selective reporting (re- High risk Data were incompletely reported porting bias)

## Osterhaus 1997

Study characteristics



### Osterhaus 1997 (Continued)

Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment and 1-year follow-up	
Participants	End of treatment: n = 39, 1-year follow-up: n = 21	
	Start of treatment: n = 39	
	Sex: 29 F, 10 M	
	Mean age = 15.2 years (SD 3.3)	
	Source = newspaper article	
	Diagnosis = headache (migraine, tension-type, mixed)	
	Mean years of pain = 5.6	
Interventions	"Behavioural treatment package" "waiting-list control"	
Outcomes	Primary pain outcome: headache index	
	Primary disability outcome: none	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	<ol> <li>Headache index</li> <li>Headache frequency</li> <li>Headache duration</li> <li>Headache intensity</li> </ol>	
Notes	COI: not reported.	
	Funding: "This study was supported by Iht: Dutch Fund for Menial Hcalqh (NFGV)."	

#### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The participants were randomly assigned to one of two groups" Comment: probably done, no method described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition was not described
Selective reporting (re- porting bias)	Low risk	Data were fully reported



### Palermo 2016

### Study characteristics

Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment and 3 month follow-up	
Participants	End of treatment: n = 60, 3 month follow-up: n = 59	
	Start of treatment: n = 61	
	Child sex: 49 F, 11 M	
	Parent sex: 60 F, 1 M	
	Child mean (SD) age = 14.07 years (1.80)	
	Source = pain clinic	
	Diagnosis = mixed chronic pain conditions	
	Mean years of pain = unknown	
Interventions	"Problem-solving skills training"	
	"Treatment-as-usual"	
Outcomes	Primary pain outcome: Child pain intensity	
outcomes	Primary disability outcome: Physical disability (BAPQ)	
	Primary depression outcome: Depression (BAPQ)	
	Primary anxiety outcome: General anxiety (BAPQ)	
	<ol> <li><u>Child-reported measures:</u></li> <li>a. Pain intensity</li> </ol>	
	b. Bath Adolescent Pain Questionnaire	
	c. Adverse events	
	2. <u>Parent-reported measures:</u>	
	a. Beck Depression Inventory	
	b. Profile of Mood States	
	c. Bath Adolescent Pain – Parental Impact Questionnaire	
	d. Pain Catastrophizing Scale - Parents e. Brief Symptoms Inventory	
	f. Short Form Health Survey 12	
	g. Parenting Stress Index - Short Form	
	h. Helping for Health Inventory	
	i. Treatment Evaluation Inventory - Short form	
	j. Adverse events	
Notes	COI: "The authors have no conflicts of interest to declare."	
	Funding: "Research reported in this publication was supported by the Eunice Kennedy Shriver Nationa Institute of Child Health & Human Development of the National Institutes of Health under Award Num- ber R21HD065180 (PI: T. M. P.)."	
Risk of bias		
Bias	Authors' judgement Support for judgement	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"A fixed allocation randomization scheme was used. The order of randomiza- tion to the 2 treatment conditions was generated separately for each site with



Palermo 2016 (Continued)

Trusted evidence. Informed decisions. Better health.

		an online program (randomizer.org). A blocked method design was used, with blocks of 4 for each identification number"
		Comment: probably done
Allocation concealment (selection bias)	Low risk	"Only the research coordinator had the password to the randomization table. Group assignment was concealed by formatting the document to block out group assignment until the time of randomization."
		Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"All study assessments were self-report measures completed in participants' homes through mailings; children and parents were instructed to complete the measures independently."
		Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was fully reported and there were no differences between completers and non-completers
Selective reporting (re- porting bias)	Low risk	All data were fully reported
	LOW FISK	All data were fully reported

### Passchier 1990

Study characteristics	5
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment
Participants	End of treatment: n = 119
	Start of treatment: n = 119
	Sex: 65 F, 54 M
	Mean age = 13.7 years (SD 1.4)
	Source = school
	Diagnosis = headache (at least weekly)
	Mean years of pain = none given
Interventions	"Progressive relaxation training" "Placebo physical concentration training"
Outcomes	Primary pain outcome: headache intensity
	Primary disability outcome: school problems
	Primary depression outcome: none
	Primary anxiety outcome: Fear of Failure
	1. Headache intensity
	2. Headache frequency
	3. Headache duration
	4. School problems (composite)



Passchier 1990 (Continued)

### 5. Fear of failure (from Hermans' Debilitating Anxiety of Achievement Motivation Test)

Notes	COI: not reported
	Funding: not reported
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The 19 classes of the participating teachers were allocated at random to a Progressive Relaxation Training or a Placebo Training group." Comment: probably done, no method described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts were reported
Selective reporting (re- porting bias)	High risk	Data were incompletely reported

# **Powers 2013 Study characteristics** Methods RCT. 2 arms. Assessed pretreatment, post-treatment, and 12 months Participants End of treatment: n = 124 Start of treatment: n = 135 Sex: 107 F, 28 M Mean age = 14.4 years (SD 2.0) Source = clinic Diagnosis = migraine Mean years of pain = none given Interventions "Cognitive behavioral therapy plus amitriptyline" "Headache education plus amitriptyline" Outcomes Primary pain outcome: headache frequency Primary disability outcome: Ped-MIDAS Primary depression outcome: none Primary anxiety outcome: none



Powers 2013 (Continued)	<ol> <li>Headache diary (use of abortive medication, headache occurrence, intensity, duration, associated symptoms for migraine).</li> <li>Ped-MIDAS</li> <li>Treatment integrity</li> <li>Treatment credibility</li> </ol>
Notes	COI: "The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported." Funding: "Funding was provided by grant R01NS05036 from the National Institute of Neurological Disorders and Stroke (Dr Powers), grant 8 UL1 TR000077 from the National Center for Research Resources and the National Center for Advancing Translational Sciences, and grant T32DK063929 from the National Institute of Diabetes and Digestive and Kidney Diseases for some of the postdoctoral fellows who contributed to the trial (Dr Powers, program director). Amitriptyline, which was provided without cost to participants, was purchased using National Institutes of Health grant funds and managed by the investigational pharmacy at Cincinnati Children's Hospital Medical Center. If prevention drug was clinically prescribed during the 12-month follow-up period, families had financial responsibility for the medications as with typical clinical practice."

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"Block randomization (with varying block sizes of 4-10) was used, and partic- ipants were stratified by age. Randomization was computer generated and supplied via secure e-mail to the study therapist." Comment: probably done
Allocation concealment (selection bias)	Low risk	"Randomization was computer generated and supplied via secure e-mail to the study therapist." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"Outcome assessments were conducted by blinded study personnel." Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not described
Selective reporting (re- porting bias)	Unclear risk	Data fully reported on request

### Richter 1986

Study characteristics	
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment
Participants	End of treatment: n = 43
	Start of treatment: n = 51
	Sex: 34 F, 17 M
	Mean age = 12.9 years

Richter 1986 (Continued)	Source = referred by pl	nysicians to children's hospital	
	Diagnosis = migraine		
		ot given: mostly over 2 years	
Interventions	"Relaxation training" "Cognitive coping" "Attention control"		
Outcomes	Primary pain outcome	: headache diary	
	Primary disability outc	ome: none	
	Primary depression ou	tcome: Child Depression Rating Scale	
	Primary anxiety outcome: State Trait Anxiety Inventory		
	<ol> <li>Headache index (intensity, frequency, duration, medication taken: diary)</li> <li>State Trait Anxiety Inventory (STAI) or State-Trait Anxiety Inventory for Children (STAI-C)</li> <li>Children's Depression Rating Scale</li> </ol>		
Notes	COI: not reported		
	Funding: "This research was supported by grants from the Ontario Ministry of Health and the Ontario Ministry of Community and Social Services."		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	" and randomly assigned to treatment" Comment: probably done, no method described	
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done	
Blinding of outcome as-	Unclear risk	No description found in text	
sessment (detection bias) All outcomes		Comment: probably not done	
Incomplete outcome data (attrition bias) All outcomes	Low risk	"Over the course of treatment there were 8 drop-outs. A chi-square analysis comparing attrition rates across interventions was not significant." Comment: attrition adequately reported and no significant differences be- tween completers and non-completers reported	
Selective reporting (re- porting bias)	High risk	Data were incompletely reported	

#### Robins 2005

Study characteristics		
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment (3 months after start), 6 to 12 months	
Participants	End of treatment: n = 69	
	Start of treatment: n = 86	



Robins 2005 (Continued)		
	Sex: 39 F, 30 M	
	Mean age = 11.4 years (SD 2.4)	
	Source = paediatric gastroenterology outpatient clinic of children's hospital	
	Diagnosis = recurrent abdominal pain	
	Mean years of pain = not stated	
Interventions	"Short term cognitive behavioural family treatment plus standard medical care"	
	"Standard medical care"	
Outcomes	Primary pain outcome: Abdominal Pain Index	
	Primary disability outcome: Functional Disability Inventory	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Abdominal Pain Index	
	2. Child Somatization Inventory	
	3. Functional Disability Inventory	
	4. Abdominal Pain Index (parent)	
	5. Child Somatization Inventory (parent)	
Notes	COI: not reported.	
	Funding: "This study was supported in part by a grant through the Nemours Research Programs, awarded to the first author."	
Risk of bias		

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	"The remaining sample of 86 were randomly assigned using a coin-flip method." Comment: probably done
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not described
Selective reporting (re- porting bias)	High risk	Data were incompletely reported

### Sanders 1994

2

### Study characteristics



anders 1994 (Continued) Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 6 months, 1 year
Participants	End of treatment: n = 44
	Start of treatment: n = 44
	Sex: 28 F, 16 M
	Mean age = 9.2 years (SD 1.9)
	Source = not given
	Diagnosis = recurrent abdominal pain
	Mean years of pain = 3.7
Interventions	"Cognitive behaviour therapy" "Standard paediatric care"
Outcomes	Primary pain outcome: pain diary
	Primary disability outcome: interference with child activity
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Pain intensity diary
	2. Parent observation of child pain behaviour (POR)
	3. Child behaviour checklist (CBCL '83)
	4. Relapse versus pain-free
	5. Interference with child activity (child report)
	6. Interference with child activity (parent report)
Notes	COI: not reported
	Funding: "This study was supported by Grant 53091 from the National Health and Medical Research Council of Australia to Matthew R. Sanders, Ross W. Shepherd, and Geoggery Cleghorn."

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The study used a randomised group comparison design with two treatment conditions." Comment: method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition was not described and significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	High risk	Data were incompletely reported



### Sartory 1998

Study characteristics	
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment (4 weeks after end of intervention), 8 months follow-up
Participants	End of treatment: n = 43
	Start of treatment: n = 43
	Sex: 17 F, 26 M
	Mean age = 11.3 years (SD 2.1)
	Source = outpatient clinic of paediatric hospital and advertising in press
	Diagnosis = migraine
	Mean years of pain = 4.6
Interventions	"Cephalic vasomotor training + stress management"
	"Relaxation training + stress management"
	"Beta-blocker (metoprolol)"
Outcomes	Primary pain outcome: headache index
	Primary disability outcome: none
	Primary depression outcome: mood faces scale
	Primary anxiety outcome: none
	1. Headache index
	<ol> <li>Episodes/week when analgesics taken</li> <li>Mood faces scale, 5-point smiling - upset</li> </ol>
Notes	COI: not reported
Notes	
	Funding: "This study was supported by the Bundesminister fuÈ r Forschung und Technologie (BMFT; Federal Minister for Research and Technology, Germany)."

#### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Children were allocated randomly to one of three treatment groups" Comment: probably done, no method described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias)	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not described



### Sartory 1998 (Continued) All outcomes

Selective reporting (re- Low risk porting bias)

Data were fully reported

### Scharff 2002

Study characteristics			
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, 3 months, 6 months, 12 months		
Participants	End of treatment: n = 34		
	Start of treatment: n =	36	
	Sex: 24 F, 12 M		
	Mean age 12.8 years (SD 2.4)		
	Source = children's hospital		
	Diagnosis = migraine (a	all), tension-type headache (minority)	
	Mean years of pain = 2.	4 (SD 2.1)	
Interventions	"Handwarming biofeed	dback and stress management"	
	"Handcooling attention	n control"	
	"Waitlist control"		
Outcomes	Primary pain outcome: headache index		
	Primary disability outcome: none		
	Primary depression outcome: Child Depression Inventory		
	Primary anxiety outcome: State Trait Anxiety Inventory for Children		
	1. Headache index		
	<ol> <li>Days with headache</li> <li>Highest headache rating</li> </ol>		
	4. Child Depression Inventory (CDI)		
	5. State-Trait Anxiety I	nventory for Children (STAIC)	
Notes	COI: not reported		
	Funding: "This research was supported by grants from the University of Pittsburgh Anethesiology and Critical Care Foundatation, the Raymond and Elizabeth Bloch Educational and Charitable Foundation, and the NIH/NICHD (HD38647)."		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	"At the assessment visit children were randomised into three groups using a randomisation table" Comment: probably done	



### Scharff 2002 (Continued)

Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was described; there were no significant differences between com- pleters and non-completers
Selective reporting (re- porting bias)	High risk	Data were incompletely reported

### Van der Veek 2013

Study characteristics	
Methods	RCT. 2 arms. Assessed pretreatment, post-treatment, 6 months, and 12 months follow-up
Participants	End of treatment: n = 92; n = 88 at 12 months follow-up
	Start of treatment: n = 104
	Sex: 24 F, 12 M
	Mean age 11.9 years (SD 2.77)
	Source = children's hospital
	Diagnosis = abdominal pain
	Mean months of pain = 34.01 (SD 37.54)
Interventions	"Cognitive behavior therapy"
	"Intensive medical care"
Outcomes	Primary pain outcome: Abdominal Pain Index (child report)
	Primary disability outcome: Functional Disability Inventory (child report)
	Primary depression outcome: Revised Child Anxiety and Depression Scale - Short Version (child report
	Primary anxiety outcome: Revised Child Anxiety and Depression Scale - Short Version (child report)
	1. Abdominal Pain Index (completed by child and parent)
	2. Functional Disability Inventory (completed by child and parent)
	3. Revised Child Anxiety and Depression Scale - Short Version (completed by child and parent)
	4. KIDSCREEN (quality of life) (completed by child and parent)
	5. Satisfaction with treatment and therapist/doctor (completed by child and parent)
	6. Pain diary (child report)
	7. Healthcare use (follow-up only)
Notes	COI: "The authors have indicated they have no potential conflicts of interest to disclose."
	Funding: "The current study was funded by the Dutch Digestive Foundation, grant SWO 05-09."

### Van der Veek 2013 (Continued)

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The first author randomized the children using a computerized randomiza- tion program" Comment: probably done, method not described
Allocation concealment (selection bias)	Unclear risk	No description found in text Comment: probably not done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	"Diary data were entered in SPSS by students who were blinded to treatment." Comment: probably not done but no description given for other measures
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not described
Selective reporting (re- porting bias)	Unclear risk	Data fully reported when requested

### Van Tilburg 2009

Study characteristics		
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 6 months	
Participants	End of treatment: n = 29; follow-up: n = 24 Start of treatment: n = 34 Sex: 25 F, 9 M Mean age = 10.25 years (SD 2.6) Source = University of North Carolina and Duke University Medical Centres Diagnosis = functional abdominal pain Mean years of pain = unknown	
Interventions	"Guided imagery treatment" "Standard medical care"	
Outcomes	Primary pain outcome: Abdominal Pain Index	
	Primary disability outcome: Functional Disability Inventory	
	Primary depression outcome: none	
	Primary anxiety outcome: none	
	1. Abdominal Pain Index	
	2. Functional Disability Inventory	
	3. School attendance	
	4. Pediatric Quality of Life Inventory	
	5. Global rating of change in abdominal pain 6. Treatment compliance	
	7. Questionnaire of paediatric gastrointestinal symptoms	
	8. Healthcare utilisation	

### Van Tilburg 2009 (Continued)

Notes

COI: the authors indicated they had no financial relationships relevant to this article to disclose

Funding: this work was supported by National Institutes of Health grants R24 DK067674 and RR00046

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Thirty-four children were assigned randomly to receive 2 months of standard medical care with or without home-based, guided imagery treatment." Comment: probably done, method not described
Allocation concealment (selection bias)	Low risk	"Children picked a closed envelope that determined whether they would re- ceive standard medical care with or without guided imagery treatment." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	Unclear risk	Data provided on request.

# Vlieger 2007 **Study characteristics** Methods RCT. 2 arms. Assessed at pretreatment, post-treatment, 6 months, 1 year Participants End of treatment: n = 51 Start of treatment: n = 52 Sex: 39 F, 13 M Mean age = 13.3 years (SD 2.7) Source = paediatric gastroenterology department in hospital Diagnosis = functional abdominal pain (n = 31) and irritable bowel syndrome (IBS) (n = 22) Mean years of pain = 3.4 Interventions "Gut-directed hypnotherapy" "Standard medical care plus supportive therapy" Outcomes Primary pain outcome: weekly pain intensity Primary disability outcome: none Primary depression outcome: none Primary anxiety outcome: none



Vlieger 2007 (Continued)		
-	1. Total pain intensity hence 0 to 21)	over 1 week (9-point Faces Affective Pain Intensity Scale, reduced to 0 to 3 points,
	2. Total pain frequenc	y over 1 week (frequency reduced to 0 to 3 scale per day)
	3. Associated sympton pain related to mea	ms (nausea, vomiting, loss of appetite, flatus, nocturnal pain, pain on wakening, ls)
Notes	COI: not reported.	
	Funding: "There was n	o external funding source."
Risk of bias		
Bias	Authors' judgement	Support for judgement
Denders services service	Louriel	"Detients were density all sectod using a semicutariand random number

Random sequence genera- tion (selection bias)	Low risk	"Patients were randomly allocated using a computerised random-number generator for concealment to either HT or standard medical care." Comment: probably done
Allocation concealment (selection bias)	Low risk	"Patients were randomly allocated using a computerised random-number generator for concealment to either HT or standard medical care." Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"Pain diaries were analysed by S. W. (medical student), who was blinded to the treatment arm." Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re-	Low risk	Data were fully reported

### Wahlund 2003

porting bias)

Study characteristics		
Methods	RCT. 3 arms. Assessed at pretreatment, post-treatment, and 6 months	
Participants	End of treatment: n = 110	
	Start of treatment: n = 122 (BI + RT = 41; BI + OA = 42; BI = 39)	
	Sex: 93 F, 29 M	
	Mean age = 15.3 years (SD 2.0)	
	Source = TMD clinic in Linköping, Sweden	
	Diagnosis = temporomandibular disorders	
	Mean years of pain = unknown	
Interventions	"Brief Information + Relaxation training (BI + RT)"*	
	"Brief Information + Occlusal appliance (BI + OA)"	
	"Brief Information"*	



### Wahlund 2003 (Continued)

\*For the purposes of this review, we excluded only BI + RT (treatment) and BI (control)

Outcomes	Primary pain outcome: pain intensity
	Primary disability outcome: none
	Primary depression outcome: none
	Primary anxiety outcome: none
	1. Pain intensity
	2. Pain frequency
	3. Pain Index
	4. Pain diary
	5. Clinical significance
	6. Subjective evaluation of treatment
	7. Analgesic consumption
	8. School absence
	9. Research diagnostic criteria for temporomandibular disorders
	10.Treatment motivation and credibility
	11.Pressure pain threshold
Notes	COI: not reported
	Funding: "The study was supported by the Public Dental Service of Östergötland (Östergötland's Coun- try Council), Sweden."

### **Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"The patients were randomly assigned to one of the following 3 treatment groups"
		Comment: randomisation procedure unclear
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	"At each evaluation, all subjects filled out a self-administered questionnaire and were clinically examined by a 'blinded' calibrated clinician."
		Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition reported, and there were no differences between completers and non-completers
Selective reporting (re- porting bias)	Low risk	All measures were reported

### Wahlund 2015

**Study characteristics** 



#### Wahlund 2015 (Continued)

Methods	RCT. 2 arms. Assessed at pretreatment and three months. Non-responders were then assigned to to other condition and assessed at 6 months. We extracted data only from the three-month time point of the three month time point.					
Participants	End of treatment: n = 57					
	Start of treatment: n = 64					
	Sex: 61 F, 3 M					
	Mean age = 16.4 years (	SD 1.87)				
	Source = two specialist	temporomandibular clinics in Sweden				
	Diagnosis = temporom	andibular pain at least once a week for more than three months				
	Mean years of pain = 23	3.9 months (SD 19.05)				
Interventions	"Occlusal appliance the	erapy"				
	"Relaxation treatment'	,				
Outcomes	Primary pain outcome:	pain intensity				
	Primary disability outc	ome: none				
	Primary depression outcome: none					
	Primary anxiety outcome: none					
Notes	<ol> <li>Analgesic consumpt</li> <li>School absence</li> <li>Maximum unassiste</li> <li>Treatment motivation</li> <li>Treatment complian</li> <li>COI: "The authors report</li> <li>Funding: "This study we (Östergötland County O</li> </ol>	pression of Change Scale tion d pain-free opening on and credibility				
Risk of bias						
Bias	Authors' judgement	Support for judgement				
Random sequence genera- tion (selection bias)	Low risk	"Using a random number table, a secretary not otherwise involved in the study generated the allocation sequence to assign patients to a treatment, either oc- clusal appliance therapy or relaxation treatment."				
		Comment: probably done				
Allocation concealment (selection bias)	Low risk	"Using a random number table, a secretary not otherwise involved in the study generated the allocation sequence to assign patients to a treatment, either oc-				
	Low risk	Comment: probably done "Using a random number table, a secretary not otherwise involved in th				



### Wahlund 2015 (Continued)

clusal appliance therapy or relaxation treatment. The secretary put these assignments in sealed opaque envelopes."

		Comment: probably done
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No description found in text Comment: probably not done
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	Low risk	Data fully reported

### Wicksell 2009

Study characteristics	S				
Methods	RCT. 2 arms. Assessed at pretreatment, post-treatment, 3.5 months, 6.8 months				
Participants	End of treatment: n = 29; follow-up 3.5 months: n = 24; follow-up 6.8 months: n = 24				
	Start of treatment: n = 32				
	Sex: 25 F, 7 M				
	Mean age = 14.8 years (SD 2.4)				
	Source = Astrid Lindgren Children's Hospital, Karolinska University Hospital				
	Diagnosis = mixed pain (headache, back/neck, widespread musculoskeletal, complex regional pain syn- drome, visceral, lower extremities, postherpetic type cheek pain)				
	Mean years of pain = 2.7				
Interventions	"Exposure and acceptance"				
	"Multidisciplinary treatment and amitriptyline"				
Outcomes	Primary pain outcome: pain intensity				
	Primary disability outcome: Functional Disability Inventory				
	Primary depression outcome: Center for Epidemiological Studies Depression Scale for Children				
	Primary anxiety outcome: Pain Coping Scale (catastrophising subscale)				
	1. Pain intensity				
	2. Functional Disability Inventory				
	3. Center for Epidemiological Studies Depression Scale for Children				
	4. Multidimensional Pain Inventory (interference scale)				
	5. Brief Pain Inventory (pain interference items)				
	6. Pain and Impairment Relationship Scale				
	7. Short form-36 Health Survey				
	8. Tampa Scale of Kinesiophobia 9. Pain Coping Questionnaire (internalising and catastrophising)				
	9. Pain Coping Questionnaire (internalising and catastrophising)				



Wicksell 20	09 (Continued)
-------------	----------------

10.5 author-generated questions on pain-related discomfort

COI: "There are no financial or other relationships that might lead to a conflict of interest."

Funding: "This study was in part financed by the Swedish Research Council and by fundings from the Karolinska Institute."

**Risk of bias** 

Notes

Bias	Authors' judgement	Support for judgement
Random sequence genera- ion (selection bias)	Low risk	"A total of 32 participants were included in the study and randomised to one of the two treatment conditions. A simple randomisation technique was used." Comment: probably done
Allocation concealment selection bias)	Low risk	"A sealed envelope (prepared by a secretary blind to the objective of the study) containing a code for 'exposure and acceptance' or 'MDT' was opened, assign- ing the participant to one of the treatment conditions." Comment: probably done
Blinding of outcome as- ressment (detection bias) All outcomes	Low risk	"All assessments were conducted by a nurse who was not involved in deliver- ing the treatment protocol." Comment: probably done
ncomplete outcome data attrition bias) \ll outcomes	Unclear risk	Attrition was described, however significant differences between completers and non-completers were not reported
Selective reporting (re- porting bias)	Low risk	Data were fully reported

CBT: cognitive behavioural therapy CDI: CDS: CHS: CMAS: COI: COPE-HEP: DIKJ: F: female FDI-C: Functional Disability Inventory - Children HCM: HT: hypnotherapy IBD: inflammatory bowel disease (IBD) IMPACT: JPFM: juvenile primary fibromyalgia KIDSCREEN: KINDL-R M: male MDT: MEMS: NRS: numeric rating scale



OA:
PCQ:
Ped-MIDAS: Pediatric Migraine Disability Assessment
PEDSQL: Paediatric Scale Quality of Life Inventory
POR:
PSSI:
RCT: randomised controlled trial
RT:
SC:
SCD: sickle cell disease
SD: standard deviation
SS:
STAI:
STAIC:
TAT:
TCM:
TMD:
TT:
VAS: visual analogue scale

### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion			
Connelly 2006	Intervention delivered remotely			
Fentress 1986	Inadequate sample size (n < 10 in 1 arm of study design)			
Gulewitsch 2017	Non-inferiority trial			
Hicks 2006	Intervention delivered remotely			
Jastrowski Mano 2013	Inadequate sample size (n < 10 in 1 arm of study design)			
Koenig 2013	Insufficient psychological treatment			
Korterink 2016	Insufficient psychological treatment			
Kroener-Herwig 1998	Inadequate sample size (n < 10 in 1 arm of study design)			
Larsson 1986	Inadequate sample size (n < 10 in 1 arm of study design)			
Olness 1987	Insufficient psychological treatment			
Palermo 2009	Intervention delivered remotely			
Rapoff 2014	Intervention delivered remotely			
Rutten 2017	Non-inferiority trial			
Sanders 1989	Inadequate sample size (n < 10 in 1 arm of study design)			
Stinson 2010	Intervention delivered remotely			
Trautmann 2008	Inadequate sample size (n < 10 in 1 arm of study design)			



Study	Reason for exclusion			
Trautmann 2010	Intervention delivered remotely			
Vlieger 2012	Follow-up period more than 1 year			
Weydert 2006	Inadequate sample size (n < 10 in 1 arm of study design)			
Youssef 2009	Inadequate sample size (n < 10 in 1 arm of study design)			

## DATA AND ANALYSES

### Comparison 1. Treatment versus control (headache) post-treatment

Outcome or sub- group title	No. of studies	No. of partici- pants	Statistical method	Effect size	
1.1 Pain	15	644	Risk Ratio (M-H, Random, 95% CI)	2.35 [1.67, 3.30]	
1.1.1 N < 20	13	437	Risk Ratio (M-H, Random, 95% CI)	2.86 [1.73, 4.72]	
1.1.2 N > 20	2	207	Risk Ratio (M-H, Random, 95% CI)	1.88 [1.36, 2.58]	
1.2 Disability	6	446	Std. Mean Difference (IV, Random, 95% CI)	-0.26 [-0.56, 0.03]	
1.2.1 N < 20	2	61	Std. Mean Difference (IV, Random, 95% CI)	0.04 [-0.47, 0.54]	
1.2.2 N > 20	4	385	Std. Mean Difference (IV, Random, 95% CI)	-0.35 [-0.69, -0.00]	
1.3 Depression	6	400	Std. Mean Difference (IV, Random, 95% CI)	-0.08 [-0.28, 0.11]	
1.3.1 N < 20	3	103	Std. Mean Difference (IV, Random, 95% CI)	-0.16 [-0.68, 0.35]	
1.3.2 N > 20	3	297	Std. Mean Difference (IV, Random, 95% CI)	-0.06 [-0.29, 0.17]	
1.4 Anxiety	7	439	Std. Mean Difference (IV, Random, 95% CI)	-0.11 [-0.39, 0.17]	
1.4.1 N < 20	4	136	Std. Mean Difference (IV, Random, 95% CI)	0.01 [-0.54, 0.57]	
1.4.2 N > 20	3	303	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.49, 0.11]	



### Analysis 1.1. Comparison 1: Treatment versus control (headache) post-treatment, Outcome 1: Pain

L1.1 N < 20         3arry 1997       2       12       2       17 $3.1\%$ $1.42 [0.23, 8.70]$ Griffiths 1996       12       15       3       12       7.6% $3.20 [1.16, 8.80]$ Gromen-Herwig 2002       16       29       8       19 $13.1\%$ $1.31 [0.70, 2.44]$ abbe 1984       13       14       1       4       2.9% $13.00 [1.96, 86.42]$ abbe 1995       19       20       6       10 $15.1\%$ $1.58 [0.59, 2.65]$ arsson 1987a       7       14       1       12 $2.7\%$ $5.50 [0.79, 38.30]$ arsson 1987b       1       10       1       12 $1.6\%$ $1.20 [0.09, 16.64]$ arsson 1987b       1       10       1 $12$ $1.6\%$ $1.20 [0.09, 16.64]$ arsson 1996       9       13       1 $32.8\%$ $9.00 [1.32, 61.24]$ Starbus 1997       13       2.3 $2.6\%$ $12.38 [1.71, 89.86]$ Grant 1996       20       30       5 $31 1.23$ $1.73 [0.83, 1.61]$ Grant 1997       13       12.38 [1.71, 89.86] $3.61 [1.73, 4.72]$ </th <th></th> <th>Experin</th> <th>nental</th> <th>Cont</th> <th>rol</th> <th></th> <th><b>Risk Ratio</b></th> <th>Risk Ratio</th>		Experin	nental	Cont	rol		<b>Risk Ratio</b>	Risk Ratio
Barry 1997 2 12 2 17 3.1% $1.42 [0.23, 8.70]$ itchel 2001 10 20 2 16 4.9% $4.00 [1.02, 15.72]$ itchel 2001 2 15 3 12 7.6% $3.20 [1.16, 8.80]$ itchel 2002 16 29 8 19 13.1% $1.31 [0.70, 2.44]$ abbe 1984 13 14 1 14 2.9% $13.00 [1.96, 86.42]$ abbe 1985 19 20 6 10 15.1% $1.58 [0.05, 2.65]$ itchel 2003 7 14 1 11 2.7% $5.50 [0.79, 38.30]$ arsson 1987a 7 14 1 11 2.7% $5.50 [0.79, 38.30]$ arsson 1987b 1 1 0 1 12 1.6% $1.20 [0.09, 1.684]$ arsson 1987b 1 1 0 1 12 1.6% $1.20 [0.09, 3.63]$ arsson 1990 6 31 0 17 1.4% $7.31 [0.44, 122, 42]$ baches 1997 13 25 0 144 $1.5\%$ 15.58 $[1.00, 243, 71]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.73 [0.83, 3.61]$ isatory 1998 20 30 5 13 11.2% $1.79 [1.26, 2.55]$ isatoral events: $135$ 31 Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 23.54; df = 12 (P = 0.02); P = 49% Total events: $68$ 32 Heterogeneity: Tau <sup>2</sup> = 0.03; df = 1 (P = 0.54); P = 0% Total events: $203$ $63$ Heterogeneity: Tau <sup>2</sup> = 0.03; df = 1 (P = 0.54); P = 0% Total (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] isatory 1.00 Favours control Favours control Favours treatment feterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 2.25, df = 14 (P = 0.07); P = 38% Total events: $203$ $63$ Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 2.25, df = 14 (P = 0.07); P = 38% Total events: $203$ $63$ Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 2.25, df = 14 (P = 0.07); P = 38\%	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Tichtel 2001       10       20       2       16       4.9%       4.00 [1.02, 15.72]         Triffiths 1996       12       15       3       12       7.6%       3.20 [1.16, 8.80]         Greener-Herwig 2002       16       29       8       19       13.1%       1.31 [0.70, 2.44]         Labbe 1984       13       14       1       14       2.9%       13.00 [1.56, 66.42]         Labbe 1995       19       20       6       10       15.1%       1.58 [0.95, 2.65]         Larsson 1987a       7       14       1       11       2.7%       5.50 [0.79, 38.30]         Larsson 1990       6       31       0       17       1.4%       7.31 [0.44, 122.42]         Larsson 1996       9       13       1       3       2.8%       9.00 [1.32, 61.24]         Sterbaus 1997       13       25       0       14       1.5%       15.58 [1.00, 243.71]         Starbaus 1997       13       2.3       2.6%       12.38 [1.71, 89.86]       1.238 [1.73, 4.72]         Fold events:       135       31       -       2.30 [1.10, 4.85]       0.0001         L12 N > 20       4.06       71       18.5%       1.79 [1.26, 2.55]       -     <	1.1.1 N < 20							
Griffiths 1996       12       15       3       12       7.6%       3.20 [1.16, 8.80]         Kroener-Herwig 2002       16       29       8       19       13.1%       1.31 [0.70, 2.44]         abbe 1995       19       20       6       10       15.1%       1.58 [0.95, 2.65]         arsson 1987a       7       14       1       12       2.7%       5.50 [0.79, 38.30]         arsson 1987b       1       10       1       12       1.6%       1.20 [0.09, 16.84]         arsson 1987b       1       10       1       12       1.6%       1.20 [0.09, 16.84]         arsson 1990       6       31       0       17       1.4%       7.31 [0.44, 122, 42]         arsson 1996       9       13       1       32       2.6%       15.58 [1.00, 243.71]         Sterthaus 1997       13       25       0       14       1.5%       1.538 [1.73, 4.72]         Fotal events:       135       31       12.2%       1.73 [0.83, 3.61]       1.74 [0.86]         Subtotal (95% CI)       246       191       70.5%       2.36 [1.10, 4.85]       1.79 [1.26, 2.55]         Fotal events:       68       32       1.28 [1.36, 2.58]       1.88 [1.36, 2.58] <td>Barry 1997</td> <td>2</td> <td>12</td> <td>2</td> <td>17</td> <td>3.1%</td> <td>1.42 [0.23 , 8.70]</td> <td><b>.</b></td>	Barry 1997	2	12	2	17	3.1%	1.42 [0.23 , 8.70]	<b>.</b>
Groener-Herwig 2002       16       29       8       19       13.1%       1.31 [0.70, 2.44]         abbe 1984       13       14       1       14       2.9%       13.00 [1.96, 86.42]         abbe 1995       19       20       6       10       15.1%       1.58 [0.55, 2.65]         arsson 1987a       7       14       1       12       2.7%       5.50 [0.79, 38.30]         arsson 1987b       1       0       1       12       1.6%       1.20 [0.09, 16.84]         arsson 1990       6       31       0       17       1.4%       7.31 [0.44, 122.42]         bartony 1998       20       30       5       13       11.5%       15.58 [1.00, 23.71]         storty 1998       20       30       5       13       11.2%       1.73 [0.83, 3.61]         bartony 1998       20       30       5       31       12.38 [1.71, 89.86]         bartony 1998       20       30       5       13       11.2%         bartony 1998       20       30       5       14       15.86 [1.00, 4.35]         feterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 2.342, df = 12 (P = 0.02); I <sup>2</sup> = 49%       12.36 [1.73, 4.72]       Image tto the tade testore table testor table testor overall effect:	Fichtel 2001	10	20	2	16	4.9%	4.00 [1.02 , 15.72]	
abbe 1984       13       14       1       14       2.9%       13.00 [1.96, 86.42]         abbe 1995       19       20       6       10       15.1%       1.58 [0.95, 2.65]         arsson 1987a       7       14       1       11       2.7%       5.50 [0.79, 38.30]         arsson 1987b       1       10       1       12       1.6%       1.20 [0.09, 16.84]         arsson 1990       6       31       0       17       1.4%       7.31 [0.44, 12.242]         arsson 1996       9       13       1       3       2.8%       9.00 [1.32, 61.24]         Sterhaus 1997       13       25       0       14       1.5%       15.58 [1.00, 243.71]         Sterhaus 1997       13       25       0       14       1.5%       15.38 [1.71, 89.86]         Subtotal (95% CI)       246       191       70.5%       2.86 [1.73, 4.72]       -         Fotal events:       135       31       -       -       -         VacGrath 1992       26       47       6       25       11.0%       2.30 [1.10, 4.85]         Yowers 2013       42       64       26       71       18.5%       1.79 [1.26, 2.55]       -	Griffiths 1996	12	15	3	12	7.6%	3.20 [1.16 , 8.80]	
Labbe 1995 19 20 6 10 15.1% 1.58 [0.95, 2.65] Larsson 1987a 7 14 1 11 2.7% 5.50 [0.79, 38.30] Larsson 1987b 1 10 1 12 1.6% 1.20 [0.09, 16.84] Larsson 1990 6 31 0 17 1.4% 7.31 [0.44, 122.42] Larsson 1990 6 31 0 17 1.4% 7.31 [0.44, 122.42] Larsson 1996 9 13 1 13 2.8% 9.00 [1.32, 61.24] Disterbaus 1997 13 25 0 14 1.5% 15.58 [1.00, 243.71] Sartory 1998 20 30 5 13 11.2% 1.73 [0.83, 3.61] Scharff 2002 7 13 1 23 2.6% 12.38 [1.71, 89.86] Diubtotal (95% CI) 246 191 70.5% 2.86 [1.73, 4.72] Fotal events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); P = 49% lest for overall effect: Z = 4.10 (P < 0.0001) L1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Diubtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Diototal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Test for overall effect: Z = 3.87 (P = 0.0001) Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Test for overall effect: Z = 4.88 (P < 0.0001) Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Test for overall effect: Z = 4.88 (P < 0.0001) Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Test for overall effect: Z = 4.88 (P < 0.0001) Favours control Favours treatments 0.01 0.1 1 0 00 Favours control Favours treatments 0.01 0.1 1 0 00 Favours control Favours treatments 1.12 N = 10 0.0000 0000 0000000000000000000000	Kroener-Herwig 2002	16	29	8	19	13.1%	1.31 [0.70 , 2.44]	_ <b>_</b>
arsson 1987a       7       14       1       12 $7$ $5.50$ [ $0.79$ , $38.30$ ]         arsson 1987b       1       10       1       12 $1.6\%$ $1.20$ [ $0.09$ , $16.84$ ]         arsson 1980       6 $31$ 0 $17$ $1.4\%$ $7.31$ [ $0.44$ , $122.42$ ]         arsson 1996       9 $13$ 1 $32$ $2.8\%$ $9.00$ [ $1.32$ , $61.24$ ]         Dsterhaus 1997 $13$ $25$ 0 $14$ $1.5\%$ $15.58$ [ $1.00$ , $243.71$ ]         Satroty 1998 $20$ $30$ $5$ $13$ $11.2\%$ $1.73$ [ $0.83$ , $3.61$ ]         Satroty 1998 $20$ $30$ $5$ $11$ $10.73$ [ $0.83$ , $3.61$ ]         Satroty 1998 $20$ $30$ $5$ $11.73$ , $4.72$ ]         Otal events: $135$ $31$ Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); P = 49\% $2.30$ [ $1.10$ , $4.85$ ]         Powers 2013 $42$ $64$ $25$ $11.0\%$ $2.30$ [ $1.10$ , $4.85$ ]         Powers 2013 $42$ $64$ $26$ $17$ $18.5\%$ $1.36$ $2.35$ [ $1.67$ , $3.30$ ] <t< td=""><td>Labbe 1984</td><td>13</td><td>14</td><td>1</td><td>14</td><td>2.9%</td><td>13.00 [1.96 , 86.42]</td><td><b>_</b></td></t<>	Labbe 1984	13	14	1	14	2.9%	13.00 [1.96 , 86.42]	<b>_</b>
Larsson 1987b 1 10 1 12 1.6% 1.20 [0.09, 16.84] Larsson 1990 6 31 0 17 1.4% 7.31 [0.44, 122.42] Larsson 1996 9 13 1 13 2.8% 9.00 [1.32, 61.24] Disterbaus 1997 13 25 0 14 1.5% 15.58 [1.00, 243.71] Sartory 1998 20 30 5 13 11.2% 1.73 [0.83, 3.61] Schaff 2002 7 13 1 23 2.6% 12.38 [1.71, 89.86] Distributed (95% CI) 246 191 70.5% 2.86 [1.73, 4.72] Total events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% Test for overall effect: Z = 4.10 (P < 0.0001) L1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Dowers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Total events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Test for overall effect: Z = 3.87 (P = 0.0001) Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Total events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Test for overall effect: Z = 4.88 (P < 0.0001) Favours control Favours control Favours treatment	Labbe 1995	19	20	6	10	15.1%	1.58 [0.95 , 2.65]	<b></b>
Larsson 1990 6 31 0 17 1.4% 7.31 [0.44, 122.42] Larsson 1996 9 13 1 13 2.8% 9.00 [1.32, 61.24] Deterhaus 1997 13 25 0 14 1.5% 15.58 [1.00, 243.71] Sartory 1998 20 30 5 13 11.2% 1.73 [0.83, 3.61] Schaff 2002 7 13 1 23 2.6% 12.38 [1.71, 89.86] Subtotal (95% CI) 246 191 70.5% 2.86 [1.73, 4.72] Total events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% fest for overall effect: Z = 4.10 (P < 0.0001) L1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Total events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Test for overall effect: Z = 3.87 (P = 0.0001) Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Fest for overall effect: Z = 4.88 (P < 0.00001) Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Fest for overall effect: Z = 4.88 (P < 0.00001) Favours treatment	Larsson 1987a	7	14	1	11	2.7%	5.50 [0.79 , 38.30]	<b></b>
arsson 1996       9       13       1       13       2.8%       9.00 [1.32, 61.24]         Dsterhaus 1997       13       25       0       14       1.5%       15.58 [1.00, 243,71]         Sartory 1998       20       30       5       13       11.2%       1.73 [0.83, 3.61]         Schaff 2002       7       13       1       23       2.6%       12.38 [1.71, 89.86]         Subtotal (95% CI)       246       191       70.5%       2.86 [1.73, 4.72]         Total events:       135       31         Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49%         Rest for overall effect: Z = 4.10 (P < 0.0001)	Larsson 1987b	1	10	1	12	1.6%	1.20 [0.09 , 16.84]	<b>_</b>
Desterhaus 1997 13 25 0 14 1.5% 15.58 [1.00, 243.71] Sartory 1998 20 30 5 13 11.2% 1.73 [0.83, 3.61] Scharff 2002 7 13 1 23 2.6% 12.38 [1.71, 89.86] Subtotal (95% CI) 246 191 70.5% 2.86 [1.73, 4.72] Total events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% Rest for overall effect: Z = 4.10 (P < 0.0001) L1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Rest for overall effect: Z = 3.87 (P = 0.0001) Total events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Rest for overall effect: Z = 4.88 (P < 0.0001) Favours control Favours control Favours treatment	Larsson 1990	6	31	0	17	1.4%	7.31 [0.44 , 122.42]	<b></b>
Sartory 1998 20 30 5 13 11.2% $1.73$ [0.83, 3.61] Schaff 2002 7 13 1 23 2.6% 12.38 [1.71, 89.86] Subtotal (95% CI) 246 191 70.5% 2.86 [1.73, 4.72] Fotal events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% Fest for overall effect: Z = 4.10 (P < 0.0001) H.1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 0.0001)	Larsson 1996	9	13	1	13	2.8%	9.00 [1.32 , 61.24]	
Scharff 2002 7 13 1 23 2.6% 12.38 [1.71, 89.86] Subtotal (95% CI) 246 191 70.5% 2.86 [1.73, 4.72] Total events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% Test for overall effect: Z = 4.10 (P < 0.0001) L1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Test for overall effect: Z = 3.87 (P = 0.0001) Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Test for overall effect: Z = 4.88 (P < 0.00001) Favours control Favours control Favours reatment	Osterhaus 1997	13	25	0	14	1.5%	15.58 [1.00 , 243.71]	
Subtotal (95% CI)       246       191       70.5%       2.86 [1.73, 4.72]         Total events:       135       31         Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49%         Test for overall effect: Z = 4.10 (P < 0.0001)	Sartory 1998	20	30	5	13	11.2%	1.73 [0.83 , 3.61]	<b></b>
Total events: 135 31 Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% Fest for overall effect: Z = 4.10 (P < 0.0001) L.1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Fest for overall effect: Z = 3.87 (P = 0.0001) Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Fest for overall effect: Z = 4.88 (P < 0.00001) Favours control Favours control Favours treatment	Scharff 2002	7	13	1	23	2.6%	12.38 [1.71 , 89.86]	<b>_</b>
Heterogeneity: Tau <sup>2</sup> = 0.32; Chi <sup>2</sup> = 23.42, df = 12 (P = 0.02); I <sup>2</sup> = 49% Fest for overall effect: Z = 4.10 (P < 0.0001) L.1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Fest for overall effect: Z = 3.87 (P = 0.0001) Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Fest for overall effect: Z = 4.88 (P < 0.00001) Favours control Favours control Favours treatment	Subtotal (95% CI)		246		191	70.5%	2.86 [1.73 , 4.72]	
Test for overall effect: $Z = 4.10 (P < 0.0001)$ L1.2 N > 20 McGrath 1992 26 47 6 25 11.0% 2.30 [1.10, 4.85] Powers 2013 42 64 26 71 18.5% 1.79 [1.26, 2.55] Subtotal (95% CI) 111 96 29.5% 1.88 [1.36, 2.58] Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Test for overall effect: $Z = 3.87 (P = 0.0001)$ Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal (95% CI) 357 287 100.0% 2.35 [1.67, 3.30] Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Fest for overall effect: $Z = 4.88 (P < 0.00001)$ Fotal (95% CI) Favours control Favours treatment	Total events:	135		31				•
<b>A.1.2 N &gt; 20</b> McGrath 1992       26       47       6       25       11.0%       2.30 [1.10, 4.85]         Powers 2013       42       64       26       71       18.5%       1.79 [1.26, 2.55]         Subtotal (95% CI)       111       96       29.5%       1.88 [1.36, 2.58]         Fotal events:       68       32         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0%         Total (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Total (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Total events:       203       63         Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ 0.1       1       10       100         Fest for overall effect: Z = 4.88 (P < 0.00001)	Heterogeneity: Tau <sup>2</sup> = 0.3	32; Chi <sup>2</sup> = 23.	42, df = 1	2 (P = 0.02)	; I <sup>2</sup> = 49%	5		
McGrath 1992       26       47       6       25       11.0%       2.30 $[1.10, 4.85]$ Powers 2013       42       64       26       71       18.5% $1.79$ $[1.26, 2.55]$ Subtotal (95% CI)       111       96       29.5%       1.88 $[1.36, 2.58]$ Fotal events:       68       32         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0%       2.35 $[1.67, 3.30]$ $\checkmark$ Total (95% CI)       357       287       100.0% $2.35$ $[1.67, 3.30]$ $\checkmark$ Total (95% CI)       357       287       100.0% $2.35$ $[1.67, 3.30]$ $\checkmark$ Total (95% CI)       357       287       100.0% $2.35$ $[1.67, 3.30]$ $\checkmark$ Fotal (95% CI)       357       287       100.0% $2.35$ $[1.67, 3.30]$ $\checkmark$ Fotal (95% CI)       357       287       100.0% $2.35$ $[1.67, 3.30]$ $\checkmark$ Cotal events: $20.3$ $63$ $0.01$ $0.1$ $1$ $10$ $100$ Fest for overall effect: $Z = 4.88$ (P < 0.00001)       Favours control       Favours t	Test for overall effect: Z	= 4.10 (P < 0.1)	.0001)					
Powers 2013 42 64 26 71 18.5% $1.79 [1.26, 2.55]$ Subtotal (95% CI) 111 96 29.5% $1.88 [1.36, 2.58]$ Fotal events: 68 32 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0% Total (95% CI) 357 287 100.0% $2.35 [1.67, 3.30]$ Fotal (95% CI) 357 287 100.0% $2.35 [1.67, 3.30]$ Fotal (95% CI) $0.1 1 1 0 100$ Fotal events: 203 63 Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% Fest for overall effect: Z = 4.88 (P < 0.00001) Favours control Favours control Favours treatment	1.1.2 N > 20							
Subtotal (95% CI)       111       96       29.5%       1.88 [1.36, 2.58]         Fotal events:       68       32         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0%         Fotal (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Fotal events:       203       63         Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ $0.1$ $1$ $10$ $100$ Fest for overall effect: Z = 4.88 (P < 0.00001)	McGrath 1992	26	47	6	25	11.0%	2.30 [1.10 , 4.85]	
Total events:       68       32         Heterogeneity:       Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0%         Fest for overall effect:       Z = 3.87 (P = 0.0001)         Fotal (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Fotal events:       203       63         Heterogeneity:       Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ $0.1$ $1$ $10$ $100$ Fest for overall effect:       Z = 4.88 (P < 0.00001)	Powers 2013	42	64	26	71	18.5%	1.79 [1.26 , 2.55]	-
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.37, df = 1 (P = 0.54); I <sup>2</sup> = 0%         Fest for overall effect: Z = 3.87 (P = 0.0001)         Fotal (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Fotal events:       203       63         Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ $0.1$ $1$ $10$ $100$ Fest for overall effect: Z = 4.88 (P < 0.00001)	Subtotal (95% CI)		111		96	29.5%	1.88 [1.36 , 2.58]	
Test for overall effect: Z = $3.87$ (P = $0.0001$ )         Fotal (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Fotal events:       203       63         Heterogeneity: Tau <sup>2</sup> = $0.13$ ; Chi <sup>2</sup> = $22.62$ , df = $14$ (P = $0.07$ ); I <sup>2</sup> = $38\%$ $0.01$ $0.1$ $1$ $10$ Fest for overall effect: Z = $4.88$ (P < $0.0001$ )       Favours control       Favours treatment	Total events:	68		32				•
Fotal (95% CI)       357       287       100.0%       2.35 [1.67, 3.30]         Fotal events:       203       63         Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ $0.1$ Fest for overall effect: Z = 4.88 (P < 0.00001)	Heterogeneity: Tau <sup>2</sup> = 0.0	00; Chi <sup>2</sup> = 0.3	7, df = 1 (	P = 0.54); I	$^{2} = 0\%$			
Total events:       203       63         Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ $0.1$ $1$ $10$ $100$ Test for overall effect: Z = 4.88 (P < 0.00001)	Test for overall effect: Z	= 3.87 (P = 0.00)	.0001)					
Total events:       203       63         Heterogeneity: Tau <sup>2</sup> = 0.13; Chi <sup>2</sup> = 22.62, df = 14 (P = 0.07); I <sup>2</sup> = 38% $0.01$ $0.1$ $1$ $10$ $100$ Test for overall effect: Z = 4.88 (P < 0.00001)	Total (95% CI)		357		287	100.0%	2.35 [1.67 , 3.30]	
Fest for overall effect: Z = 4.88 (P < 0.00001)	Total events:	203		63				•
Fest for overall effect: Z = 4.88 (P < 0.00001)	Heterogeneity: $Tau^2 = 0.2$	13; Chi <sup>2</sup> = 22.	62, df = 1	4(P = 0.07)	; I <sup>2</sup> = 38%	)		0.01 0.1 1 10 100
	0 ,			. ,				
				1 (P = 0.17)	, I <sup>2</sup> = 47.9	%		

# Analysis 1.2. Comparison 1: Treatment versus control (headache) post-treatment, Outcome 2: Disability

	Ex	perimenta	1		Control			Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
1.2.1 N < 20											
Hickman 2015	38.25	32.21	16	30.88	30.02	16	11.5%	0.23 [-0.46 , 0.93]	]		
Wicksell 2009	12.3	13.9	15	14.6	11.3	14	10.8%	-0.18 [-0.91 , 0.55	]		
Subtotal (95% CI)			31			30	22.3%	0.04 [-0.47 , 0.54	1 🔶		
Heterogeneity: $Tau^2 = 0$ .	.00; Chi <sup>2</sup> = 0.	62, df = 1	(P = 0.43)	; I <sup>2</sup> = 0%					Ť		
Test for overall effect: Z	= 0.15 (P =	0.88)									
1.2.2 N > 20											
Chen 2014	16	8	45	20	10	45	19.3%	-0.44 [-0.86 , -0.02]	]		
Hechler 2014	27.9	9.7	47	34.2	8.8	52	19.8%	-0.68 [-1.08 , -0.27]	]		
Palermo 2016	9.52	6.47	31	8.1	4.28	30	16.4%	0.25 [-0.25 , 0.76	]		
Powers 2013	15.5	17.4	64	29.6	42.2	71	22.2%	-0.43 [-0.77 , -0.08]	]		
Subtotal (95% CI)			187			198	77.7%	-0.35 [-0.69 , -0.00	1 🔶		
Heterogeneity: $Tau^2 = 0$ .	.08; Chi <sup>2</sup> = 8.	29, df = 3	(P = 0.04)	; I <sup>2</sup> = 64%					•		
Test for overall effect: Z	= 1.99 (P =	0.05)									
Total (95% CI)			218			228	100.0%	-0.26 [-0.56 , 0.03]	]		
Heterogeneity: $Tau^2 = 0$ .	.07; Chi <sup>2</sup> = 1	1.19, df = 5	5 (P = 0.05	5); I <sup>2</sup> = 55%					•		
Test for overall effect: Z	= 1.75 (P =	0.08)									
Test for subgroup differe	ences: Chi <sup>2</sup> =	1.53, df =	1 (P = 0.2)	2), $I^2 = 34.8$	3%				Favours treatment Favours con		

### Analysis 1.3. Comparison 1: Treatment versus control (headache) post-treatment, Outcome 3: Depression

	Exp	oerimenta	1		Control			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
1.3.1 N < 20										
Griffiths 1996	2.45	0.64	30	2.6	0.9	12	8.8%	-0.20 [-0.88 , 0.47]	·	
Hickman 2015	51.69	6.65	16	49.69	6.46	16	8.1%	0.30 [-0.40 , 0.99]	·	
Wicksell 2009	18.4	10	15	25	10.5	14	7.0%	-0.63 [-1.37 , 0.12]	·	
Subtotal (95% CI)			61			42	23.9%	-0.16 [-0.68 , 0.35]		
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z	,	· ·	(P = 0.21)	; I <sup>2</sup> = 37%						
1.3.2 N > 20										
Hechler 2014	50.3	12	47	50.7	8.5	46	23.9%	-0.04 [-0.44 , 0.37]	·	
Palermo 2016	12.03	5.13	31	11.2	5.37	30	15.6%	0.16 [-0.35 , 0.66]	│ _ <b></b>	
Powers 2013	4.6	5.6	71	5.56	5.83	72	36.6%	-0.17 [-0.50 , 0.16]	·	
Subtotal (95% CI)			149			148	76.1%	-0.06 [-0.29 , 0.17]	└	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z			(P = 0.57)	; I <sup>2</sup> = 0%						
Total (95% CI)			210			190	100.0%	-0.08 [-0.28 , 0.11]	•	
Heterogeneity: $Tau^2 = 0$			(P = 0.49)	; I <sup>2</sup> = 0%						
Test for overall effect: Z		· ·							-2 -1 0 1	
Test for subgroup differ	ences: Chi <sup>2</sup> =	0.13, df =	1 (P = 0.7)	(1), $I^2 = 0\%$					Favours treatment Favours con	

### Analysis 1.4. Comparison 1: Treatment versus control (headache) post-treatment, Outcome 4: Anxiety

	Exp	perimenta	1		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.4.1 N < 20									
Bussone 1998	28.1	3.49	20	29.2	5.1	10	9.5%	-0.26 [-1.02 , 0.50]	I
Griffiths 1996	9.6	5.9	30	13.6	9.5	12	11.1%	-0.55 [-1.24, 0.13]	I
Hickman 2015	52.56	7.36	16	47.38	6.1	16	10.3%	0.75 [0.03 , 1.47]	I
Wicksell 2009	13.4	3.9	16	12.8	5.5	16	10.9%	0.12 [-0.57, 0.82]	I
Subtotal (95% CI)			82			54	41.9%	0.01 [-0.54 , 0.57]	
Heterogeneity: Tau <sup>2</sup> = 0	.19; Chi <sup>2</sup> = 7.	26, df = 3	(P = 0.06)	; I <sup>2</sup> = 59%					Ť
Test for overall effect: Z	z = 0.04 (P = 0.04)	0.97)							
1.4.2 N > 20									
Hechler 2014	2.2	1	50	2.6	0.9	49	19.7%	-0.42 [-0.82 , -0.02]	I
Palermo 2016	11.42	5.33	31	13	6.03	30	15.9%	-0.27 [-0.78 , 0.23]	∣ _∎∔
Powers 2013	0.49	1.07	71	0.45	0.78	72	22.6%	0.04 [-0.29 , 0.37]	I
Subtotal (95% CI)			152			151	58.1%	-0.19 [-0.49 , 0.11]	
Heterogeneity: Tau <sup>2</sup> = 0	.03; Chi <sup>2</sup> = 3.	26, df = 2	(P = 0.20)	; I <sup>2</sup> = 39%					•
Test for overall effect: Z	Z = 1.26 (P =	0.21)							
Total (95% CI)			234			205	100.0%	-0.11 [-0.39 , 0.17]	
Heterogeneity: $Tau^2 = 0$	.06; Chi <sup>2</sup> = 1	L.18, df =	6 (P = 0.08	s); I <sup>2</sup> = 46%					<b>T</b>
Test for overall effect: Z									$-\frac{1}{2}$ $-\frac{1}{2}$ $-\frac{1}{2}$ $0$ $1$ $2$
Test for subgroup differ			1 (P = 0.5)	3), $I^2 = 0\%$					Favours treatment Favours control

### Comparison 2. Treatment versus control (headache) follow-up

Outcome or sub- group title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.1 Pain	5	223	Risk Ratio (M-H, Random, 95% CI)	2.73 [0.98, 7.63]
2.1.1 N < 20	4	99	Risk Ratio (M-H, Random, 95% CI)	3.49 [1.31, 9.26]
2.1.2 N > 20	1	124	Risk Ratio (M-H, Random, 95% CI)	1.25 [1.03, 1.52]
2.2 Disability	3	209	Std. Mean Difference (IV, Random, 95% CI)	-0.37 [-0.65, -0.10]
2.2.1 N < 20	1	24	Std. Mean Difference (IV, Random, 95% CI)	-0.45 [-1.27, 0.36]
2.2.2 N > 20	2	185	Std. Mean Difference (IV, Random, 95% CI)	-0.36 [-0.65, -0.07]
2.3 Depression	3	228	Std. Mean Difference (IV, Random, 95% CI)	-0.05 [-0.62, 0.52]
2.3.1 N < 20	1	24	Std. Mean Difference (IV, Random, 95% CI)	-0.54 [-1.36, 0.28]
2.3.2 N > 20	2	204	Std. Mean Difference (IV, Random, 95% CI)	0.11 [-0.61, 0.83]
2.4 Anxiety	4	271	Std. Mean Difference (IV, Random, 95% CI)	-0.12 [-0.46, 0.21]
2.4.1 N < 20	2	67	Std. Mean Difference (IV, Random, 95% CI)	-0.28 [-1.00, 0.45]
2.4.2 N > 20	2	204	Std. Mean Difference (IV, Random, 95% CI)	-0.04 [-0.48, 0.41]



	Experin	nental	Cont	rol		<b>Risk Ratio</b>	<b>Risk Ratio</b>		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI		
2.1.1 N < 20									
Labbe 1995	19	20	1	10	15.3%	9.50 [1.48 , 61.15]			
Larsson 1987a	9	14	0	11	9.6%	15.20 [0.98 , 235.55]	<b>_</b>	_	
Larsson 1987b	4	10	3	12	21.2%	1.60 [0.46 , 5.53]			
Larsson 1996	8	11	3	11	23.5%	2.67 [0.95 , 7.47]			
Subtotal (95% CI)		55		44	69.6%	3.49 [1.31 , 9.26]	•		
Total events:	40		7				-		
Heterogeneity: Tau <sup>2</sup> = 0	).38; Chi <sup>2</sup> = 4	.90, df = 3	B(P=0.18)	; I <sup>2</sup> = 39%					
Test for overall effect: 2	Z = 2.51 (P =	0.01)							
2.1.2 N > 20									
Powers 2013	49	57	46	67	30.4%	1.25 [1.03 , 1.52]	_		
Subtotal (95% CI)		57		67	30.4%	1.25 [1.03 , 1.52]	•		
Total events:	49		46				ľ		
Heterogeneity: Not app	licable								
Test for overall effect: 2	Z = 2.29 (P =	0.02)							
Total (95% CI)		112		111	100.0%	2.73 [0.98 , 7.63]			
Total events:	89		53				-		
Heterogeneity: Tau <sup>2</sup> = 0	).89; Chi <sup>2</sup> = 1	7.18, df =	4 (P = 0.00	2); I <sup>2</sup> = 77	%		0.005 0.1 1 10 2	200	
Test for overall effect: 2	Z = 1.92 (P =	0.06)					Favours control Favours treat		
Test for subgroup differ	rences: Chi <sup>2</sup> =	= 4.07, df =	= 1 (P = 0.0	4), I <sup>2</sup> = 75	.4%				

### Analysis 2.1. Comparison 2: Treatment versus control (headache) follow-up, Outcome 1: Pain

### Analysis 2.2. Comparison 2: Treatment versus control (headache) follow-up, Outcome 2: Disability

Study or Subgroup	Exj Mean	perimenta SD	ıl Total	Mean	Control SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI
2.2.1 N < 20									
Wicksell 2009	8.8	12.9	13	14.7	12.1	11	11.3%	-0.45 [-1.27 , 0.36	]
Subtotal (95% CI)			13			11	11.3%	-0.45 [-1.27 , 0.36	
Heterogeneity: Not appl	licable								-
Test for overall effect: Z	Z = 1.09 (P =	0.27)							
2.2.2 N > 20									
Palermo 2016	7.84	5.5	31	8.75	4.64	30	29.8%	-0.18 [-0.68 , 0.33]	]
Powers 2013	7.6	16.9	57	19	30	67	58.9%	-0.46 [-0.81 , -0.10]	]
Subtotal (95% CI)			88			97	88.7%	-0.36 [-0.65 , -0.07	1 📥
Heterogeneity: Tau <sup>2</sup> = 0	.00; Chi <sup>2</sup> = 0.	79, df = 1	(P = 0.37)	; I <sup>2</sup> = 0%					•
Test for overall effect: Z	Z = 2.43 (P =	0.02)							
Total (95% CI)			101			108	100.0%	-0.37 [-0.65 , -0.10	1 🔶
Heterogeneity: Tau <sup>2</sup> = 0	.00; Chi <sup>2</sup> = 0.	83, df = 2	(P = 0.66)	; I <sup>2</sup> = 0%					•
Test for overall effect: Z	z = 2.66 (P =	0.008)							-2 $-1$ $0$ $1$ $2$
Test for subgroup differ	ences: Chi <sup>2</sup> =	0.04, df =	= 1 (P = 0.8	3), I <sup>2</sup> = 0%					Favours treatment Favours control

Favours treatment

Favours control



Test for subgroup differences:  $Chi^2 = 1.36$ , df = 1 (P = 0.24), I<sup>2</sup> = 26.5%

#### Favours experimental Control Std. Mean Difference Std. Mean Difference Study or Subgroup SD Total SD Total Weight IV, Random, 95% CI IV, Random, 95% CI Mean Mean 2.3.1 N < 20 Wicksell 2009 18.1 9.1 13 25.5 16.9 1124.1% -0.54 [-1.36 , 0.28] Subtotal (95% CI) -0.54 [-1.36 , 0.28] 13 24.1% 11 Heterogeneity: Not applicable Test for overall effect: Z = 1.29 (P = 0.20) 2.3.2 N > 20 Palermo 2016 11.53 5.37 31 8.71 5.6 30 34.6% 0.51 [-0.00 , 1.02] Powers 2013 71 72 41.3% -0.23 [-0.56 , 0.10] 2.85 4.9 4.07 5.51 Subtotal (95% CI) 102 102 75**.9%** 0.11 [-0.61 , 0.83] Heterogeneity: Tau<sup>2</sup> = 0.23; Chi<sup>2</sup> = 5.71, df = 1 (P = 0.02); I<sup>2</sup> = 82% Test for overall effect: Z = 0.30 (P = 0.76) Total (95% CI) 115 113 100.0% -0.05 [-0.62 , 0.52] Heterogeneity: Tau<sup>2</sup> = 0.18; Chi<sup>2</sup> = 7.12, df = 2 (P = 0.03); I<sup>2</sup> = 72% Test for overall effect: Z = 0.17 (P = 0.86) -2 2 -1

### Analysis 2.3. Comparison 2: Treatment versus control (headache) follow-up, Outcome 3: Depression

Analysis 2.4. Comparison 2: Treatment versus control (headache) follow-up, Outcome 4: Anxiety

	Exp	perimenta	1		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.4.1 N < 20									
Bussone 1998	27.8	2.3	20	29.1	1.4	15	17.2%	-0.65 [-1.33 , 0.04	]
Wicksell 2009	12.2	4.6	16	11.7	5.8	16	17.1%	0.09 [-0.60 , 0.79]	]
Subtotal (95% CI)			36			31	34.3%	-0.28 [-1.00 , 0.45	
Heterogeneity: Tau <sup>2</sup> = 0	.15; Chi <sup>2</sup> = 2.	19, df = 1	(P = 0.14)	; I <sup>2</sup> = 54%					
Test for overall effect: Z	Z = 0.75 (P = 0.75)	0.45)							
2.4.2 N > 20									
Palermo 2016	12.61	6.05	31	11.21	5.55	30	26.1%	0.24 [-0.27 , 0.74	]
Powers 2013	0.14	0.39	71	0.25	0.56	72	39.6%	-0.23 [-0.56 , 0.10]	]
Subtotal (95% CI)			102			102	65.7%	-0.04 [-0.48 , 0.41]	1 📥
Heterogeneity: Tau <sup>2</sup> = 0	0.06; Chi <sup>2</sup> = 2.	29, df = 1	(P = 0.13)	; I <sup>2</sup> = 56%					Ť
Test for overall effect: Z	Z = 0.15 (P = 0.15)	0.88)							
Total (95% CI)			138			133	100.0%	-0.12 [-0.46 , 0.21]	1
Heterogeneity: Tau <sup>2</sup> = 0	0.05; Chi <sup>2</sup> = 4.	93, df = 3	(P = 0.18)	; I <sup>2</sup> = 39%					
Test for overall effect: Z	Z = 0.72 (P =	0.47)							-2 -1 0 1 2
Test for subgroup differ	ences: Chi <sup>2</sup> =	0.31, df =	1 (P = 0.5	8), I <sup>2</sup> = 0%					Favours treatment Favours con

### Comparison 3. Treatment versus control (mixed pain) post-treatment

Outcome or sub- group title	No. of studies	No. of partici- pants	Statistical method	Effect size
3.1 Pain	16	1210	Std. Mean Difference (IV, Random, 95% CI)	-0.43 [-0.67, -0.19]
3.1.1 N < 20	7	250	Std. Mean Difference (IV, Random, 95% CI)	-0.83 [-1.19, -0.46]
3.1.2 N > 20	9	960	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.45, 0.05]
3.2 Disability	14	1226	Std. Mean Difference (IV, Random, 95% CI)	-0.34 [-0.54, -0.15]

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Outcome or sub- group title	No. of studies	No. of partici- pants	Statistical method	Effect size
3.2.1 N < 20	6	213	Std. Mean Difference (IV, Random, 95% CI)	-0.72 [-1.17, -0.26]
3.2.2 N > 20	8	1013	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.37, -0.04]
3.3 Depression	8	757	Std. Mean Difference (IV, Random, 95% CI)	-0.05 [-0.23, 0.12]
3.3.1 N < 20	2	59	Std. Mean Difference (IV, Random, 95% CI)	-0.27 [-0.95, 0.41]
3.3.2 N > 20	6	698	Std. Mean Difference (IV, Random, 95% CI)	-0.03 [-0.21, 0.15]
3.4 Anxiety	8	957	Std. Mean Difference (IV, Random, 95% CI)	-0.16 [-0.29, -0.03]
3.4.1 N < 20	1	32	Std. Mean Difference (IV, Random, 95% CI)	0.12 [-0.57, 0.82]
3.4.2 N > 20	7	925	Std. Mean Difference (IV, Random, 95% CI)	-0.17 [-0.30, -0.04]

# Analysis 3.1. Comparison 3: Treatment versus control (mixed pain) post-treatment, Outcome 1: Pain

	Exp	Experimental			Control			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
3.1.1 N < 20										
Barakat 2010	16.6	16.57	17	17.29	23.21	20	5.6%	-0.03 [-0.68 , 0.61]		
Grob 2013	0.16	0.32	15	1.93	1.64	14	4.4%	-1.48 [-2.32 , -0.65]	<b>_</b>	
Gulewitsch 2013	1.6	2.45	20	4.46	2.33	18	5.2%	-1.17 [-1.86 , -0.47]		
Humphreys 2000	0.77	3.04	46	4.3	2.77	15	5.8%	-1.17 [-1.79 , -0.55]	I	
Kashikar-Zuck 2005	4.4	1.91	13	5.92	2.04	14	4.7%	-0.74 [-1.53 , 0.04]		
Van Tilburg 2009	9	8.3	15	16.9	11.5	14	4.8%	-0.77 [-1.53 , -0.01]		
Wicksell 2009	3.6	2.3	15	5	2.9	14	4.9%	-0.52 [-1.26 , 0.22]		
Subtotal (95% CI)			141			109	35.4%	-0.83 [-1.19 , -0.46]		
Heterogeneity: Tau <sup>2</sup> = 0	).11; Chi <sup>2</sup> = 10	).96, df =	6 (P = 0.09	); I <sup>2</sup> = 45%					•	
Test for overall effect: 2	$Z = 4.40 (P < 10^{-1})$	0.0001)								
3.1.2 N > 20										
Hechler 2014	5.7	2.4	51	5.9	2.5	52	7.5%	-0.08 [-0.47 , 0.31]		
Kashikar-Zuck 2012	5.3	2.3	57	6	1.9	57	7.6%	-0.33 [-0.70 , 0.04]		
Levy 2010	1.64	2.02	84	1.25	1.75	84	8.1%	0.21 [-0.10 , 0.51]	_ <b>_</b>	
Levy 2017	4.09	2.21	159	4.57	2.28	81	8.3%	-0.21 [-0.48 , 0.05]		
Palermo 2016	5.58	2.03	31	5.7	2.05	30	6.6%	-0.06 [-0.56 , 0.44]		
Robins 2005	16.19	7.76	36	19.72	9.66	25	6.5%	-0.41 [-0.92 , 0.11]	<b>_</b> _	
Van der Veek 2013	23.1	15.9	52	26.51	14.38	52	7.5%	-0.22 [-0.61 , 0.16]		
Vlieger 2007	3	3.4	27	9.4	5.7	25	5.8%	-1.36 [-1.96 , -0.75]		
Wahlund 2015	4.4	1.8	28	3.7	2	29	6.5%	0.36 [-0.16 , 0.89]		
Subtotal (95% CI)			525			435	64.6%	-0.20 [-0.45 , 0.05]		
Heterogeneity: Tau <sup>2</sup> = 0	0.09; Chi <sup>2</sup> = 20	5.54, df =	8 (P = 0.00	009); I <sup>2</sup> = 70	1%				•	
Test for overall effect: 2	Z = 1.60 (P =	0.11)								
Total (95% CI)			666			544	100.0%	-0.43 [-0.67 , -0.19]		
Heterogeneity: $Tau^2 = 0$	0.16; Chi <sup>2</sup> = 56	5.09, df =	15 (P < 0.0	00001); I <sup>2</sup> =	73%				•	
Test for overall effect: 2									-2 -1 0 1 2	
Test for subgroup differ			1 (D - 0.0)	(0.6) $12 - 0.7$	00/				Favours treatment Favours con	

### Analysis 3.2. Comparison 3: Treatment versus control (mixed pain) post-treatment, Outcome 2: Disability

	Ex	perimenta	վ		Control			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
3.2.1 N < 20										
Grob 2013	5.33	6.64	15	24.52	14.06	14	3.7%	-1.72 [-2.59 , -0.85]	]	
Gulewitsch 2013	18.53	9.44	20	27.67	7.07	18	5.1%	-1.06 [-1.75 , -0.38]	]	
Humphreys 2000	0.07	0.28	46	0.23	0.72	15	6.1%	-0.37 [-0.96 , 0.22]	]	
Kashikar-Zuck 2005	15.07	9.08	13	16.64	8.3	14	4.5%	-0.18 [-0.93 , 0.58]	]	
Van Tilburg 2009	17.1	5.1	15	25.4	10.6	14	4.3%	-0.98 [-1.76 , -0.20]	]	
Wicksell 2009	12.3	13.9	15	14.6	11.3	14	4.7%	-0.18 [-0.91 , 0.55]	1	
Subtotal (95% CI)			124			89	28.3%	-0.72 [-1.17 , -0.26]		
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2	,	· ·	5 (P = 0.04	l); I <sup>2</sup> = 58%						
3.2.2 N > 20										
Hechler 2014	27.9	9.7	47	34.2	8.8	52	8.5%	-0.68 [-1.08 , -0.27]	]	
Kashikar-Zuck 2012	16.7	8.7	57	19.8	9.4	57	9.1%	-0.34 [-0.71, 0.03]	]	
Levy 2010	0.56	0.54	84	0.55	0.48	84	10.2%	0.02 [-0.28, 0.32]	1 _	
Levy 2016	5.6	5.7	80	7.3	8.3	78	10.0%	-0.24 [-0.55 , 0.07]	1	
Levy 2017	5.51	8.14	159	7.65	10.44	84	10.8%	-0.24 [-0.50 , 0.03]	]	
Palermo 2016	9.52	6.47	31	8.1	4.28	30	7.1%	0.25 [-0.25 , 0.76]	1 4.	
Robins 2005	18.08	4.9	40	19.58	5.87	26	7.2%	-0.28 [-0.78 , 0.22]	1	
Van der Veek 2013	7.17	8.76	52	7.79	8.78	52	8.8%	-0.07 [-0.45 , 0.31]	]	
Subtotal (95% CI)			550			463	71.7%	-0.20 [-0.37 , -0.04]	I 🔶	
Heterogeneity: Tau <sup>2</sup> = 0	0.02; Chi <sup>2</sup> = 1	1.66, df =	7 (P = 0.11	); I <sup>2</sup> = 40%					•	
Test for overall effect: 2	Z = 2.38 (P =	0.02)								
Total (95% CI)			674			552	100.0%	-0.34 [-0.54 , -0.15]	। ♦	
Heterogeneity: Tau <sup>2</sup> = 0	,	· ·	13 (P = 0.0	002); I <sup>2</sup> = 59	9%					
Test for overall effect: 2	Z = 3.43 (P =	0.0006)							-2 -1 0 1 2	
Test for subgroup diffe	rences: Chi <sup>2</sup> =	4.28, df =	= 1 (P = 0.0	4), I <sup>2</sup> = 76.6	5%				Favours treatment Favours con	

### Analysis 3.3. Comparison 3: Treatment versus control (mixed pain) post-treatment, Outcome 3: Depression

	Ex	perimenta	1		Control			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
3.3.1 N < 20										
Kashikar-Zuck 2005	49.57	17.6	15	48.46	12.89	15	5.3%	0.07 [-0.65 , 0.79]	]	
Wicksell 2009	18.4	10	15	25	10.5	14	4.9%	-0.63 [-1.37 , 0.12]	]	
Subtotal (95% CI)			30			29	10.2%	-0.27 [-0.95 , 0.41]		
Heterogeneity: Tau <sup>2</sup> = 0	).10; Chi <sup>2</sup> = 1.	74, df = 1	(P = 0.19)	; I <sup>2</sup> = 42%						
Test for overall effect: 2	Z = 0.77 (P = 0.77)	0.44)								
3.3.2 N > 20										
Hechler 2014	50.3	12	47	50.7	8.5	46	13.2%	-0.04 [-0.44 , 0.37]	]	
Kashikar-Zuck 2012	9.9	6.2	57	11.8	5.8	57	15.0%	-0.31 [-0.68 , 0.06]	」	
Levy 2010	9.96	6.16	84	8.35	5.73	84	19.2%	0.27 [-0.03 , 0.57]	]	
Levy 2016	7.6	7.1	80	8.8	7.6	78	18.6%	-0.16 [-0.47 , 0.15]	」 _∎∔	
Palermo 2016	12.03	5.13	31	11.2	5.37	30	9.6%	0.16 [-0.35 , 0.66]	]	
Van der Veek 2013	2.17	1.96	52	2.33	1.97	52	14.2%	-0.08 [-0.47 , 0.30]	]	
Subtotal (95% CI)			351			347	89.8%	-0.03 [-0.21 , 0.15]	I 🔶	
Heterogeneity: Tau <sup>2</sup> = 0	).02; Chi <sup>2</sup> = 7.	29, df = 5	(P = 0.20)	; I <sup>2</sup> = 31%					Ĭ	
Test for overall effect: 2	Z = 0.33 (P =	0.74)								
Fotal (95% CI)			381			376	100.0%	-0.05 [-0.23 , 0.12]	Ⅰ ▲	
Heterogeneity: Tau <sup>2</sup> = 0	).02; Chi <sup>2</sup> = 9.	76, df = 7	(P = 0.20)	; I <sup>2</sup> = 28%					Ĩ	
Test for overall effect: 2	Z = 0.61 (P =	0.54)								
Fest for subgroup diffe	rences: Chi <sup>2</sup> =	0.44, df =	1 (P = 0.5)	(1), $I^2 = 0\%$					Favours treatment Favours con	



### Analysis 3.4. Comparison 3: Treatment versus control (mixed pain) post-treatment, Outcome 4: Anxiety

	Exp	perimenta	ıl		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.4.1 N < 20									
Wicksell 2009	13.4	3.9	16	12.8	5.5	16	3.5%	0.12 [-0.57 , 0.82]	]
Subtotal (95% CI)			16			16	3.5%	0.12 [-0.57 , 0.82	
Heterogeneity: Not appl	icable								
Test for overall effect: Z	Z = 0.35 (P =	0.73)							
3.4.2 N > 20									
Hechler 2014	2.2	1	50	2.6	0.9	49	10.5%	-0.42 [-0.82 , -0.02]	]
Kashikar-Zuck 2012	2.11	0.72	50	2.39	0.95	50	10.7%	-0.33 [-0.72 , 0.07	]
Levy 2010	13.5	4.86	83	13.04	4.04	80	17.6%	0.10 [-0.21 , 0.41]	]
Levy 2016	8.2	2.8	80	8.6	2.9	78	17.0%	-0.14 [-0.45 , 0.17	]
Levy 2017	1.09	0.94	159	1.28	1.07	81	23.1%	-0.19 [-0.46 , 0.08	]
Palermo 2016	11.42	5.33	31	13	6.03	30	6.5%	-0.27 [-0.78, 0.23]	]
Van der Veek 2013	6.83	6	52	7.76	6.33	52	11.2%	-0.15 [-0.53 , 0.24	]
Subtotal (95% CI)			505			420	96.5%	-0.17 [-0.30 , -0.04	1 🔶
Heterogeneity: Tau <sup>2</sup> = 0.	.00; Chi <sup>2</sup> = 5.	36, df = 6	(P = 0.50)	; I <sup>2</sup> = 0%					· ·
Test for overall effect: Z	Z = 2.53 (P =	0.01)							
Total (95% CI)			521			436	100.0%	-0.16 [-0.29 , -0.03	」 ▲
Heterogeneity: Tau <sup>2</sup> = 0.	.00; Chi <sup>2</sup> = 6.	02, df = 7	(P = 0.54)	; I <sup>2</sup> = 0%					•
Test for overall effect: Z	z = 2.42 (P =	0.02)							-2 $-1$ $0$ $1$ $2$
Test for subgroup differe	ences: Chi² =	0.66, df =	1 (P = 0.4	2), I <sup>2</sup> = 0%					Favours treatment Favours control

### Comparison 4. Treatment versus control (mixed pain) follow-up

Outcome or sub- group title	No. of studies	No. of partici- pants	Statistical method	Effect size
4.1 Pain	9	833	Std. Mean Difference (IV, Random, 95% CI)	-0.08 [-0.30, 0.13]
4.1.1 N < 20	2	53	Std. Mean Difference (IV, Random, 95% CI)	-0.94 [-1.75, -0.13]
4.1.2 N > 20	7	780	Std. Mean Difference (IV, Random, 95% CI)	-0.00 [-0.15, 0.14]
4.2 Disability	9	935	Std. Mean Difference (IV, Random, 95% CI)	-0.27 [-0.49, -0.06]
4.2.1 N < 20	2	53	Std. Mean Difference (IV, Random, 95% CI)	-1.17 [-2.60, 0.26]
4.2.2 N > 20	7	882	Std. Mean Difference (IV, Random, 95% CI)	-0.20 [-0.34, -0.07]
4.3 Depression	7	667	Std. Mean Difference (IV, Random, 95% CI)	0.09 [-0.10, 0.28]
4.3.1 N < 20	1	24	Std. Mean Difference (IV, Random, 95% CI)	-0.53 [-1.35, 0.29]
4.3.2 N > 20	6	643	Std. Mean Difference (IV, Random, 95% CI)	0.12 [-0.06, 0.30]
4.4 Anxiety	8	875	Std. Mean Difference (IV, Random, 95% CI)	-0.01 [-0.20, 0.18]
4.4.1 N < 20	1	32	Std. Mean Difference (IV, Random, 95% CI)	0.09 [-0.60, 0.79]
4.4.2 N > 20	7	843	Std. Mean Difference (IV, Random, 95% CI)	-0.01 [-0.22, 0.19]



### Analysis 4.1. Comparison 4: Treatment versus control (mixed pain) follow-up, Outcome 1: Pain

	Exp	perimenta	1		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.1.1 N < 20									
Grob 2013	0.08	0.31	15	1.55	1.49	14	5.3%	-1.35 [-2.17 , -0.53]	<b>_</b>
Wicksell 2009	3.1	2.7	13	4.5	2.4	11	5.3%	-0.53 [-1.35 , 0.29]	
Subtotal (95% CI)			28			25	10.6%	-0.94 [-1.75 , -0.13]	
Heterogeneity: $Tau^2 = 0$ .	.17; Chi <sup>2</sup> = 1.	.95, df = 1	(P = 0.16)	; I <sup>2</sup> = 49%					-
Test for overall effect: Z	z = 2.28 (P =	0.02)							
4.1.2 N > 20									
Barakat 2010	16.71	23.03	13	7.84	12.31	20	6.6%	0.50 [-0.21 , 1.21]	↓ <b></b>
Hechler 2014	3.3	2.9	45	3.5	3.2	40	12.3%	-0.07 [-0.49 , 0.36]	·
Kashikar-Zuck 2012	4.9	2.2	57	5.3	2.1	57	14.0%	-0.18 [-0.55 , 0.18]	_ <b>_</b>
Levy 2010	0.93	1.42	78	0.7	1.53	76	15.7%	0.16 [-0.16 , 0.47]	↓_ <b>_</b> _
Levy 2017	3.48	2.33	151	3.79	2.48	78	17.1%	-0.13 [-0.40 , 0.14]	
Palermo 2016	5.42	2.05	31	5.3	2.12	30	10.3%	0.06 [-0.45 , 0.56]	
Van der Veek 2013	19.03	17.04	52	17.72	15.19	52	13.5%	0.08 [-0.30 , 0.47]	
Subtotal (95% CI)			427			353	89.4%	-0.00 [-0.15 , 0.14]	⊢ ▲
Heterogeneity: $Tau^2 = 0$ .	.00; Chi <sup>2</sup> = 4.	.98, df = 6	(P = 0.55)	$I^2 = 0\%$					The second se
Test for overall effect: Z	z = 0.04 (P =	0.97)							
Total (95% CI)			455			378	100.0%	-0.08 [-0.30 , 0.13]	
Heterogeneity: $Tau^2 = 0$ .	.05; Chi <sup>2</sup> = 10	6.38, df =	8 (P = 0.04	); I <sup>2</sup> = 51%					•
Test for overall effect: Z	= 0.75 (P =	0.45)							-+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Test for subgroup differe	ences: Chi <sup>2</sup> =	5.00, df =	1 (P = 0.0)	3), I <sup>2</sup> = 80.0	)%				Favours treatment Favours control

### Analysis 4.2. Comparison 4: Treatment versus control (mixed pain) follow-up, Outcome 2: Disability

	Exp	perimenta	ıl		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.2.1 N < 20									
Grob 2013	4.22	5.26	15	24.76	14	14	4.6%	-1.91 [-2.82 , -1.01	]
Wicksell 2009	8.8	12.9	13	14.7	12.1	11	5.3%	-0.45 [-1.27 , 0.36	]
Subtotal (95% CI)			28			25	9.9%	-1.17 [-2.60 , 0.26	
Heterogeneity: Tau <sup>2</sup> = 0	.87; Chi <sup>2</sup> = 5.	55, df = 1	(P = 0.02)	; I <sup>2</sup> = 82%					
Test for overall effect: Z	z = 1.60 (P = 0)	0.11)							
4.2.2 N > 20									
Hechler 2014	21.2	11.1	44	21.7	13.8	39	11.4%	-0.04 [-0.47 , 0.39]	]
Kashikar-Zuck 2012	13.4	8.9	57	17	10.5	57	12.9%	-0.37 [-0.74 , 0.00]	]
Levy 2010	0.36	0.39	78	0.48	0.56	76	14.3%	-0.25 [-0.57 , 0.07	] _
Levy 2016	5.1	6.4	67	5.9	6.8	66	13.7%	-0.12 [-0.46 , 0.22]	]
Levy 2017	4.5	6.64	151	7.6	10.85	82	15.5%	-0.37 [-0.64 , -0.10]	]
Palermo 2016	7.84	5.5	31	8.75	4.64	30	9.8%	-0.18 [-0.68 , 0.33]	]
Van der Veek 2013	5.8	8.2	52	4.87	6.6	52	12.5%	0.12 [-0.26 , 0.51]	]
Subtotal (95% CI)			480			402	90.1%	-0.20 [-0.34 , -0.07	1 🔺
Heterogeneity: Tau <sup>2</sup> = 0	.00; Chi <sup>2</sup> = 5.	85, df = 6	(P = 0.44)	; I <sup>2</sup> = 0%					•
Test for overall effect: Z	z = 2.97 (P = 0)	0.003)							
Total (95% CI)			508			427	100.0%	-0.27 [-0.49 , -0.06	1
Heterogeneity: Tau <sup>2</sup> = 0	.06; Chi <sup>2</sup> = 19	9.67, df =	8 (P = 0.01	); I <sup>2</sup> = 59%					•
Test for overall effect: Z	2 = 2.46 (P =	0.01)							
Test for subgroup differ	ences: Chi <sup>2</sup> =	1.74, df =	= 1 (P = 0.1	9), I <sup>2</sup> = 42.6	5%				Favours treatment Favours control



### Analysis 4.3. Comparison 4: Treatment versus control (mixed pain) follow-up, Outcome 3: Depression

	Exp	oerimenta	1		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.3.1 N < 20									
Wicksell 2009	18.1	9.8	13	25.5	16.9	11	4.8%	-0.53 [-1.35 , 0.29]	I
Subtotal (95% CI)			13			11	4.8%	-0.53 [-1.35 , 0.29]	
Heterogeneity: Not appl	icable								
Test for overall effect: Z	L = 1.27 (P =	0.21)							
4.3.2 N > 20									
Hechler 2014	48.6	13.8	40	43.4	8.3	37	12.7%	0.45 [-0.01 , 0.90]	I <b>—</b> —
Kashikar-Zuck 2012	8.7	6.1	57	9.3	5.9	57	16.9%	-0.10 [-0.47 , 0.27]	l
Levy 2010	7.89	6.99	78	7.19	5.27	76	20.3%	0.11 [-0.20 , 0.43]	
Levy 2016	4.4	5.8	67	4.6	5.9	66	18.6%	-0.03 [-0.37 , 0.31]	l
Palermo 2016	11.53	5.37	31	8.71	5.6	30	10.7%	0.51 [-0.00 , 1.02]	I <b></b>
Van der Veek 2013	1.85	1.93	52	1.79	2.14	52	16.0%	0.03 [-0.36 , 0.41]	
Subtotal (95% CI)			325			318	95.2%	0.12 [-0.06 , 0.30]	
Heterogeneity: Tau <sup>2</sup> = 0	.01; Chi <sup>2</sup> = 6.	57, df = 5	(P = 0.25)	; I <sup>2</sup> = 24%					•
Test for overall effect: Z	L = 1.27 (P =	0.20)							
Total (95% CI)			338			329	100.0%	0.09 [-0.10 , 0.28]	
Heterogeneity: Tau <sup>2</sup> = 0	.02; Chi <sup>2</sup> = 8.	80, df = 6	(P = 0.18)	; I <sup>2</sup> = 32%					<b>•</b>
Test for overall effect: Z	z = 0.93 (P =	0.35)							-2 $-1$ $0$ $1$ $2$
Test for subgroup different	ences: Chi <sup>2</sup> =	2.27, df =	1 (P = 0.1	3), I² = 56.0	)%				Favours treatment Favours control

### Analysis 4.4. Comparison 4: Treatment versus control (mixed pain) follow-up, Outcome 4: Anxiety

	Exp	perimenta	1	Control			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.4.1 N < 20									
Wicksell 2009	12.2	4.6	16	11.7	5.8	16	6.0%	0.09 [-0.60 , 0.79]	I
Subtotal (95% CI)			16			16	6.0%	0.09 [-0.60 , 0.79]	
Heterogeneity: Not app	licable								
Test for overall effect: 2	Z = 0.26 (P = 0.26)	0.79)							
4.4.2 N > 20									
Hechler 2014	2	0.9	41	1.6	0.7	37	10.9%	0.49 [0.04 , 0.94]	I
Kashikar-Zuck 2012	1.89	0.82	50	2.22	0.91	50	12.7%	-0.38 [-0.77 , 0.02]	I
Levy 2010	13.21	3.98	75	12.59	4.14	63	15.1%	0.15 [-0.18 , 0.49]	Ⅰ
Levy 2016	7.9	3.3	67	8.2	3.2	66	14.9%	-0.09 [-0.43 , 0.25]	l
Levy 2017	0.87	0.88	151	1.1	0.98	78	17.8%	-0.25 [-0.52 , 0.02]	l
Palermo 2016	12.61	6.05	31	11.21	5.55	30	9.5%	0.24 [-0.27 , 0.74]	I
Van der Veek 2013	5.47	5.22	52	5.82	6.09	52	13.1%	-0.06 [-0.45 , 0.32]	l
Subtotal (95% CI)			467			376	94.0%	-0.01 [-0.22 , 0.19]	└ ♠
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2			6 (P = 0.05	i); I <sup>2</sup> = 53%					
Total (95% CI)			483			392	100.0%	-0.01 [-0.20 , 0.18]	•
Heterogeneity: $Tau^2 = 0$ Test for overall effect: 2	,	· ·	7 (P = 0.07	'); I <sup>2</sup> = 46%					-1 -0.5 0 0.5 1
Test for subgroup differ			1(P = 0.7)	(7) $I^2 = 0\%$					-1 -0.5 0 0.5 1 Favours treatment Favours con
reserior subgroup unier	chees. Chi <sup>-</sup> =	0.00, ui –	r (r = 0.7	/ ), 1 = 0 /0					ravours accument ravours con

#### ADDITIONAL TABLES

### Table 1. Duration of treatment and setting by condition

### **Headache Studies**



### Table 1. Duration of treatment and setting by condition (Continued)

Author	Illness	Treatment dura- tion (hours)	Setting
Abram 2007	Headache	1.5	Clinic
Barry 1997	Headache	3	Unknown
Bussone 1998	Headache	7	Clinic
Chen 2014	Headache	Unknown	Unknown
Cottrell 2007	Headache	4 hours plus tasks	Home
Fichtel 2001	Headache	6.75	Clinic
Griffiths 1996	Headache	12	Home/clinic
Hickman 2015	Headache	2.8	Home/clinic
Hechler 2014*	Mixed	136.5 (3-week in- tensive therapy)	Clinic
Kroener-Herwig 2002	Headache	12	Clinic
Labbe 1984	Headache	6.7	Clinic
Labbe 1995	Headache	7.5	Clinic
Larsson 1987a	Headache	6.75	School
Larsson 1987b	Headache	5	School
Larsson 1990	Headache	Unknown	Home
Larsson 1996	Headache	3.3	Clinic
McGrath 1988	Headache	6	Unknown
McGrath 1992	Headache	8	Home/clinic
Osterhaus 1997	Headache	9.3	Clinic
Passchier 1990	Headache	2.5	School
Palermo 2016*	Mixed	5	Home/clinic
Powers 2013	Headache	13	Clinic
Richter 1986	Headache	9	Unknown
Sartory 1998	Headache	Unknown	Clinic
Scharff 2002	Headache	4	Clinic
Wicksell 2009*	Mixed	10	Clinic

### Table 1. Duration of treatment and setting by condition (Continued)

### **Mixed Chronic Pain Studies**

Author	Illness	Treatment dura- tion hours)	Setting
Alfven 2007	RAP	Unknown	Clinic
Barakat 2010	SCD	6	Home
Daniel 2015	SCD	9.5	Home/clinic
Duarte 2006	RAP	3.3	Unknown
Gil 1997	SCD	0.75	Clinic
Greenley 2015	IBD	4	Home
Grob 2013	RAP	9	Clinic
Gulewitsch 2013	RAP/IBS	2	Clinic
Hechler 2014*	Mixed	136.5 (3-week in- tensive therapy)	Clinic
Humphreys 2000	RAP	Unknown	Clinic
Kashikar-Zuck 2005	Fibromyalgia	6	Clinic
Kashikar-Zuck 2012	Fibromyalgia	7.5	Unknown
Levy 2010	RAP	4	Home/clinic
Levy 2016	IBD	3.5	Home/clinic
Levy 2017	RAP	3	Home/clinic
Palermo 2016*	Mixed	5	Home/clinic
Robins 2005	RAP	3.5	Clinic
Sanders 1994	RAP	6	Clinic
Van der Veek 2013	RAP	4.5	Clinic
Van Tilburg 2009	RAP	1.8	Home
Vlieger 2007	RAP/IBS	5	Clinic
Wahlund 2003	TMD	Unknown	Unknown
Wahlund 2015	TMD	6	Clinic
Wicksell 2009*	Mixed	10	Clinic

\*Headache and mixed chronic pain studies were entered twice. IBD: inflammatory bowel disease

IBS: irritable bowel syndrome JIA: Juvenile idiopathic arthritis RAP: Recurrent abdominal pain SCD: Sickle cell disease TMD: temporomandibular disorders

### Table 2. Scorecard of findings

Psychological treatments for children and adolescents with headache pain

	Pain	Disability	Depression	Anxiety
Post-treatment	Effect (15)	No effect (6)	No effect (6)	No effect (7)
< 20/arm	Effect (13)	No effect (2)	No effect (3)	No effect (4)
> 20/arm	Effect (2)	Effect (4)	No effect (3)	No effect (3)
Follow-up	No effect (5)	Effect (3)	No effect (3)	No effect (4)
< 20/arm	Effect (4)	Unknown*	Unknown*	No effect (2)
> 20/arm	Unknown*	Effect (2)	No effect (2)	No effect (2)

Psychological treatments for children and adolescents with mixed pain conditions

	Pain	Disability	Depression	Anxiety
Post-treatment	Effect (16)	Effect (14)	No effect (8)	Effect (8)
< 20/arm	Effect (7)	Effect (6)	No effect (2)	Unknown*
> 20/arm	No effect (9)	Effect (8)	No effect (6)	Effect (7)
Follow-up	No effect (9)	Effect (9)	No effect (7)	No effect (8)
< 20/arm	Effect (2)	No effect (2)	Unknown*	Unknown*
> 20/arm	No effect (7)	Effect (7)	No effect (6)	No effect (7)

Unknown (no data); Unknown\* (only one study); Number in brackets denotes number of studies in analysis.

Outcome	Sensitivity analysis
Pain, children with headache, post-treatment	RR 2.79, 95% CI 2.01 to 3.89; participants = 325; studies = 15; I <sup>2</sup> = 56%
N < 20	RR 2.79, 95% CI 2.01 to 3.89; participants = 325; studies = 15; I <sup>2</sup> = 56%
N > 20	No studies could be included in the analysis
Pain, children with mixed pain conditions, post-treatment	SMD -0.57, 95% CI -0.90 to -0.24; participants = 671; studies = 16; I <sup>2</sup> = 74%

Table 3. Results of sensitivity analyses

### Table 3. Results of sensitivity analyses (Continued)

N < 20	SMD -0.84, 95% CI -1.27 to -0.41; participants = 221; studies = 7; I <sup>2</sup> = 54%
N > 20	SMD -0.31, 95% CI -0.73 to 0.12; participants = 450; studies = 9; I <sup>2</sup> = 79%
Disability, children with mixed pain conditions, post-treat- ment	SMD -0.37, 95% CI -0.64 to -0.11; participants = 687; studies = 14; I <sup>2</sup> = 60%
N < 20	SMD -0.67, 95% CI -1.21 to -0.13; participants = 184; studies = 6; I <sup>2</sup> = 64%
N > 20	SMD -0.21, 95% CI -0.41 to -0.00; participants = 503; studies = 8; I <sup>2</sup> = 25%

CI: confidence intervals

SMD: standardised mean difference

### APPENDICES

### **Appendix 1. Previous search results**

Four separate searches were undertaken. The first search was undertaken from inception of the abstracting services to the end of 1999 (Eccleston 2003). This yielded 3715 abstracts, of which 123 were read in full, identifying 18 RCTs.

The second search, which updated the original review, was undertaken focusing on the 10 years since the previous search, overlapping by one year (from 1999 to 2008) and was later published (Eccleston 2009). This yielded 1319 abstracts, of which 45 papers were read in full, identifying a further 16 RCTs, giving a total set of 34. However, five studies were later excluded because they did not meet the minimum criteria of 10 participants in each arm, therefore, leaving 29 studies.

The third search, which searched databases from 2008 to March 2012, yielded 851 abstracts, of which 25 papers were read in full, and eight further RCTs were included in the review (Eccleston 2012).

The fourth search, which searched databases from March 2012 to January 2014, yielded 443 abstracts, of which 19 were read in full, and seven papers were included (Grob 2013; Gulewitsch 2013; Hechler 2014; Kashikar-Zuck 2012; Levy 2010; Powers 2013; Van der Veek 2013). Kashikar-Zuck 2012 and Levy 2010 provided additional data for studies previously included in this review. Five studies that were previously included, were excluded from this review since treatment was delivered remotely (Connelly 2006; Hicks 2006; Palermo 2009; Stinson 2010; Trautmann 2010). Therefore, a total of 37 RCTs were included (39 papers; Eccleston 2014).

### Appendix 2. Model over-fitting

We used AIC to mitigate the risk of overfitting due to repeated sensitivity analyses. The AIC scores indicate that all meta-analyses are more parsimonious than meta-regressions/subgroup analyses except pain intensity in children with mixed pain conditions at post-treatment. Here, sample size explained enough variation to be worth including in the model based on change in AIC score. The model had very high inconsistency, partly explained by publication bias, but there was further heterogeneity not explained by our subgroup and sensitivity analyses. This reduced our confidence in the estimate of effect which is reflected in the GRADE assessment and 'summary of findings' tables.

### Appendix 3. 2017 Search strategies

### **CENTRAL (CRSO)**

#1 MeSH descriptor: [Child] explode all trees

- #2 MeSH descriptor: [Infant] explode all trees
- #3 MeSH descriptor: [Adolescent] explode all trees

#4 (child\* or adolescent\* or infant\*or juvenil\* or pediatric\* or paediatric\* or "young person\*" or "young people" or youth\* or "young adult\*"):it,ab,kw (Word variations have been searched)

#5 #1 or #2 or #3 or #4

#6 MeSH descriptor: [Psychology] explode all trees

#7 MeSH descriptor: [Psychotherapy] explode all trees

#8 MeSH descriptor: [Behavior Therapy] explode all trees

#9 (psycholog\* or (behavio?r and therapy) or hypnos\* or relaxation\* or ((family or color or colour or music or play) next therap\*) or imagery or cogniti\* or psychotherap\*):it,ab,kw (Word variations have been searched)



### #10 #6 or #7 or #8 or #9

#11 (pain\* or headache\* or "head ache\*" or head-ache\* or migraine\* or cephalalgi\* or "stomach ache\*" or "tummy ache\*" or "abdominal ache\*" or "belly ache\*" or earache\* or ear-ache\* or toothache\* or tooth-ache\* or odontalgi\* or dysmenorrh\* or neuralgi\*):it,ab,kw (Word variations have been searched) #12 MeSH descriptor: [Pain] explode all trees #13 MeSH descriptor: [Headache Disorders] explode all trees

#14 #11 or #12 or #13 #15 #5 and #10 and #14

### **MEDLINE via Ovid search strategy**

1. exp child/

2. Infant/

3. Adolescent/

4. (child\$ or adolescent\$ or infant\$ or juvenil\$ or pediatric\$ or paediatric\$ or "young person\$" or "young people" or youth\$ or "young adult\$").ab,it,kf.

5. 1 or 2 or 3 or 4

6. exp Psychology/

7. exp Psychotherapy/

8. exp Behavior Therapy/

9. (psycholog\$ or (behavio?r and therapy) or hypnos\$ or relaxation\$ or ((family or color or colour or music or play) adj therap\$) or imagery or cogniti\$ or psychotherap\$).ab,it,kf.

10.6 or 7 or 8 or 9

11. (pain\$ or headache\$ or "head ache\$" or head-ache\$ or migraine\$ or cephalalgi\$ or "stomach ache\$" or "tummy ache\$" or "abdominal ache\$" or "belly ache\$" or earache\$ or ear-ache\$ or toothache\$ or tooth-ache\$ or odontalgi\$ or dysmenorrh\$ or neuralgi\$).ab,it,kf.

12. exp Pain/

13. exp Headache Disorders/

14. 11 or 12 or 13

15. 5 and 10 and 14

16 randomized controlled trial.pt.

17 controlled clinical trial.pt.

18 randomized.ab.

19 placebo.ab.

20 drug therapy.fs.

21 randomly.ab.

22 trial.ab.

23 or/16-22

24 exp animals/ not humans.sh.

25 23 not 24

26 25 and 15



### **Embase via Ovid search strategy**

1. Child/

2. Infant/

3. Adolescent/

4. (child\$ or adolescent\$ or infant\$ or juvenil\$ or pediatric\$ or paediatric\$ or "young person\$" or "young people" or youth\$ or "young adult\$").ab,it.

5. 1 or 2 or 3 or 4

6. exp PSYCHOLOGY/

7. exp PSYCHOTHERAPY/

8. behavior therapy/

9. (psycholog\$ or (behavio?r and therapy) or hypnos\$ or relaxation\$ or ((family or color or colour or music or play) adj therap\$) or imagery or cogniti\$ or psychotherap\$).ab,it.

10.6 or 7 or 8 or 9

11. (pain\$ or headache\$ or "head ache\$" or head-ache\$ or migraine\$ or cephalalgi\$ or "stomach ache\$" or "tummy ache\$" or "abdominal ache\$" or "belly ache\$" or earache\$ or ear-ache\$ or toothache\$ or tooth-ache\$ or odontalgi\$ or dysmenorrh\$ or neuralgi\$).ab,it.

12. exp Pain/

13. exp "Headache and Facial Pain"/

- 14. 11 or 12 or 13
- 15. 5 and 10 and 14
- 16 random\$.tw.

17 factorial\$.tw.

18 crossover\$.tw.

19 cross over\$.tw.

- 20 cross-over\$.tw.
- 21 placebo\$.tw.
- 22 (doubl\$ adj blind\$).tw.
- 23 (singl\$ adj blind\$).tw.
- 24 assign\$.tw.

25 allocat\$.tw.

- 26 volunteer\$.tw.
- 27 Crossover Procedure/
- 28 double-blind procedure.tw.
- 29 Randomized Controlled Trial/
- 30 Single Blind Procedure/

31 or/16-30

32 (animal/ or nonhuman/) not human/



33 31 not 32

34 15 and 33

#### **PsycINFO via OVID**

1. (child\$ or adolescent\$ or infant\$ or juvenil\$ or pediatric\$ or paediatric\$ or "young person\$" or "young people" or youth\$ or "young adult\$").ab,it.

2. exp PSYCHOLOGY/

- 3. exp PSYCHOTHERAPY/
- 4. behavior therapy/

5. (psycholog\$ or (behavio?r and therapy) or hypnos\$ or relaxation\$ or ((family or color or colour or music or play) adj therap\$) or imagery or cogniti\$ or psychotherap\$).ab,it.

6. 2 or 3 or 4 or 5

7. (pain\$ or headache\$ or "head ache\$" or head-ache\$ or migraine\$ or cephalalgi\$ or "stomach ache\$" or "tummy ache\$" or "abdominal ache\$" or "belly ache\$" or earache\$ or ear-ache\$ or toothache\$ or tooth-ache\$ or odontalgi\$ or dysmenorrh\$ or neuralgi\$).ab,it.

- 8. exp Pain/
- 9. Headache/
- 10. Migraine Headache/
- 11. Muscle Contraction Headache/
- 12. 7 or 8 or 9 or 10 or 11
- 13. 1 and 6 and 12
- 14 clinical trials/
- 15 (randomis\* or randomiz\*).tw.
- 16 (random\$ adj3 (allocat\$ or assign\$)).tw.
- 17 ((clinic\$ or control\$) adj trial\$).tw.
- 18 ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj3 (blind\$ or mask\$)).tw.
- 19 (crossover\$ or "cross over\$").tw.
- 20 random sampling/
- 21 Experiment Controls/
- 22 Placebo/
- 23 placebo\$.tw.
- 24 exp program evaluation/
- 25 treatment effectiveness evaluation/
- 26 ((effectiveness or evaluat\$) adj3 (stud\$ or research\$)).tw.
- 27 or/14-26
- 28 13 and 27
- WHAT'S NEW



Date	Event	Description
13 October 2020	Review declared as stable	See Published notes.

### HISTORY

Protocol first published: Issue 1, 2003 Review first published: Issue 1, 2003

Date	Event	Description
30 September 2019	Amended	Clarification added to Declarations of interest.
1 October 2018	Amended	Date Next Stage Expected updated.
23 May 2018	New search has been performed	This review has been updated to include the results of a new search on 1 May 2018.
23 May 2018	New citation required but conclusions have not changed	10 new studies (869 additional participants). Findings not sub- stantially different from previous review. GRADE ratings were similar.
9 February 2016	Review declared as stable	See Published notes.
14 May 2014	Amended	Minor change to the GRADE assessment wording.
30 April 2014	New citation required but conclusions have not changed	A new search was run in January 2014.
14 March 2014	New search has been performed	Five new studies were added. Two trials containing additional information for previously included studies were included. Five studies that were previously included were excluded as they de- livered treatment remotely. These will be included in the new Cochrane review ('Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents'). 'Mood' outcome was split into two discrete domains; anxiety and depression.
21 August 2013	Amended	'Summary of findings' tables have been updated.
24 October 2012	New citation required and conclusions have changed	The previous review reported that psychological treatments were effective for headache and non-headache groups at post- treatment and effects were maintained at follow-up. Updated studies have altered the previous results. The current update found that pain improved at post-treatment for headache and non-headache groups, and for headache groups at follow-up. An additional significant finding for disability at post-treatment for the non-headache group was found. Conclusions have been up- dated accordingly.
24 October 2012	New search has been performed	New authors have been added to this review. A new search was run in March 2012. Eight new studies were added (Barakat 2010; Kashikar-Zuck 2012; Levy 2010; Palermo 2009; Stinson 2010; Trautmann 2010; van Tilburg 2009a; Wicksell 2009), and four new studies were excluded (Trautmann 2008; Vlieger 2012; Weydert 2006; Youssef 2009).



Date	Event	Description
16 May 2008	Amended	Converted to new review format.

### CONTRIBUTIONS OF AUTHORS

Emma Fisher oversaw the project, contributed to the design, analysis and authoring of the text, and is responsible for any future update of this review.

Christopher Eccleston, Emily Law, Joanne Dudeney, and Tonya Palermo all contributed to the design, analysis, and authoring of the text.

### DECLARATIONS OF INTEREST

#### EF: None known.

EL: None known; EL is a paediatric psychologist and provides clinical service to children and adolescents with chronic pain. EL is an author on one study included in this review (Palermo 2016) and was not involved in data extraction or assessments of this study. During the completion of this work, EL received salary support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (Grant number K23NS089966, PI: Law).

#### JD: None known.

TP: None known; TP is an author on one study included in this review (Palermo 2016) and was not involved in data extraction or assessments of this study. During the completion of this work, TP received salary support from the National Institutes of Health/National Institute of Child Health, behaviour and Development (K24HD060068, PI: Palermo).

CE: None known; CE is an author on one study included in this review (Palermo 2016) and was not involved in data extraction or assessments of this study. Since CE is an author as well as the PaPaS Co-ordinating Editor at the time of writing, we acknowledge the input of Amanda C de C Williams who acted as Sign Off Editor for this review. CE had no input into the editorial decisions or processes for this review.

### SOURCES OF SUPPORT

#### Internal sources

• No sources of support supplied

### **External sources**

• National Institutes of Health/National Institute of Neurological Disorders and Stroke, USA

Grant number K23NS089966 (PI: EL).

• National Institutes of Health, USA

Grant number K24HD060068 (PI: TP)

### DIFFERENCES BETWEEN PROTOCOL AND REVIEW

- In Eccleston 2009, odds ratios and risk ratios were reported for dichotomous outcomes. In this review we only reported risk ratio.
- In Eccleston 2014, therapy that was delivered remotely (e.g. via Internet, telephone) was removed as an outcome and the 'mood' outcome was separated into two discrete outcomes: depression and anxiety.
- In the latest update, we updated the references in the background section and included a section on problem-solving therapy, as this was a new therapy delivered to parents of children with chronic pain.
- In the latest update, we clarified the inclusion criteria of participants included in the studies. We also expanded our definition of 'faceto-face' interventions to include therapies delivered by phone or written instruction book. The authors felt that these types of therapies were more similar to interventions included in this review, and that the Fisher 2015 review on remotely delivered interventions should be exclusively for those delivered via technology.
- In the latest update, we included trials that delivered therapy to parents of children with chronic pain.
- In the latest update, we ran subgroup analyses of smaller (i.e. n < 20 participants per arm) versus larger (i.e. n > 20 participants per arm).
- In the latest update, we assessed and reported potential reporting biases.
- In the latest update, we added the following sections 'Unit of analysis issues', 'Dealing with missing data', 'Assessment of reporting biases', 'Data synthesis', and 'Sensitivity analyses'.



• In the latest update, we searched MEDLINE in Process in addition to other databases.

### NOTES

At October 2020, we are not aware of any new potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. The review will be reassessed for updating in two years. If appropriate, we will update the review before this date if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.

### INDEX TERMS

### Medical Subject Headings (MeSH)

Abdominal Pain [therapy]; Anxiety [drug therapy]; Chronic Pain [etiology] [psychology] [\*therapy]; Cognitive Behavioral Therapy; Depression [drug therapy]; Fibromyalgia [therapy]; Headache [therapy]; Hemoglobin SC Disease [complications]; Pain Management [\*methods] [psychology]; Psychotherapy [\*methods]; Randomized Controlled Trials as Topic; Recurrence; Temporomandibular Joint Disorders [therapy]

### **MeSH check words**

Adolescent; Child; Humans